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ABSTRACT 
Badr Mostafa Sadek Ibrahim. MECHANISMS FOR CENTRAL CANNABINOID 
RECEPTOR 1 EVOKED SYMPATHOEXCITATION/PRESSOR RESPONSE IN 
CONSCIOUS RATS (Under the direction of Dr. Abdel A. Abdel-Rahman) Department of 
Pharmacology and Toxicology, November, 2010 
The main goal of the current study was to elucidate the molecular mechanisms implicated 
in central cannabinoid receptor subtype 1 (CB1R)-evoked sympathoexcitation/pressor response. 
In pursuit of this goal, the candidate first characterized the centrally elicited hemodynamic 
effects of CB1R activation (WIN55,212-2) in a conscious rat model. The results showed that the 
pressor response elicited by central CB1R stimulation was associated with enhanced neuronal 
activity of presympathetic neurons in the rostral ventrolateral medulla (RVLM). The findings of 
multiple in vivo and in vitro studies have suggested a functional crosstalk between central CB1R 
and orexins. Therefore, the candidate hypothesized that orexin-A/orexin receptor 1 (OX1R) 
signaling in the RVLM is essential for the central CB1R-mediated pressor response. In support of 
this hypothesis, central CB1R activation elevated orexin-A levels in the RVLM and inhibition of 
orexin-A/OX1R signaling abrogated the CB1R-evoked pressor response. Colocalization studies 
have unraveled close proximity of orexin-A/OX1R to CB1R immuno-reactive neurons and 
punctate-like structures in the RVLM, which support the pharmacological findings. Furthermore, 
the present study delineated a novel role for PI3K/Akt/ERK1/2 signaling in RVLM and nucleus 
tractus solitarii (NTS) in the sympathoexcitation elicited by central CB1R activation in conscious 
rats. The latter findings inferred a causal role for a down-regulated PI3K/Akt signaling in the 
RVLM and NTS in the central CB1R-evoked pressor response. This conclusion is supported by 
the exacerbation of the WIN55,212-2-evoked pressor response following PI3K/Akt inhibition 
(wortmannin). By contrast, ERK1/2 phosphorylation was enhanced in the same neuronal pools 
and the pharmacological and molecular studies suggest that this effect, which is mediated, at 
least partly, via the reduction in PI3K/Akt signaling, contributes to the central CB1R-evoked 
pressor response. Finally, the findings demonstrated that direct CB1R activation in the RVLM 
enhanced the activity of two distinct neuronal pools (catecholaminergic and nitroxidergic), which 
may be linked to the modulation of brainstem GABAergic neurotransmission (GABAAR) and 
subsequently to the central CB1R-evoked sympathoexcitatory and pressor response. The findings 
yield new insight into a functional crosstalk between CB1R and OX1R signaling in the RVLM, a 
neuronal pool that is heavily implicated in blood pressure control and in hypertension. 
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 CHAPTER ONE-GENERAL INTRODUCTION 
1. 1. Cannabinoid CB1 Receptor 
 Cannabinoid receptors are the site of action of a heterogeneous group of compounds 
broadly termed cannabinoids. These compounds include those isolated from the plant Cannabis 
sativa (marijuana)-derived Δ9-tetra-hydrocannabinol (Δ9-THC), the naturally occurring prototype 
compound, as well as other synthetic compounds (discussed below). Cannabis has long been 
used for recreational and medical purposes since at least 2000 B.C. It is now known that 
cannabinoids exert their actions via two subtypes of G protein-coupled receptors: CB1 and CB2. 
Our study focuses on the CB1R, which is found primarily in the CNS, including the 
cardiovascular regulatory nuclei in the brainstem, unlike CB2R, which is present mainly 
peripherally. 
1. 1. 1. Topography of CB1 receptor 
The CB1 receptor, a 473-amino-acid protein, was first cloned from a rat cerebral cortex 
cDNA library (Matsuda, Lolait et al. 1990) and a human brainstem library (Gerard, Mollereau et 
al. 1991), which maintains the essential topographical features for a G-protein coupled receptor 
(GPCR) as shown in Fig. 1. 1, published by Howlett A.C. (Howlett 1998). This two-dimensional 
model of CB1R includes; (i) seven hydrophobic transmembrane domain regions that extend 
through the plasma membrane; (ii) three extracellular loops (EL1/EL2/EL3); (iii) three 
intracellular loops (IL1/IL2/IL3); (iv) an extracellular N-terminal (NT); (v) and an intracellular 
C-terminal (CT). 
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Fig. 1. 1. Topography of cannabinoid receptor 1. [Taken from Howlett, A.C. 1998: with 
permission].  
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1. 1. 2. Signal transduction following CB1R activation 
Activation of CB1R results in activation or inhibition of several downstream signaling 
molecules, which are site-specific e.g. inhibition of adenylyl cyclase activity, stimulation of 
inwardly rectifying potassium channels, inhibition of N- and P/Q-type voltage-dependent 
calcium channels (Twitchell, Brown et al. 1997; Mu, Zhuang et al. 1999), and activation of 
mitogen-activated protein (MAP) kinase pathway, Fig. 1. 2. 
1. 1. 2. 1. Inhibition of adenylyl cyclase  
Multiple lines of evidence suggest that cannabinoids act on CB1R to inhibit adenylyl 
cyclase resulting in the reduction of cAMP production (Howlett, Qualy et al. 1986; Bidaut-
Russell, Devane et al. 1990; Childers, Fleming et al. 1992). Further, it has been shown that the 
selective CB1R antagonists, SR141716A and LY320135 can antagonize the inhibition of cAMP 
production induced by cannabinoids (Felder, Joyce et al. 1998).The involvement of an inhibitory 
G-protein (Gα
i/o
) through which the CB1R is negatively coupled to adenylyl cyclase has been 
demonstrated through cannabinoid-induced inhibition of adenylyl cyclase. This cyclase 
inhibition was blocked by Gα
i/o
-selective pertussis toxin in mammalian brain and in cultured 
neuronal cells (Howlett, Qualy et al. 1986; Bidaut-Russell, Devane et al. 1990; Childers, Fleming 
et al. 1992).  
1. 1. 2. 2. Modulation of ERK1/2 and PI3K/Akt signaling   
Cannabinoids are highly potent activators of extracellular-signal regulated kinase1/2 
(ERK1/2), which was evident in stably transfected Chinese hamster ovary cells expressing 
human CB1R. This effect was (i) inhibited by SR141716A; (ii) sensitive to pertussis toxin; (iii) 
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and independent of the cannabinoid-induced inhibition of cAMP production (Bouaboula, Poinot-
Chazel et al. 1995). Importantly, in U373 MG human astrocytoma cells (Galve-Roperh, Rueda et 
al. 2002) and hippocampal slices (Derkinderen, Valjent et al. 2003) CB1R activation rapidly led 
to ERK1/2 phosphorylation via the phosphotidylinositol 3-kinase (PI3K) pathway in the U373 
MG human astrocytoma cells but not in the hippocampus. Notably, studies on the 
neuroprotective and/or anti-oncogenic effects of cannabinoids via PI3K/Akt signaling pathway 
have yielded controversial results. First, intraperitoneal injection of 9-THC activated PI3K/Akt 
pathway in mouse hippocampus, striatum, and cerebellum via a mechanism that was ERK1/2-
independent (Ozaita, Puighermanal et al. 2007). Second, THC-mediated anti-cancer effect in 
human prostate cells involved PI3K/AKT and ERK1/2 signaling pathway activation (Sanchez, 
Ruiz-Llorente et al. 2003). On the other hand, it was demonstrated in multiple cancer cell lines 
that CB1R activation down regulates both PI3K/Akt and ERK1/2 signaling pathway (Ellert-
Miklaszewska, Kaminska et al. 2005; Greenhough, Patsos et al. 2007). Whether PI3K/Akt and or 
ERK1/2 signaling pathways are involved in central CB1R-elicited sympathoexcitation has yet to 
be elucidated.  
1. 1. 2. 3. Other CB1R signaling 
Many of CB1R-mediated physiological functions are G protein Gi/o mediated (Howlett, 
Qualy et al. 1986; Howlett and Mukhopadhyay 2000; Piomelli 2003). However, the diverse, 
sometimes opposing, CB1R-evoked physiological functions that are not completely attributable 
to simply lowering intracellular cAMP levels, have led to investigations of the role of other non-
Gi/o signaling mechanisms (Lauckner, Hille et al. 2005).  
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Fig. 1. 2. Main signaling transduction pathways of CB1 receptor activation. Modified 
with permission from www.CNSforum.com 
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For instance, central CB1R activation evokes sympathoexcitation/pressor responses while 
activation of Gi/o coupled receptors in the brainstem 2A adrenergic receptors (El-Mas and 
Abdel-Rahman 2004; Li, Wang et al. 2005) evokes depressor responses. In this line, recent 
studies have linked CB1R coupling to activation of Gq/11 or Gs. It is possible that 
heterodimerization between CB1R and other receptor(s) contribute, at least partly, to this 
divergent signal transduction. This notion is supported by the reported interaction between CB1R 
and other co-localized receptors. First, evidence of CB1R coupling with Gs was demonstrated 
by simultaneous activation of dopamine D2R, which resulted in accumulation of cAMP (Glass 
and Felder 1997; Kearn, Blake-Palmer et al. 2005). Second, CB1R behaves as a Gq/11- G 
protein-coupled receptor in cultured hippocampal neurons and trabecular meshwork cells 
(Lauckner, Hille et al. 2005; McIntosh, Hudson et al. 2007). Most pertinent to the proposed 
studies are the findings that heterodimerization between CB1R and OX1R resulted in enhanced 
Gq/11-dependent OX1R signaling in presence of CB1R (Ellis, Pediani et al. 2006) (discussed 
below) 
1.1. 2. 4. Retrograde CB1R-mediated signaling 
An accumulating body of evidence suggests that CB1 receptors are located mostly 
presynaptically and play crucial roles in controlling the release of neurotransmitters at both 
excitatory and inhibitory synapses. As illustrated by Scotter et al. (Scotter, Graham et al. 2009)  
this mechanism is defined as retrograde signaling (Fig. 1.3); in this regards, endocannabinoids, 
which are postsynaptically released upon depolarization, activate presynaptic CB1R which in 
turn inhibits Ca
2+
-dependent exocytosis of various neurotransmitters (Freund, Katona et al. 2003; 
Piomelli 2003). For example, WIN55,212-2 inhibited GABA release from presynaptic terminals 
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in cultured hippocampal or RVLM neurons following postsynaptic depolarization, a 
phenomenon termed depolarization induced suppression of inhibition or (DSI); this effect was 
completely abolished in presence of selective CB1 receptor antagonists (Vaughan, McGregor et 
al. 1999; Ohno-Shosaku, Maejima et al. 2001). 
It seems that postsynaptically-released endocannabinoids act as retrograde secondary 
messengers at both inhibitory, as well as, excitatory synapses. In support of this notion, findings 
from cerebellar Purkinje cells, which upon elevation of calcium levels following depolarization, 
release endocannabinoids, which stimulate presynaptic CB1R and ultimately suppress 
presynaptic calcium-induced glutamate release (Kreitzer and Regehr 2001). The latter 
phenomenon is termed depolarization-induced suppression of excitation or (DSE). Both CB1R 
mediated DSE and DSI are considered key mechanisms for many of the central effects of 
endogenous and exogenous cannabinoids. For this reason, it was proposed that central CB1R-
elicited sympathoexcitation is mediated via indirect stimulation of the tonically active 
presympathetic neurons in the RVLM regulated by an array of tonic excitatory and inhibitory 
inputs (Padley, Li et al. 2003). Although, this hypothesis has not been investigated in vivo, the 
findings that  CB1R activation inhibited GABAergic transmission in cultured RVLM neurons 
(Vaughan, McGregor et al. 1999) further support this  hypothesis. 
  
 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. 3. CB1R-mediated retrograde signaling at both excitatory and inhibitory 
synapses through postsynaptically released endocannabinoids. 2-AG: 2-
Arachidonoylglycerol; DSI: depolarization induced suppression of inhibition; DSE: 
depolarization induced suppression of excitation. Taken from (Scotter, Graham et al. 
2009) with permission.  
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Table. 1.1. Representative phyto-, synthetic, and endogenous cannabinoid compounds. 
WIN55,212-2 and AM251 were used in this studies.  
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Phytocannabinoids Δ
9–tetra-hydrocannabinol Cannabidiol (CBD) 
Synthetic 
cannabinoids 
WIN55,212-2 
 
CP-55.940 
Endogenous 
cannabinoids 
2-Arachidonylglycrol (2-AG) Anandamide 
antagonist/inverse 
agonists 
SR141716A (Rimonabant) AM251 
 
Peptide inverse 
agonist Hemopressin (H-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His-OH) 
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1. 2. Cannabinoid Ligands 
Cannabinoids are a heterogeneous group of compounds that include plant derived, 
naturally occurring and synthetic compounds (Table.1.1). Δ9–THC, Cannabidiol (CBD) and 
cannabinol are the most abundant natural cannabinoids active at CB1 and CB2 receptors, present 
in the abused drug Marijuana (Cannabis sativa). Δ9–THC has an equal affinity for both CB1 and 
CB2 receptors (Munro, Thomas et al. 1993). In 1992, an endogenous ligand for cannabinoid 
receptors was isolated from pig brain, arachidonoyl ethanolamide (AEA), a derivative of 
arachidonic acid, and was named anandamide (Devane, Hanus et al. 1992). 2-arachidonoyl 
glycerol (2-AG) is a more abundant endocannabinoid, but less potent than Δ9–THC (Sugiura, 
Kodaka et al. 1999). Most of the endogenous cannabinoids discovered so far are high or low 
efficacy agonists. However, recently Pertwee et al. reported an inverse agonist called 
virodhamine after the Sanskrit word virodh meaning oppose (Porter, Sauer et al. 2002).  
Pfizer was the first to develop high affinity non-eicosanoid cannabinoids (e.g. CP55940). 
Later, the aminoalkylindole cannabinoid, WIN55,212-2, extensively used in cannabinoid 
research, including our studies, was developed by a Sterling Winthrop. SR141716A and AM251, 
used in our study, are selective antagonists for the CB1R while SR144528 is selective for the 
CB2R (Rinaldi-Carmona, Barth et al. 1998). Notably, most of these compounds are highly 
lipophilic and water insoluble except for O-1057, which is highly water soluble and almost as 
potent as CP55940 (Pertwee, Gibson et al. 2000). Adding to the heterogeneous chemical 
composition of cannabinoids is the very recent discovery of the short peptide, hemopressin, 
which was identified in rat brain and acts on CB1R as an inverse agonist (Heimann, Gomes et al. 
2007; Dodd, Mancini et al. 2010).   
 15 
 
1. 3. Brainstem Nuclei and Central Regulation of Cardiovascular Function 
Many brainstem nuclei are implicated in the cardiovascular responses elicited by central 
CB1R activation; in this study, attention has been focused on the rostral ventrolateral medulla 
(RVLM) and nucleus tractus solitarii (NTS), which play pivotal roles in central control of 
cardiovascular function (Strack, Sawyer et al. 1989; Dampney, Polson et al. 2003; Nassar and 
Abdel-Rahman 2006). 
 1. 3. 1. Rostral Ventrolateral Medulla (RVLM) 
RVLM is the final supraspinal site within the central nervous system that integrates 
multitudes of influences on blood pressure (BP) from higher brain regions such as 
paraventricular nucleus, lateral hypothalamus, and periaqueductal gray (Guyenet, Haselton et al. 
1989; Dampney, Polson et al. 2003). The RVLM is of high significance in controlling BP since 
bilateral lesioning leads to a profound fall in BP (Dampney, Czachurski et al. 1987).  
1. 3. 1. 1. Location 
The RVLM is located in the ventral part of the brainstem, lateral to the inferior olive, 
caudal to the facial nucleus, and ventral to the nucleus ambiguous (Farlow, Goodchild et al. 
1984; Dampney, Czachurski et al. 1987). It is heterogeneous in composition containing multiple 
cell groups that are different in their neurochemical phenotype (e.g. rostroventrolateralis, 
gigantocellular nucleus and paragigantocellularis lateralis (Andrezik, Chan-Palay et al. 1981; 
Ruggiero DA, Cravo SL et al. 1989; Villanueva, de Pommery et al. 1991; Watanabe, Kitamura et 
al. 2003). 
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1. 3. 1. 2. Receptors and transmitters 
Catecholamine containing neurons in the brainstem are divided into the noradrenergic 
groups (A1-A12) and adrenergic groups (C1-C3), which can be identified by tyrosine 
hydroxylase (TH), the enzyme that converts tyrosine into dopa (Hokfelt T., Johansson O. et al. 
1984). Within the RVLM, C1 neurons, alternatively known as adrenergic neurons, are defined 
based on their expression of phenylethanolamine-n-methyltransferase (PNMT), the enzyme that 
synthesizes epinephrine from norepinephrine (Ross, Ruggiero et al. 1984; Jeske and McKenna 
1992). The noradrenergic neurons are categorized into two groups: the A1 cell group located in 
the rostral ventromedial medulla oblongata, and the A2 group located in the dorsal vagal nucleus 
(Hokfelt T., Johansson O. et al. 1984). The rostral C1 subgroup contains barosensitive neurons 
with axonal projections to the spinal cord (Kanjhan, Lipski et al. 1995; Schreihofer and Guyenet 
1997), which provides tonic excitatory inputs to the sympathetic preganglionic neurons 
(Guyenet, Koshiya et al. 1996; Guyenet 2006). On the other hand, caudal C1 subgroup projects 
to the hypothalamus and forebrain regions (Tucker, Saper et al. 1987; Verberne, Stornetta et al. 
1999). Beside catecholamine-containing neurons in RVLM (Goodchild, Phillips et al. 2001), a 
wide variety of neurotransmitters and receptors are present in the RVLM including substance P 
(Pilowsky, Minson et al. 1986), neuropeptide Y (Polson, Halliday et al. 1992), enkephalin 
(Polson, Halliday et al. 1992; Boone and Corry 1996), adenosine receptors (A2A) (Nassar and 
Abdel-Rahman 2008), P2X receptors (Ralevic 2000), Angiotensin II AT1 receptors (Potts, Allen 
et al. 2000), imidazoline I1 receptors (Zhang and Abdel-Rahman 2002; Zhang and Abdel-
Rahman 2005), 2A adrenergic receptors (El-Mas and Abdel-Rahman 2004; Li, Wang et al. 
2005), cannabinoid CB1 receptors (Herkenham, Lynn et al. 1991; Padley, Li et al. 2003), CB2 
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receptors (Van Sickle, Duncan et al. 2005) and mu-opioid receptors (Aicher, Kraus et al. 2001; 
Drake, Aicher et al. 2005). 
1. 3. 1. 3. Function 
The RVLM is a crucial brainstem nucleus for the tonic generation of sympathetic nerve 
activity (Ross, Ruggiero et al. 1985; Dampney, Czachurski et al. 1987). Activation of specific 
neurons within the RVLM causes an increase in BP by increasing peripheral resistance and 
cardiac output via released catecholamines (Guertzenstein 1972; Guertzenstein and Silver 1974; 
Feldberg and Guertzenstein 1976; McAllen and Dampney 1989). In addition to cardiovascular 
control, specific neurons within the RVLM are involved in nociception (Javanmardi, Parviz et al. 
2005; Karlsson, Preuss et al. 2006) and breathing (Nattie and Li 1990). 
 1. 3. 2.  Nucleus Tractus Solitarii (NTS) 
The NTS is the first relay station in the baroreflex arc; upon stimulation, it elicits a 
reduction in the BP, HR and sympathetic outflow (Miura and Reis 1972; Aicher and Randich 
1990). The NTS is located in the brainstem flanked on each side of the fourth ventricle and 
consists of groups of cells in a column-like structure dorsal to the RVLM. The most 
cardiovascularly relevant part of the NTS is located at the most caudal part of the NTS 
containing synapses from chemo and aortic baroreceptor processes that contact with secondary 
order neurons within the NTS (Nomura and Mizuno 1982; Seiders and Stuesse 1984). The latter 
communicate either directly or indirectly through third order neurons with other nuclei including. 
RVLM, hypothalamus or CVLM (Ross, Ruggiero et al. 1985; Dampney, Czachurski et al. 1987; 
Aicher, Kurucz et al. 1995; Aicher, Saravay et al. 1996). Functionally, activation of 
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cardiovascular afferents (chemo or baroreceptors) enhances the release of excitatory amino acid 
L-glutamate within the NTS (Miura and Reis 1972), which prompts the excitation of NTS-
projections to other baroreflex arc nuclei e.g. RVLM and CVLM. Several reports have shown 
important roles for activation of CB1R in the NTS in blood pressure regulation (Van Sickle, 
Oland et al. 2001; Rademacher, Patel et al. 2003; Seagard, Dean et al. 2004; Seagard, Hopp et al. 
2005). 
1. 4. CB1R-Mediated Cardiovascular Effects  
Cannabinoids elicit complex cardiovascular responses involving both peripheral and 
central sites. The presence of anesthesia has dramatically confounded these responses (Lake, 
Martin et al. 1997) and introduced additional parameters to be considered upon investigation of 
the CB1R role in controlling cardiovascular functions; in particular the central part. For this 
reason, the cannabinoid-evoked cardiovascular effects in anesthetized animals are significantly 
different when compared to responses reported in studies conducted in conscious animals or in 
humans. 
1. 4. 1. Systemic CB1R-evoked cardiovascular effects  
In anesthetized animals, systemically administered cannabinoids elicit predominantly 
hypotension and bradycardia. These effects are mediated peripherally through prejunctional 
inhibition of sympathetic outflow and vagal stimulation resulting in reduction of BP and HR, 
respectively (Varga, Lake et al. 1995; Varga, Lake et al. 1996; Lake, Compton et al. 1997; 
Niederhoffer and Szabo 1999). Systemic administration of anandamide, an endogenous 
cannabinoid or the synthetic cannabinoid, WIN55,212-2, elicited tri-phasic effects on BP in 
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anesthetized rats. An initial brief hypotensive phase, secondary to the bradycardia and was 
blocked by atropine pretreatment or vagotomy, followed by a transient pressor response, which 
was followed by more predominant depressor phase. The prolonged depressor phase was 
mediated via peripheral sympathoinhibition because it was attenuated by cervical spinal 
transection and blockade of -adrenoceptors (Varga, Lake et al. 1995; Varga, Lake et al. 1996; 
Lake, Compton et al. 1997; Niederhoffer and Szabo 1999).  
The cardiovascular responses of systemically administered cannabinoids in conscious 
animals are quite different. Systemically injected anandamide or WIN55,212-2 in conscious rats 
cause pressor responses along with bradycardic responses (Stein, Fuller et al. 1996; Gardiner, 
March et al. 2001). The elicited pressor response by systemic WIN55,212-2 in conscious animals 
was attenuated by ganglion blockade, providing evidence for a central site of action for the 
pressor  response. However, in the presence of anesthesia the latter response was altered (Lake, 
Martin et al. 1997). Importantly, in humans, acute administration of cannabinoid is associated 
with tachycardia and a rise in BP (Benowitz, Rosenberg et al. 1979; Foltin, Fischman et al. 1987; 
Sidney 2002). 
1. 4. 2. Central CB1R-evoked cardiovascular effects  
Centrally administered cannabinoids have been shown to predominantly elicit 
sympathoexcitation/pressor responses. This pressor response seems to involve sympathetic 
neurons in the (RVLM) because: (i) intracisternal (i.c) CB1 receptor agonists (WIN55,212-2 or 
CP-55940) caused increases in sympathetic nerve activity, plasma norepinephrine and blood 
pressure, in conscious rabbits (Niederhoffer and Szabo 2000) and anesthetized rats (Pfitzer, 
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Niederhoffer et al. 2004) that was attenuated by pretreatment with the CB1R antagonist 
SR171416A; (ii) microinjection of WIN55,212-2 into RVLM elicited a pressor response (Padley, 
Li et al. 2003). However, a recent study showed that in anesthetized animals, 
intracerebroventricular (i.c.v.) anandamide elicited pressor responses only in the presence of a 
CB1R antagonist; while alone, anandamide elicited a tri-phasic blood pressure response similar 
to that  induced by systemically administered anandamide (Malinowska, Zakrzeska et al. 2010).  
1. 5. Orexin Peptides and Receptors 
Orexins are a family of two peptides, the 33 amino acid orexin-A (hypocretin-1) and the 
shorter 28 amino acid orexin-B (hypocretin-2), derived through proteolytic cleavage from the 
precursor protein, prepro-orexin (PPO). Orexins were simultaneously discovered by two 
different groups (Sakurai, Amemiya et al. 1998) and (de Lecea, Kilduff et al. 1998) and was 
dubbed orexin by the former group after the Greek word „orexis‟, meaning appetite and 
hypocretin by the latter group because of some homology with the secretin/incretin family of 
peptides (de Lecea, Kilduff et al. 1998). Orexins were initially reported to be exclusively located 
in the lateral hypothalamus (LH), yet, orexin axons were found in other brain areas including the 
RVLM (Machado, Bonagamba et al. 2002; Ciriello, Li et al. 2003). 
Two GPCRs, Orexin 1 (OX1R) and Orexin 2 (OX2R) mediate the actions of orexins 
(Sakurai, Amemiya et al. 1998). While OX1R has higher affinity for orexin-A, OX2R binds 
orexin-A and orexin-B with similar affinities (van den Pol, Gao et al. 1998; Smart, Jerman et al. 
1999). OX1R couples to the Gq/11 G proteins, while OX2R coupled to Gq/11 or Gi/o in a neuronal 
cell line (Zhu, Miwa et al. 2003). 
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In addition to their role in regulation of feeding and sleep/wakefulness (Hara, Beuckmann 
et al. 2001; Farr, Banks et al. 2005; Verty, Boon et al. 2009), orexins have also been shown to be 
essential regulators of many autonomic functions, including central cardiovascular and 
respiratory regulation (Zhang, Fukuda et al. 2005; Zheng, Patterson et al. 2005; Shih and Chuang 
2007; Huang, Dai YW et al. 2010).  
1. 6. Therapeutic Potentials of Cannabinoids 
Clinical assessment of existing or investigational CB1R ligands is the focus of a worldwide 
research effort that affects the public health with regard to many diseases. The pharmacological 
modulations of cannabinoid and orexin systems are considered to be promising therapeutic 
strategies for many pathological conditions (e.g. obesity, metabolic syndrome, anorexia, and 
pain). Because of their well-documented antinociceptive action, cannabinoid receptors are being 
considered as therapeutic targets for pain relief. Sativex®, a mixture of Δ9-THC and CBD 
developed by GW Pharmaceuticals, was approved in Canada for the treatment of neuropathic 
pain in multiple sclerosis. Further, due to the potent anti-emetic effects of cannabinoids, many 
pharmaceuticals were produced (e.g. Marinol® and Cesamet®), containing Δ9-THC and its 
analogue nabilone and marketed as medicines for suppressing chemotherapy associated nausea 
and vomiting. Many of these drugs are also used as appetite stimulants in AIDS patients. 
Cannabinoids have many other potential uses in Parkinson‟s disease, Alzheimer‟s disease, 
inflammation, fertility, epilepsy and alcohol withdrawal (Alen, Moreno-Sanz et al. 2008; 
Morrish, Hill et al. 2009; de Bruin, Prickaerts et al. 2010; Dudek, Pouliot et al. 2010; Walsh, 
Mnich et al. 2010). SR141716A (Rimonabant) was approved under the trade name Acomplia® 
in the European Union, as an anti-obesity agent. However, the use of many of these drugs has 
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been associated with psychiatric side effects, presumably mediated by the central actions on 
CB1R. This led to the breakthrough development of peripherally “restricted” cannabinoid ligands 
that possess very limited central access and centrally-mediated side effects. For instance, 
AZ11713908 is a new bivalent chemical entity tested for pain relief in rodents with limited 
central access (Xiao Hong, Chang Qing et al. 2010). In addition, the physiological role of 
cannabinoids and orexins in blood pressure control highlights their importance in cardiovascular 
disease management. The findings of the proposed research will yield neurobiological and 
pharmacological insight into the crosstalk between CB1R and OX1R in vivo. In an effort to 
understand the interaction between these two systems, Thomas, B. F. et al, at the Research 
Triangle Institute in North Carolina, is developing bivalent ligands that target the GPRC 
homodimeric (Zhang, Gilliam et al. 2010) or heterodimeric structures including the CB1R and 
OX1R heterodimer by using existing or newly developed ligands e.g. SR141716, a CB1R 
antagonist and ACT-078573 OX1R antagonist linked together by a spacer (Zhang, Perrey et al. 
2010).   
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1.7. Aims of Study 
Studies on the cardiovascular effects of cannabinoids have yielded controversial results. 
While CB1R activation causes hypotension in anesthetized animals, it elicits a pressor response 
in conscious animals (Stein, Fuller et al. 1996; Gardiner, March et al. 2001; Randall, Harris et al. 
2002; Randall, Kendall et al. 2004; Mendizabal and Adler-Graschinsky 2007). The latter 
findings replicate the responses reported in humans (Benowitz, Rosenberg et al. 1979; Foltin, 
Fischman et al. 1987; Sidney 2002). This pressor response involves central mechanisms and 
probably implicates sympathetic neurons in RVLM (Niederhoffer and Szabo 2000; Padley, Li et 
al. 2003). However, the mechanisms that underlie the central CB1R mediated pressor response 
are still not clearly resolved.  
It has been shown that CB1R modulates synaptic transmission of many neurotransmitters 
via retrograde mechanism (Kreitzer and Regehr 2001; Ohno-Shosaku, Maejima et al. 2001; 
Freund, Katona et al. 2003; Piomelli 2003; Drew, Mitchell et al. 2008). Pertinent to the current 
studies, behavioral (feeding) and molecular findings corroborated the demonstration of an 
interplay between CB1R and OX1R signaling in a number of studies (Hilairet, Bouaboula et al. 
2003; Huang, Acuna-Goycolea et al. 2007; Crespo, Heras et al. 2008; Matias, Cristino et al. 
2008). Notably, studies on OX1R signaling have demonstrated the ability of an orexin-A, 
endogenous OX1R ligand, to elicit a sympathoexcitation/pressor response (Samson, Gosnell et al. 
1999; Shirasaka, Nakazato et al. 1999; Chen, Hwang et al. 2000; Machado, Bonagamba et al. 
2002; Ciriello, Li et al. 2003; Zhang, Fukuda et al. 2005). However, the possibility has not been 
considered that functional crosstalk between CB1R and OX1R/orexin-A in the brainstem 
(RVLM) might be involved in the blood pressure response elicited by the activation of either 
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receptor in vivo. Therefore, the present studies tested the novel hypothesis that OX1R/orexin-A 
signaling in the RVLM is essential for the central CB1R-mediated pressor response. 
Additionally, the current study tested the hypothesis that modulation of PI3K/Akt and/or 
ERK1/2 signaling contributes to the central CB1R-mediated pressor response. Our studies 
have, further elucidated the role of GABAAR/p-nNOS/NO signaling in these responses. 
Pharmacological, signal transduction and biochemical studies were undertaken in conscious 
normotensive rats, under the following interrelated aims: 
Specific Aim 1 studies characterized the CB1R-evoked sympathoexcitation/pressor 
response in conscious rats and tested the hypothesis that the central CB1R-evoked pressor/ 
sympathoexcitation response involves activation of rat RVLM neurons. 
Rationale: Anesthesia confounds the cannabinoid evoked hemodynamic responses (Stein, 
Fuller et al. 1996; Lake, Martin et al. 1997; Gardiner, March et al. 2001). To our knowledge, 
only one study investigated the central CB1R-evoked hemodynamic responses in conscious 
rabbits (Niederhoffer and Szabo 2000) and no other studies have reported such findings in 
conscious rats (Pfitzer, Niederhoffer et al. 2004). Thus, the current studies aimed to investigate 
the hemodynamic responses of activation of brainstem CB1R in conscious rats to circumvent the 
negative impacts of anesthesia on CB1R-mediated hemodynamic effects (Lake, Martin et al. 
1997). This pressor response is centrally mediated and possibly involves sympathetic neurons in 
the (RVLM) (Niederhoffer and Szabo 2000; Padley, Li et al. 2003). Therefore, a major goal of 
this study was to elucidate whether RVLM neurons are implicated in the CB1R-evoked 
sympathoexcitation/pressor response. This was achieved by quantifying the expression of the 
immediate early gene c-Fos protein product as a marker of sympathetic neuron activity (Hirooka, 
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Polson et al. 1997; Horiuchi, Potts et al. 1999; Dampney, Polson et al. 2003) and addressing the 
following questions: 
1- Is the CB1R (protein) expressed in the RVLM? 
2- What are the effects of CB1R agonist, WIN55,212-2 (3, 10, 30 g/rat, i.c) on BP, HR 
and plasma NE in conscious freely moving rats? 
3-What are the effects of WIN55,212-2 (15 g/rat, i.c) on BP, HR, plasma NE and RVLM-
c-Fos expression in presence or absence of the CB1R antagonist, AM251? 
Specific Aim 2 studies tested the hypothesis that OX1R/orexin-A signaling in the RVLM is 
pivotal for the central CB1R-mediated pressor response in conscious rats. 
Rationale: Recent studies have suggested a crosstalk between CB1R and OX1R signaling. 
For example, functional relevance of the central interaction between the two receptors has been 
shown in feeding behavioral studies where orexin-A induced-feeding was abrogated by 
pretreatment with sub-anorectic doses of the CB1R antagonist SR141716A (Crespo, Heras et al. 
2008). Not only CB1R and OX1R activation triggers similar downstream signaling targets e.g. 
ERK1/2 phosphorylation; intriguingly, the CB1R antagonist SR-141716A, that does not have 
affinity for OX1R, attenuated the OX1R-evoked increase in pERK1/2 in cells co-expressing the 
two receptors, inferring a reciprocal physical interaction (macromolecule formation) between the 
two receptors (Hilairet, Bouaboula et al. 2003; Ellis, Pediani et al. 2006). Pertinent to the 
proposed hypothesis central administration of CB1R or OX1R agonists, elicits pressor response 
(Niederhoffer and Szabo 1999; Chen, Hwang et al. 2000; Niederhoffer and Szabo 2000; Zhang, 
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Fukuda et al. 2005). Although, orexin-A-containing neurons are exclusive to the hypothalamus, 
orexin-A immunoreactive (orexin-A-ir) fibers, were found in close proximity to catecholamine 
immunoreactive (CAir) neurons in the RVLM (Machado, Bonagamba et al. 2002; Ciriello, Li et 
al. 2003). Expression of the CB1R exhibits similar patterns in RVLM (Herkenham, Lynn et al. 
1991; Padley, Li et al. 2003). Collectively, these reported findings highlight the possibility that 
functional crosstalk between CB1R and OX1R/orexin-A in the RVLM might be involved in the 
blood pressure response elicited by the activation of either receptor in vivo. Studies under this 
aim addressed the following specific questions: 
1- Does central CB1R activation (WIN55,212-2) elevate RVLM-orexin-A levels? 
2- What are the BP and HR effects of graded doses of the OX1R agonist, orexin-A (0.3, 1, 
3 nmol/rat, i.c) in conscious freely moving rats? 
3- Does central OX1R blockade (SB-408124) attenuate orexin-A- and WIN55,212-2-
centrally-mediated cardiovascular effects? 
4- Does central CB1R blockade (AM251) attenuate orexin-A-mediated cardiovascular 
effects? 
Specific Aim 3 studies tested the novel hypothesis that PI3K/Akt-ERK1/2 signaling is 
pivotal for the central CB1R-mediated sympathoexcitation/pressor response. 
Rationale: The cellular mechanism(s) underlying the sympathoexcitatory/pressor effects of 
central CB1R activation are understudied. Cellular and behavioral (feeding) studies identified a 
crucial role for the PI3K/Akt and ERK1/2 pathway in CB1R-evoked pharmacological responses. 
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For instance, it was demonstrated that CB1R activation inhibits both PI3K/Akt and ERK1/2 
signaling in some in vitro studies (Ellert-Miklaszewska, Kaminska et al. 2005; Greenhough, 
Patsos et al. 2007). In contrast, CB1R activation caused rapid ERK1/2 phosphorylation via PI3K 
pathway in some cell lines, e.g. U373 MG human astrocytoma and prostate cells (Galve-Roperh, 
Rueda et al. 2002; Sanchez, Ruiz-Llorente et al. 2003). Further, systemic THC activated the 
PI3K/Akt pathway in mouse hippocampus, striatum, and cerebellum via a mechanism that does 
not involve activation of ERK1/2. Brainstem PI3K/Akt and ERK1/2 signaling play a tonic role in 
central control of blood pressure. It has been shown that prolonged inhibition of ERK1/2 
phosphorylation in the RVLM gradually lowered blood pressure in both normotensive and 
hypertensive rats (Seyedabadi, Goodchild et al. 2001). Moreover, activation of ERK1/2 signaling 
in the RVLM underlies Angiotensin II-mediated pressor responses (Chan, Hsu et al. 2005; Chan, 
Wang et al. 2007). Notably, PI3K/Akt signaling evokes a depressor response and its activation in 
NTS mediated insulin-evoked hypotensive and bradycardic responses (Huang, Lu et al. 2004). 
Importantly, it was shown that brainstem (RVLM and NTS) and hypothalamic (PVN) PI3K 
pathway is elevated in spontaneous hypertensive rats (SHR) compared to the normotensive 
counterparts, Wister-Kyoto rats (WKY) (Veerasingham, Yamazato et al. 2005; Zubcevic, Waki 
et al. 2009). In the latter study, chronic blockade of PI3K in the NTS resulted in exacerbation of 
hypertension in SHR but not WKY, suggesting a restraining role (depressor) for the PI3K 
pathway on BP in SHR. Collectively, the above discussed cellular and behavioral studies raised 
the interesting possibility that modulation of PI3K/Akt and or ERK1/2 signaling might underlie 
central CB1 receptor-mediated pressor response. Therefore, studies under this aim addressed the 
following specific questions: 
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1- Does i.c. WIN55,212-2 (15 g/rat, i.c) enhance ERK1/2 and Akt phosphorylation in the 
rat RVLM and NTS? 
2- What are the effects of PI3K inhibition (wortmannin) on the CB1R-evoked (WIN55,212-
2) dose-related pressor response? 
3- What are the effects of inhibition of ERK1/2 phosphorylation on the CB1R-evoked 
(WIN55,212-2) pressor effect? 
4- What are the effects of i.c. WIN55,212-2 on ERK1/2 and Akt phosphorylation in the 
RVLM and NTS of rats pretreated with the CB1R antagonist, AM251, the PI3K inhibitor, 
wortmannin or the ERK1/2 inhibitor, PD98059? 
Specific Aim 4 elucidated the novel hypothesis that the central CB1R-evoked pressor 
response is mediated via modulation of GABAergic neurotransmission in the brainstem. Studies 
under this aim were further expanded to investigate whether RVLM-p-nNOS/NO signaling is 
implicated in central CB1R-evoked pressor response. 
Rationale: Multiple lines of evidence has shown that that postsynaptically-released 
endocannabinoids act as retrograde secondary messengers at both inhibitory, as well as, 
excitatory synapses, to inhibit the release of GABA and glutamate, respectively (Vaughan, 
McGregor et al. 1999; Kreitzer and Regehr 2001; Ohno-Shosaku, Maejima et al. 2001). 
Therefore, Padley et al. and others have proposed that RVLM CB1R-evoked sympathoexcitation 
is, mediated via disinhibition of the tonic inhibitory (GABAergic) neurotransmission in the 
RVLM, which consequently results in increased central sympathetic outflow (Randall, Harris et 
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al. 2002; Padley, Li et al. 2003). To our knowledge, this was only tested in vitro, by Vaughan et 
al. in cultured RVLM neurons, where CB1R activation inhibited the release of GABA (Vaughan, 
McGregor et al. 1999). Whether modulation of GABAergic transmission mediated by CB1R 
activation, has a significant role in the central CB1R-evoked pressor response had not been 
investigated.  
CB1 receptor-mediated effects have been shown to involve activation of the neuronal nitric 
oxide synthase- nitric oxide (nNOS-NO) signaling pathway (Azad, Marsicano et al. 2001; Jones, 
Carney et al. 2008). Furthermore, studies on hippocampus suggest that NO is involved in 
depolarization-induced CB1R-mediated suppression of IPSCs as a retrograde signal molecule and 
that operation of this cascade is conditional on cholinergic receptor activation (Makara, Katona 
et al. 2007). Pertinent to the current investigation, nNOS-NO signaling in the RVLM has been 
shown to be critically implicated in the central regulation of autonomic functions (Martins-Pinge, 
Araujo et al. 1999; Martins-Pinge, Garcia et al. 2007; Mayorov 2007; Nassar and Abdel-Rahman 
2008). Yet, it remains unclear whether p-nNOS/NO signaling is implicated in the CB1R-evoked 
pressor response. Studies under this aim investigated the hypothesis that GABAA receptor/p-
nNOS/NO signaling is crucial to cardiovascular effects mediated via central CB1 receptor 
activation by addressing the following questions: 
1- What are the effects of inra-RVLM microinjection of WIN55,212-2 on BP, HR, RVLM 
p-nNOS and NO? 
2- What are the effects of GABAAR stimulation (muscimol) on the central CB1R-mediated 
effects on BP, HR and activity of catecholaminergic and nitroxidergic neurons? 
 CHAPTER TWO- MATERIALS AND METHODS 
2. 1. Preparation of the Rats 
Male Sprague-Dawley rats, weighing 300-350 g (Charles River, Raleigh, NC) were  
received and housed two per cage in a room with controlled environment at a constant 
temperature of 23 ± 1°C, humidity of 50% ± 10% and a  12:12-h light/dark cycle. Food (Prolab 
Rodent Chow, Prolab RMH 3000; Granville Milling, Creedmoor, NC) and water were provided 
ad libitum. All surgical and animal care procedures were performed in accordance with and 
approved by the Institutional Animal Care and use committee and in accordance with the 
Institute of Laboratory Animal Resources, (2010) Guide for the Care and Use of Laboratory 
Animals 8
th
 ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, 
National Research Council, Washington, D.C. 
2. 1. 1. Intra-arterial catheterization and intracisternal cannulation  
Intra-arterial catheterization and intracisternal cannulation (i.c) were performed as in 
reported studies by Abdel-Rahman et al., (Zhang and Abdel-Rahman 2005; Nassar and Abdel-
Rahman 2008). Five days before the experiment, rats were anesthetized with i.p ketamine (90 
mg/kg) and xylazine (10 mg/kg). A polyethylene catheter (PE50 connected to PE10) was placed 
in the abdominal aorta via the femoral artery for BP measurement. The catheters were advanced 
5 cm into the femoral vessels and secured with sutures. Finally, the catheters were tunneled 
subcutaneously and exteriorized at the back of the neck between the scapulae. The catheters were 
flushed with heparin in saline (200 U/ml) and plugged by stainless steel pins.  For (i.c) the head 
was placed in a David Kopf stereotaxic frame and a stainless steel guide cannula (23G; Small 
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Parts, Miami, FL) was implanted into the cisterna magna. The dura matter covering the foramen 
magnum was exposed. The guide cannula was passed between the occipital lobe and the 
cerebellum through a hole drilled 1 to 1.5 mm distal to the caudal edge of the occipital bone so 
that the guide cannula tip protruded into the cisterna magna. The cannula was secured in place 
with small metal screws and dental acrylic cement (Durelon; Thompson Dental Supply, Raleigh, 
NC). The patency of the guide cannula was verified when a spontaneous flow of cerebrospinal 
fluid was observed and by gross post-mortem histological verification after routine injection of 2 
L of fast green dye (EM Sciences, Cherry Hill, NJ) at the end of the experiment.  Incisions were 
closed by surgical staples and swabbed with povidone-iodine solution. Each rat received an 
intramuscular injection of 30,000U of penicillin G benzathine and penicillin G procaine in 
aqueous suspension (Durapen) and a subcutaneous injection of buprenorphine hydrochloride 
(Buprenex, 30 µg/kg) and was housed in a separate cage. 
2. 1. 2. Blood pressure (BP) and heart rate (HR) measurements 
On the day of experiment, arterial catheter was flushed with heparin 100 IU/ml saline and 
connected to a Gould-Statham pressure transducer (Oxnard-CA). BP was recorded by ML870 
(PowerLab 8/30), and analyzed using LabChart (v. 6) pro software (ADInstruments, Colorado 
Spring, CO). Data were continuously recorded and stored for offline analysis. Heart rate readings 
were extracted from BP recordings using the LabChart (v.6) blood pressure analysis module. 
Under these settings, four animals were connected simultaneously, each receiving different 
treatment for optimal comparisons. BP and HR were allowed to stabilize for at least 60 min;data 
collected during the last 30 min represented basal MAP and HR.  
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2. 2. Immunofluorescence 
2. 2. 1. Preparation of tissues  
A modified protocol similar to that previously reported (Wang and Abdel-Rahman 2005; 
Nassar and Abdel-Rahman 2006; Matias, Cristino et al. 2008) was used for brain tissues 
preparation before being processed for immunohistochemistry (IHC) or immunofluorescence 
(IF). At the conclusion of hemodynamic measurements, unless otherwise indicated, the rats were 
deeply anesthetized by sodium pentobarbital (i.p.), transcardially perfused with 4% 
paraformaldehyde in phosphate buffered saline (PBS) for 20 min with approximately 400 mL 
after flushing with ice-cold saline (100 mL). Brains were removed, and placed in the same 
fixative buffer for 24 h, then transferred to 30% sucrose in PBS solution, pH 7.4 and kept until 
they sank. Brains were then either directly sectioned or embedded in OCT and then flash frozen 
in 2-methylbutane (cooled on dry ice for at least 30 min). Serial coronal frozen sections of 30 m 
thickness of brainstem containing RVLM, rostrally from -12.8 to -11.8 mm, relative to bregma 
(Paxinos and Watson 2005) were cut at -24°C with a microtome cryostat (HM 505 E; Microm 
International GmbH, Walldorf, Germany) and collected in each well of a cell culture plate 
containing ice-cold PBS. Free-floating sections were then processed for (IF) or (IHC) whereas, 
for long-term storage, sections were kept at (–20°C) in cryoprotectant solution (50% PBS, 30% 
ethylene glycol, 20% glycerol). 
2.2. 2. Staining and image acquisition 
Free floating sections, prepared as above, were then washed 3X in TBS for 15 min, and 
incubated for 3 h in blocking buffer (1% bovine serum albumin, 5% normal donkey serum in 
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TBS containing 0.1% Triton X-100; TBST) at RT with continuous shaking, before they were 
incubated 48-72 h at 4ºC with shaking in specific antibody or antibodies mixture diluted in 
blocking buffer as indicated for each experiment. After being washed 3X in TBST, 
immunofluorescence was revealed by incubation for 2 h in fluorescent (e.g. FITC, Cy3 or Cy5) 
conjugated donkey anti IgG . 
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Fig. 2.1. Schematic of coronal section in rat brainstem showing sites of rostral 
ventrolateral medulla (RVLM), nucleus tractus solitarii (NTS) and adjacent anatomical 
landmarks used to identify each nucleus at -12.80 mm from the bregma. 4V: fourth ventricle;  
AmbC: ambiguus nucleus, combact part; Bo; Botzinger complex; C1: adrenaline cells; IOPr: 
Inferior Olive, principle nucleus; py: Pyramidal tract; solDL and solV: solitary tract 
dorsolateral and ventral part, respectively. Adapted from (Paxinos and Watson 2005) with 
modification.   
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Sections were washed twice in TBS in dark and mounted on slides and coverslipped with 
Vectashield mounting medium containing DAPI as counterstain (Vector Laboratories, 
Burlingame, CA) and left in dark overnight to harden. Images were acquired by multi-track 
acquisition mode to eliminate channels-cross talk, if needed, using confocal laser microscopy 
(Carl Zeiss LSM 510, Thornwood, New York). Representative images were edited by the Zeiss 
LSM Image Browser software (v 4.2) and Adobe Photoshop (v. CS4, Adobe Systems, San Jose, 
CA), where only image brightness and contrast only were adjusted for clarity. 
2. 3. Western Blot Analysis.  
A modified protocol from recent study (Bender and Abdel-Rahman 2009) was employed. 
Generally, at the conclusion of hemodynamic measurements, animals received a lethal dose of 
sodium pentobarbital (i.p.), brains were removed, flash frozen in 2-methylbutane (cooled on dry 
ice for at least 30 min), and stored at -80ºC until use. Brains were equilibrated to -20ºC and 
sectioned with a cryostat (HM505E; Microm International GmbH, Waldorf, Germany) rostrally 
to the NTS and RVLM according to atlas coordinates. Tissue from both nuclei was collected 
bilaterally using a 0.75 mm punch instrument (Stoelting Co., Wood Dale, IL), approximately -
12.8 to -11.8 or -13.92 to -12.84 mm, respectively, relative to bregma according to atlas 
coordinates (Paxinos and Watson 2005). Tissue was homogenized on ice by sonication in cell 
lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 
2.5 mM sodium pyrophosphate, 1 mM -glycerolphosphate, 1 mM activated sodium 
orthovanadate) containing protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, 
IN). After centrifugation at 4ºC at 10,600g for 20 min, protein in the supernatant was quantified 
using a standard Bio-Rad protein assay system (Bio-Rad Laboratories, Hercules, CA). Equal 
 37 
 
amounts of protein were denatured at 97ºC for 5 to10 min, separated on NuPAGE Novex Bis-
Tris 4 to 12% SDS-PAGE gels (Invitrogen, Carlsbad, CA) using MOPS NuPAGE running 
buffer, and electroblotted to nitrocellulose membranes in semi-dry transfer cell TRANS-BLOT 
SD (Bio-Rad Laboratories, Hercules, CA) using transfer buffer (containing 230 mM glycine, 25 
mM Tris, 0.7 mM SDS, 20% methanol) at 26 volts for 1 hr. Nonspecific binding sites on the 
membranes were blocked at room temperature using Odyssey blocking buffer (LI-COR 
Biosciences, Lincoln, NE) for 1 hr. Membranes were then incubated with a selected specific 
antibody according to experimental design (see methods under individual experiments). 
 
 
 
 
 CHAPTER THREE-CHARACTERIZATION OF CANNABINOID RECEPTOR AGONIST 
WIN55,212-2 CENTRALLY EVOKED SYMPATHOEXCITATION/PRESSOR RESPONSE 
IN CONSCIOUS RATS; INVOLVEMENT OF ROSTRAL VENTROLATERAL MEDULLA 
NEURONS 
3. 1. Abstract 
Previous studies on the cardiovascular effects of cannabinoids, mainly via cannabinoid 
receptor 1 (CB1R), have yielded controversial results perhaps due to the use of anesthesia.  
Therefore, it was important to investigate the central cardiovascular effects of the cannabinoid 
agonist WIN55,212-2 in conscious Sprague-Dawley rats to circumvent the confounding effects 
of anesthesia on these responses. Intracisternal (i.c) administration of WIN55,212-2 (3, 10, 30 
g/rat) in conscious freely moving rats (n=4) dose-dependently elevated mean arterial pressure 
(MAP), reduced heart rate (HR) and increased plasma norepinephrine (NE) levels; the latter 
reflects central sympathoexcitation. Further, the responses evoked by a median dose of 
WIN55,212-2 (15 g/rat, i.c) were abolished by the selective CB1R antagonist AM251 (30 
g/rat, i.c) indicating CB1R-mediated effects. Further, we measured the catecholaminergic 
(tyrosine hydroxylase immunoreactivity, TH-ir) neuronal activity, indirectly via a marker of 
neuronal activity, c-Fos, within the RVLM following activation of CB1R in the presence or 
absence of AM251. WIN55,212-2 (15 g/rat, i.c) significantly (P < 0.05) increased the 
percentage of TH-ir and nNOS-ir neurons expressing c-Fos; AM251 pretreatment mitigated the 
increase in RVLM-catecholaminergic neuronal activity. Taken together, these findings, highlight 
a pivotal role for the RVLM in the central WIN55,212-2 evoked pressor response in conscious 
rats. 
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3. 2. Introduction 
Cannabinoids elicit complex cardiovascular responses involving both peripheral and 
central sites of action via cannabinoid receptors; CB1 and CB2 (Gardiner, March et al. 2002; 
Niederhoffer, Schmid et al. 2003; Pfitzer, Niederhoffer et al. 2004; Seagard, Dean et al. 2004; 
O'Sullivan, Randall et al. 2007; Wheal, Bennett et al. 2007; Malinowska, Zakrzeska et al. 2010). 
The presence of anesthesia has dramatically confounded these responses (Stein, Fuller et al. 
1996; Lake, Martin et al. 1997; Gardiner, March et al. 2001) and introduced additional 
parameters to be considered upon investigation of the CB1R role in controlling cardiovascular 
functions; in particular the central part. For this reason, the cannabinoid-evoked cardiovascular 
effects in anesthetized animals are significantly different when compared to responses reported 
in studies conducted in conscious animals or in humans. Whereas, systemically administered 
cannabinoids caused hypotension in anesthetized animals, studies on conscious animals showed 
that CB1R activation via systemically administered cannabinoids elicits pressor response (Stein, 
Fuller et al. 1996; Gardiner, March et al. 2001; Randall, Harris et al. 2002; Randall, Kendall et 
al. 2004; Mendizabal and Adler-Graschinsky 2007). The latter findings are relevant because they 
replicate the responses reported in humans (Benowitz, Rosenberg et al. 1979; Foltin, Fischman et 
al. 1987; Sidney 2002).  
To our knowledge, only one study investigated the hemodynamic responses of centrally 
administered cannabinoids in conscious rabbits (Niederhoffer and Szabo 2000) and no other 
studies have reported such findings in conscious rats (Pfitzer, Niederhoffer et al. 2004). Our 
studies focus on cardiovascular responses elicited by activation of central CB1R, which are 
 40 
 
expressed in various brainstem nuclei that are implicated in the central regulation of 
cardiovascular function (Tsou, Brown et al. 1997; Padley, Li et al. 2003). 
Many brainstem nuclei might be implicated in the cardiovascular responses elicited by 
central CB1R activation; in this study, attention has been focused on the RVLM, which plays 
pivotal role in controlling sympathetic tone (Strack, Sawyer et al. 1989; Dampney, Polson et al. 
2003; Nassar and Abdel-Rahman 2006). The RVLM is the final supraspinal site within the 
central nervous system that contains tonically active pre-sympathetic neurons, which are 
regulated by an array of tonic excitatory and inhibitory inputs (Ross, Ruggiero et al. 1984; 
Guyenet, Filtz et al. 1987; Guyenet, Haselton et al. 1989). The mechanism by which the central 
CB1R activation induces sympathoexcitation is not fully delineated. The notion that presynaptic 
stimulation of CB1R modulates neurotransmitter release (Freund, Katona et al. 2003; Padley, Li 
et al. 2003; Piomelli 2003; Drew, Mitchell et al. 2008), and the in vitro findings that CB1R 
activation inhibited GABAergic transmission in cultured RVLM neurons (Vaughan, McGregor 
et al. 1999) have led to the suggestion that central CB1R-evoked sympathoexcitation could be 
mediated via indirect activation of pre-sympathetic neurons within the RVLM. Therefore, we 
tested the hypothesis that the RVLM neurons are implicated in CB1R-evoked 
sympathoexcitation/pressor responses. This was achieved by exploiting the rapid response of the 
immediate early gene c-Fos protein product, which has been extensively used as a marker of 
neuronal activity (Hirooka, Polson et al. 1997; Horiuchi, Potts et al. 1999; Dampney, Polson et 
al. 2003).  
In the current study, we investigated the effects of the CB1R agonist WIN55,212-2, 
administered into the cisterna magna, on blood pressure, heart rate and plasma norepinephrine 
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(NE) (an index of sympathetic activity)(Micalizzi and Pals 1979; Weinstock, Zavadil et al. 1979; 
Hubbard, Buchholz et al. 1986; Pfitzer, Niederhoffer et al. 2004) in conscious freely moving rats, 
in presence or absence of the selective CB1R antagonist, AM251. In a parallel experiment, c-Fos 
expression was evaluated to delineate whether RVLM neurons are implicated in the CB1R-
elicited pressor response. We have additionally examined the expression of CB1R (protein) in the 
RVLM as only one study reported the expression of CB1R mRNA without investigating its 
protein product (Padley, Li et al. 2003). 
3. 3. Material and Methods 
3. 3. 1. Measurement of plasma norepinephrine (NE) 
Plasma norepinephrine was measured using a commercially available ELISA kit (cat. # 17-
NORHU-E01-RES; ALPCO Diagnostics, Windham, NH) following the manufacturer‟s 
instructions. Data were represented as percentage change from baseline plasma NE levels prior 
to vehicle or WIN55,212-2 injection. 
3. 3. 2. Western blotting 
RVLM protein samples from naïve non-treated rats were prepared as detailed under 
general methods, Chapter 2, for detection of CB1R. Membranes were incubated overnight at 4ºC 
with either polyclonal rabbit anti-CB1R antibody (Ab) diluted 1:500 (Abcam, Cambridge, MA) 
or the same Ab preincubated with blocking peptide (CB1R-antigen) overnight at 4°C. 
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3. 3. 3. Immunofluorescence 
3.3. 3. 1. Tissue and slide preparation 
At the conclusion of the experiment, free-floating sections were prepared as detailed under 
general methods (see Chapter 2). For co-labeling and quantification of TH-ir neurons expressing 
c-Fos, brainstem sections containing the RVLM were incubated with either mixture of primary 
antibodies outlined in Table 3.1 for 48 h at 4 ºC. Sections were then washed and incubated with 
one of the mixtures of secondary antibodies for 2 h as indicated in Table 3.1.  
3. 3. 3. 2. Quantification of labeled neurons  
Images were acquired and projected simultaneously on the attached monitor for 
quantification of co-localization. For immunohistochemical analysis of brainstem sections, the 
RVLM of 4-6 sections per animal was examined in rostral–caudal sections -12.8 to -11.8 mm 
relative to the bregma. Criteria used to identify positively labeled cells were: c-Fos-ir labeling 
was identified as nuclear staining (red) with a visible nucleolus. TH-ir cells were identified by 
cytosolic labeling (green) with visible processes and a blank nuclear region. TH-ir neuron 
containing c-Fos were counted manually using 20 X objective. Cells were considered to be co-
labeled if the location of nuclear c-Fos staining corresponded to the blank region in cytosolic 
labeling of nNOS or TH-ir in the same focal plane. All slides were coded and the examiner was 
blinded to the treatment at all time.  
3. 3. 3. 3. Image acquisition and processing: 
Representative images were acquired and processed following procedures outlined under 
general methods (Chapter 2). 
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3. 3. 4. Drugs  
WIN55,212-2 and DMSO were purchased from Sigma-Aldrich (St. Louis, MO). AM251 
was purchased from Cayman Chemical (Ann Arbor, MI). Alkamus was purchased from Rhone-
Poulenc (Cranbury, NJ). WIN55,212-2 and AM251 (30 g/rat) were dissolved in (1:1:18) 
mixture of DMSO/ Alkamus/ sterile saline. All drugs were delivered i.c in a volume of 5 l/ rat. 
3. 4. Protocols and Experimental Groups 
3. 4. 1. Experiment 1: WIN55,212-2 dose-related centrally-elicited hemodynamic effects 
A pilot study showed that the use of previously reported doses of WIN55,212-2, in 
conscious rabbit (Niederhoffer and Szabo 2000) or anesthetized rats (Pfitzer, Niederhoffer et al. 
2004) failed in to elicit similar hemodynamic responses (n=3; data not shown). Therefore we 
have investigated the changes in BP, HR and plasma NE in freely moving rats in response to i.c. 
administration of WIN55,212-2 in a group of rats (n=4) that received 5 l vehicle and 3 
successive doses of WIN55,212-2 (3, 10, 30 g/rat, i.c). Injections were made into the cisterna 
magnum via a 30-guage stainless-steel injector extended 2.0 mm beyond the tip of the previously 
implanted guide cannula and connected to a 20 l Hamilton syringe through PE-10 tubing. 
WIN55,212-2 or vehicle doses were loaded together and separated by air bubbles to avoid any 
potential problems caused by frequent removal and reinsertion of the injector. Each dose or the 
vehicle was delivered in a total volume of 5 l by hand over one min and at least one hr lapsed 
between injections to allow BP and HR to return to baseline. 
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3. 4. 2. Experiment 2: Hemodynamic and neurochemical effects of i.c. WIN55,212-2 in 
presence or absence of central CB1R blockade (AM251) 
Four groups of rats (n=6-8) received WIN55,212-2 (15 g/rat, i.c); a dose selected based 
on the results of experiment 1 above or an equal volume of its vehicle 30 min after i.c. 
administration of the selective CB1R antagonist AM251 (30 g/rat) or an equal volume of 
vehicle. The dose of AM251 was chosen based on preliminary study where 3 doses were tested 
(10, 30, 100 g/rat, i.c). This dose range was based on a previous study (O'Sullivan, Randall et 
al. 2007; Wheal, Bennett et al. 2007). In all experimental groups, BP and HR were recorded as 
detailed under methods. Experiments were terminated 30 min after WIN55,212-2 or its vehicle 
administration. 
Brain tissues were processed for detection and quantification of c-Fos in C1 area of the 
RVLM, identified by positive labeling for tyrosine hydroxylase (TH-ir) as detailed under 
methods to delineate whether RVLM neurons are implicated in central cardiovascular effects 
evoked by WIN55,212-2. 
3.5. Statistical Analysis 
Mean arterial pressure (MAP) was calculated as: diastolic pressure + one third (systolic 
pressure - diastolic pressure). MAP and HR values are expressed as mean ± S.E.M. change from 
their respective baseline before AM251 treatment. Hemodynamic data were analyzed by 
repeated measures ANOVA using SPSS 16.0 statistical package for Windows®, for differences 
in time and treatment trends followed by a one way ANOVA to assess individual differences at 
different time points among different groups. Tukey‟s (equal variance) and Games Howell 
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(unequal variance) tests were used for post hoc analysis. Contrasts based on the t-test and the 
ANOVA error terms were used to compare pre-treatment-to-post-treatment values in each group. 
These contrasts examined whether there were drug-evoked changes from baseline. P < 0.05 was 
considered significant. A one-way ANOVA followed by Bonferroni comparison test was used to 
evaluate the effect of various treatments on c-Fos. P < 0.05 was considered significant. 
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Fig. 3.1. Time line for surgical procedures and experimental protocols for experiment 1. 
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Fig. 3.2. Time line for surgical procedures and experimental protocols for experiment 2. 
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Table. 3.1. Combination of primary and secondary antibodies used in 
colocalization studies of c-Fos and TH-ir in RVLM neurons. All secondary 
conjugated antibodies were purchased from Jackson Immunoresearch, CA. 
TH: tyrosine hydroxylase; Ab: antibody. 
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 c-Fos/TH 
1
st
 primary Ab 
1
st
 secondary Ab 
Mouse anti-TH (1:500; Chemicon., Temecula, CA) 
FITC conjugated donkey anti-mouse; 1:200 
2
nd
  primary Ab 
2
nd
  secondary Ab 
Rabbit anti-c-Fos (1:2000; Calbiochem, San Diego, CA) 
Cy3 conjugated donkey anti-rabbit, 1:200 
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3. 6. Results 
3. 6.1. Identification of cannabinoid receptor 1 in the rat RVLM 
Fig. 3.3 shows representative Western blots depicting RVLM CB1R with a predominant 
band at approximately 64 kDa. and two more bands at 53 and 37 kDa corresponding to different 
glycosylated and non-glycosylated forms of CB1R (Song C and Howlett 1995). The detected 
bands were undetectable in membrane (Fig. 3.3) that was prepared similarly and the anti-CB1R 
antibody was pre-incubated with its specific blocking peptide (antigen) recommended by the 
manufacturer (Abcam, Cambridge, MA) confirming the specificity of the utilized antibody. 
3. 6. 2. WIN55,212-2-evoked dose-related increases in MAP and plasma NE and 
bradycardia in conscious rats  
Baseline parameters (MAP, HR) were not significantly different in all groups used in the 
study (Table 3.1). Further, MAP and HR and plasma NE were similar following the different 
pretreatments (vehicle or AM251) at the time of WIN55,212-2 or vehicle injection. The mean 
Plasma NE value prior to vehicle or WIN55,212-2 injection was 1050 ± 80 pg/ml (n=26). The 
effects of the cannabinoid receptor agonist WIN55,212-2 on MAP, HR and percentage change of 
plasma NE are shown in Figs. 3.4 and 3.5. Three increasing doses of WIN55,212-2 (3, 10 and 30 
g/rat, i.c) dose-dependently increased MAP and reduced HR; plasma NE was also increased in 
a dose-dependent manner. The pressor effect of WIN55,212-2 peaked at approximately 7-10 min 
post-injection, and subsided by 30 min. Similarly, a significant (P < 0.05) increase in plasma NE 
paralleled the pressor response as it peaked at 10 min and subsided 30 min post-injection. On the 
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other hand, the bradycardic response was immediate and lasted longer than the increases in blood 
pressure and plasma NE (Fig. 3.4). 
3. 6. 3. Hemodynamic, biochemical and neurochemical effects of i.c WIN55,212-2 in the 
presence or absence of central CB1R blockade (AM251)  
The objective of this study was to verify the involvement of central CB1R in the 
WIN55,212-2-evoked pressor response and the potentially underlying causes of this response, 
the elevation in plasma NE and RVLM neuronal activation. We selected a dose of WIN55, 212-2 
(15 g/rat, i.c), which produced responses (MAP, HR and plasma NE) lower than those 
produced by the 30 g but higher than those produced by the 10 g WIN55,212-2 (Fig. 3.5). The 
CB1R antagonist AM251 (30 g/rat, i.c) or its vehicle was injected 30 min prior to WIN55 212-2 
or its vehicle. AM251 did not significantly alter the baseline of the measured parameters (Table 
3.1 and Fig. 3.5); however, it virtually abolished the pressor and bradycardic responses as well as 
the elevation of plasma NE elicited by subsequent WIN55,212-2 (15 g/rat, i.c) administration. 
WIN55,212-2 significantly (P < 0.05) enhanced c-Fos expression within the RVLM neurons, 
compared to vehicle treated animals (Figs. 3.6 and 3.7). AM251 (30 g/rat, i.c) had no 
significant effect on the basal c-Fos (P > 0.05). However, in animals pretreated with AM251, the 
WIN55,212-2-evoked increase in c-Fos expression in RVLM neurons was abrogated (Fig. 3.6 
and 3.7). 
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Fig. 3.3. Identification of CB1R in the RVLM by Western blotting. Rabbit anti-
CB1R antibody (1:500, Abcam, left lane), or antibody blocked by cprresponding 
CB1R antigen (right panel) incubated overnight with the membrane. The multiple 
bands that represented the CB1R (left lane) were virtually undetectable when the 
same Ab was pre-incubated with CB1R antigen.  
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Table. 3.2. MAP (mmHg) and HR (bpm) values before WIN55,212-2 and before 
and after pretreatment with the CB1R antagonist, AM251or corresponding vehicle, 
(when applicable). Values are means ± S.E.M 
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Treatment n 
Before 
 ____________________ 
After 
________________ 
MAP HR MAP HR 
Vehicle 4 115.0±6.0 395±12 ------ ----- 
3 gWIN55,212-2 4 111.3±3.0 375±10 ------ ----- 
10 gWIN55,212-2 4 108 ± 6.0 360± 11 ------ ----- 
30 gWIN55,212-2 4 112.0±6.0 356±15 ------ ----- 
Vehicle + 15 g WIN55,212-2 6 111.3±3.0 375±10 112.0±3.0 363±13 
AM251 + Vehicle 5 113.0 ±4.0 398±16 110.0 ±4.0 390±20 
Vehicle 4 117.0±6.0 400±12 115.0±4.0 410±12 
AM251 + 15 g WIN55,212-2 8 110.0±4.0 392±16 111.0±2.0 388±16 
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Fig. 3.4. WIN55,212-2 dose-related cardiovascular and plasma NE responses in 
conscious rats. Typical tracings depicting the dose-dependent changes in arterial pressure 
(AP) (top panel) elicited by WIN55,212-2. Changes in mean arterial pressure (MAP, top 
panel), heart rate (HR, middle panel) and percentage change of plasma NE from baseline 
(bottom panel) evoked by intracisternal WIN55,212-2 (WIN55; 3, 10 and 30 µg/rat) or an 
equal volume of vehicle (veh) in conscious rats (n=4) (bottom panel). One hour was allowed 
between consequetive doses to allow BP and HR to return to baseline values. Arrow marks 
WIN55,212-2 injection. Values are mean ± S.E.M. of 4 observations. * or # P<0.05 
significantly different compared to vehicle (veh) or low dose WIN55,212-2 (3 g WIN55) 
values, respectively.   
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Fig. 3.5. Cardiovascular and plasma NE responses elicited by i.c WIN55,212-2 in 
absence or presence of central CB1R blockade (AM251). Time course of changes in mean 
arterial pressure (MAP, top panel), heart rate (HR, middle panel) and percentage change 
of plasma NE from baseline (bottom panel) evoked by intracisternal WIN55,212-2 (Veh+15 
g WIN55) or an equal volume of its vehicle, indicated by the arrow (top panel), in 
conscious rats intracisternally pretreated, 30 minutes earlier, with the selective CB1R 
antagonist AM251 (30 g/rat) or equal volume of vehicle. Values are mean ± S.E.M. of 4 to 
8 observations. * or # P < 0.05 versus respective “AM251+Veh” or “AM251+15 g WIN” 
values, respectively 
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Fig. 3.6. Photomicrographs depicting CB1R-induced c-Fos expression in 
catecholaminergic neurons in the RVLM. Confocal dual-channel images showing 
tyrosine hydroxylase immunoreactive (TH-ir) neurons (green) and c-Fos 
immunoreactive (Fos-ir) cell nuclei (red) in RVLM of rats treated as described under 
methods section with (A) vehicle, (B) 15 g WIN55,212-2, (C) AM251 + vehicle and 
(D) AM251 + 15 g WIN55,212-2. White or yellow arrowheads indicate single 
labeled TH-ir neurons or c-Fos-ir cell nuclei, respectively. White arrows denote c-
Fos/TH colabeled cells. Scale bar, 20 µm. 
 
. 
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Fig. 3.7. Quantitative analysis of CB1R-induced c-Fos expression in RVLM 
catecholaminergic neurons. The number of TH-ir neurons, the number c-Fos/TH-
ir double-labeled neurons and the percentage of TH-ir neurons co-labeled with c-
Fos-ir in the RVLM of rats treated as described under methods with either vehicle, 
WIN55,212-2 (.15 g/rat, i.c), AM251 (30 g/rat, i.c), AM251 prior to 
WIN55,212-2, are shown. Bar graphs represent mean ± S.E.M. counts in coronal 
brainstem sections from 4-6/animal, (n=3-5)/group using one-way ANOVA 
followed by Bonferroni comparison test. * or # P <0.05 vs respective vehicle or all 
other treatments values, respectively. 
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3. 7. Discussion 
The most important findings of this study are: (i) i.c. WIN55,212-2, a non-selective CB1-
CB2 receptor agonist, elicited dose-dependent increases in blood pressure and plasma NE along 
with bradycardic response in conscious rats; (ii) these responses were virtually abolished by prior 
treatment with selective CB1R antagonist (AM251); (iii) activation of central CB1R 
(WIN55,212-2) enhanced RVLM-catecholaminergic activity (c-Fos) and this response was 
attenuated by prior blockade of central CB1R (AM251). Together, the present findings yield 
insight into the pivotal role of the enhanced sympathetic nervous system, at least in part at the 
RVLM level, in the pressor response elicited by central CB1R activation.  
The aim of this study was to investigate the centrally elicited hemodynamic effects of 
CB1R in a conscious animal model that will be used in the subsequent molecular studies and to 
determine if the RVLM is implicated in CB1R-evoked sympathoexcitation/pressor response. As a 
first step, we confirmed the expression of CB1R (protein) in the RVLM by detecting the 
calculated bands at 64 and 53 kDa of the N-glycosylated and non-glycosylated forms of CB1R, 
respectively (Song C and Howlett 1995). Although Padley et al. have reported the expression of 
CB1R gene in the RVLM (Padley, Li et al. 2003), to our knowledge, this is the first study to 
detect CB1R protein expression in the RVLM. 
In the present study, i.c administration of WIN55,212-2, dose-dependently increased MAP 
and NE  plasma levels, denoting an increase in central sympathetic tone in conscious rats. This 
finding contrasts with the reduction in plasma NE levels caused by peripheral CB1R activation 
(systemic cannabinoids delivery) (Niederhoffer, Schmid et al. 2003). Additionally, i.c. 
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WIN55,212-2 elicited a dose-dependent reduction in HR, which seems to be vagally-mediated 
because such bradycardic responses were absent in presence of atropine or vagotomy 
(Niederhoffer and Szabo 1999; Niederhoffer and Szabo 2000). The pressor response peaked at 5-
10 min after WIN55,2122 administration and lasted for additional an 15 min. However, the 
bradycardic response was immediate and lasted beyond the 30 min recording time. Our studies 
were conducted in conscious rats, to circumvent the negative impact of anesthesia that was 
shown to dramatically compromise cannabinoid evoked hemodynamic responses; in particular 
the central part (Stein, Fuller et al. 1996; Lake, Martin et al. 1997; Gardiner, March et al. 2001). 
Notably, the pressor response elicited by central WIN55,212-2 administration fully agrees with 
reported findings in experimental animals (Niederhoffer and Szabo 1999; Niederhoffer and 
Szabo 2000; Pfitzer, Niederhoffer et al. 2004), and reflects a similar response n humans (Foltin, 
Fischman et al. 1987; Sidney 2002). WIN55,212-2 doses used were relatively higher than those 
reported in previous studies (Pfitzer, Niederhoffer et al. 2004). This may be attributed to: (i) the 
use of conscious animals, which exhibit a higher sympathetic tone compared to anesthetized 
animals utilized; (ii) the difference in experimental set up; enough time was given, in our hand, 
between successive WIN55,212-2 doses to allow BP and HR return to baseline, whereas Pfitzer 
et al. allowed only 20 minutes interval between doses that resulted in cumulative responses.  
Because there are no currently available selective CB1R agonists, it was important that we 
confirm the involvement of CB1R in the pressor response elicited by WIN55,212-2. The latter is 
a mixed CB1R/CB2R agonist (Showalter, Compton et al. 1996; Griffin, Atkinson et al. 1998) and 
both receptors are expressed in the brainstem. The ability of the selective CB1R antagonist 
AM251 to virtually abolish the pressor response and the elevation of plasma NE levels elicited 
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by i.c. WIN55,212-2, agrees with reported findings (Niederhoffer and Szabo 1999; Niederhoffer 
and Szabo 2000; Pfitzer, Niederhoffer et al. 2004), and suggests that the pressor response was 
mediated via activation of central CB1R in our model system. It is important to note, however, 
that the lack of a change in blood pressure following AM251 administration argues against the 
involvement of central CB1R signaling in tonic control of blood pressure. 
Another main objective of the current study was to directly elucidate the role of the RVLM 
neurons in the central CB1R-evoked pressor response. We present the first in vivo evidence that 
central CB1R-evoked activation of RVLM neurons underlies, at least partly, the 
sympathoexcitation/pressor response elicited by central CB1R activation as demonstrated by the 
significant increase in catecholaminergic neurons (TH-ir) expressing c-Fos, a marker of neuronal 
activity, following i.c WIN55,212-2 versus vehicle treated animals. While the CB1R antagonist, 
AM251, has not altered the number of RVLM-TH-ir neurons expressing c-Fos compared to 
vehicle treated rats, it abrogated the WIN55,212-2-evoked increase in c-Fos expressing neurons. 
These neurochemical responses parallel and further confirm the blood pressure responses elicited 
by WIN55,212-2 and AM251 discussed above. 
In summary, the present study highlights the importance of the sympathoexcitation in the 
pressor response elicited by brainstem-CB1R activation. This new evidence in conscious rats 
yields insight into the RVLM as an important neuroanatomical substrate for CB1R agonists. On 
the other hand, the activation of RVLM-catecholaminergic neurons could have resulted from 
input from other neuronal pools that send projections to the RVLM because WIN55,212-2 was 
administered intracisternally in the present study. This important issue will be addressed in 
Chapter 4.  
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 CHAPTER FOUR-A PIVOTAL ROLE FOR BRAINSTEM OREXIN IN THE CENTRAL 
PRESSOR RESPONSE ELICITED BY THE CANNABINOID RECEPTOR AGONIST 
WIN55,212-2 IN CONSCIOUS RATS 
4. 1. Abstract 
Despite the well-established evidence for crosstalk between the cannabinoid receptor 1 
(CB1R) and the orexin receptor 1 (OX1R), a potential role for orexin in the pressor response 
mediated by central CB1R activation has not been explored. In the current study, we tested the 
novel hypothesis that brainstem OX1R/orexin-A signaling is implicated in the pressor response 
induced by central CB1R activation. We demonstrated, for the first time, a significant increase in 
orexin-A levels in the RVLM along with the pressor response elicited by intracisternal (i.c) 
injection of the CB1R agonist WIN55,212-2, (15 g/rat), in conscious rats. Additional studies in 
conscious rats established a causal role for orexin-A in WIN55,212-2 evoked pressor response 
because: (i) the WIN55,212-2-evoked pressor response and the elevation of RVLM orexin-A 
level were abolished by selective blockade of brainstem CB1R (AM251, 30 g/rat, i.c); (ii) the 
selective OX1R antagonist SB-408124 (10 nmoles/rat, i.c) abrogated the pressor response elicited 
by either orexin-A (3 nmoles/rat, i.c) or WIN55,212-2( 15 g/rat, i.c). On the other hand, central 
blockade of CB1R (AM251) had no effect on the pressor response elicited by i.c. orexin-A. 
Equally important, multiple labeling immunofluorescence revealed co-localization of CB1R, 
OX1R and orexin-A within the C1 area of the RVLM. Our findings yield new insight into a 
functional crosstalk between central CB1R and OX1R signaling and identify brainstem orexin-A 
as a possible neuronal mediator of CB1R-evoked pressor response in conscious rats. 
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4. 2. Introduction 
Recent in vivo evidence supports the demonstration of an interplay between CB1 and OX1 
receptors signaling (Hilairet, Bouaboula et al. 2003; Ellis, Pediani et al. 2006). For example, in 
feeding regulation studies, CB1R activation in lateral hypothalamic neurons results in modulation 
of orexin signaling (Huang, Acuna-Goycolea et al. 2007; Matias, Cristino et al. 2008). The 
functional relevance of the central interaction between the two receptors has been demonstrated 
in feeding behavioral studies where orexin-A induced-feeding was abrogated by pretreatment 
with sub-anorectic doses of the CB1R antagonist SR141716A (Crespo, Heras et al. 2008). This 
interaction is possible because CB1R modulates synaptic transmission of many neurotransmitters 
(Freund, Katona et al. 2003; Piomelli 2003; Drew, Mitchell et al. 2008) including orexins 
(Huang, Acuna-Goycolea et al. 2007; Matias, Cristino et al. 2008; Verty, Boon et al. 2009).  
Although, orexin-A neurons are exclusive to the hypothalamus, orexin-A immunoreactive 
(orexin-A-ir) fibers, were found in close proximity to catecholamine reactive (CAir) neurons in 
the RVLM (Machado, Bonagamba et al. 2002; Ciriello, Li et al. 2003). Importantly, the 
expression of CB1R exhibits similar patterns in RVLM (Herkenham, Lynn et al. 1991; Padley, Li 
et al. 2003). While most of the in vivo studies on OX1R signaling dealt with feeding behavior, a 
few studies have demonstrated the ability of orexin-A to elicit sympathoexcitation/ pressor 
responses following intracisternal (Chen, Hwang et al. 2000; Zhang, Fukuda et al. 2005), 
intracerebroventricular (Samson, Gosnell et al. 1999; Shirasaka, Nakazato et al. 1999) or 
microinjection into the RVLM (Chen, Hwang et al. 2000; Machado, Bonagamba et al. 2002; 
Ciriello, Li et al. 2003). Notably, the hypothalamic peptide orexin-A possesses 10-fold higher 
affinity than orexin-B, at the OX1R (van den Pol, Gao et al. 1998; Smart, Jerman et al. 1999). 
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Collectively, these reported findings highlight the possibility that functional crosstalk between 
CB1R and OX1R/orexin-A in the RVLM might be involved in the blood pressure response 
elicited by activation of either receptor in vivo.  
The aim of the present study was to test the hypothesis that OX1R/orexin-A signaling in 
the RVLM is essential for the central CB1R-mediated pressor response. To test this hypothesis, 
we conducted integrative cardiovascular studies on the effects of i.c. CB1R (WIN55,212-2) or 
OX1R (orexin-A) agonists on blood pressure and heart rate in conscious unrestrained rats. The 
experimental design permitted investigation of the effect of selectively blocking either receptor 
on the cardiovascular responses elicited by both agonists as well as the orexin-A levels 
(following CB1R activation) in the RVLM. Finally, we investigated whether the OX1R/orexin-A 
and CB1R are co-localized in catecholamine expressing neurons in the RVLM. 
4. 3. Materials and Methods 
4. 3. 1. Immunofluorescence 
The IF protocol detailed under general methods (Chapter 2) was utilized for colocalization 
studies. Sections were incubated for 48 h at 4ºC in the presence of Ab mixtures shown in Table. 
4.1. After washing 3X in TBST, multiple immunofluorescence was revealed by incubation for 2 
h in a mixture of fluorescent conjugated donkey anti IgG as indicated in Table 4.1. Specificity of 
the rabbit anti-orexin-A antibody (Novus Biologicals, Littleton, CO) was tested by Western 
blotting, which detected a single band at ~ 3.5 kDa corresponding to synthetic orexin-A (Phoenix 
Pharmaceutical; Burlingame, CA).  
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4. 3. 2. Orexin-A detection 
RVLM orexin-A levels were quantified using a standard ELISA kit (EK-003-30; Phoenix 
Pharmaceutical, Burlingame, CA) in accordance with procedures provided by the manufacturer 
and reported elsewhere (Feng, Vurbic et al. 2007). Briefly, at the conclusion of experiment 1 (see 
below), animals were euthanized, brains were removed, flash frozen in 2-methylbutane (cooled 
on dry ice for at least 30 min), and stored at -80ºC until use. Tissues from the bilateral RVLM 
were collected and pooled from each animal using a 0.75-mm punch tool (Stoelting Co., Wood 
Dale, IL), approximately -12.8 to -11.8 mm relative to bregma (Paxinos and Watson 2005). 
Samples were then acid-extracted, protein was quantified using a standard Bio-Rad protein assay 
system (Bio-Rad Laboratories, Hercules, CA) and assayed in duplicate wells for orexin-A. 
Values, for each sample, were averaged and expressed as ng/mg total protein. 
4. 3. 3. Drugs 
WIN55,212-2, SB-408124 and DMSO were purchased from Sigma-Aldrich (St. Louis, 
MO). AM251 was purchased from Cayman Chemical (Ann Arbor, MI). Alkamus was purchased 
from Rhone-Poulenc (Cranbury, NJ). WIN55,212-2 and AM251 were dissolved in (1:1:18) 
mixture of DMSO/Alkamus/sterile saline. Orexin-A was purchased from Phoenix 
Pharmaceutical (Burlingame, CA), freshly prepared in sterile saline and kept on ice during the 
experiment. SB-408124 was dissolved in 10% DMSO in saline. All drugs were delivered i.c in 
volume of 5 l/ rat over a period of 1-3 min. Each vehicle was tested on at least three animals 
prior its utilization. As none of these vehicles significantly changed the basal MAP and HR, we 
refer to all of them as (vehicle). 
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4. 4. Protocols and Experimental groups 
 Drug or vehicle injections were made into the cisterna magna of conscious unrestrained 
rats as detailed in Chapters 2 and 3 following procedures in previous studies (Zhang and Abdel-
Rahman 2005; Nassar and Abdel-Rahman 2006; Zhang and Abdel-Rahman 2008).  
4. 4. 1 Experiment 1: Effect of central CB1R activation (WIN55,212-2) on blood pressure 
and RVLM-orexin-A levels 
A total of 17 conscious rats, divided into 4 groups (n=3-5, each) were used in this part of 
the study. In all rats, blood pressure and heart were allowed to stabilize at baseline before 
drug/vehicle administration and were continuously monitored for 10-15 min after i.c. 
WIN55,212-2 or its vehicle. Two groups received WIN55,212-2 (15 g/rat, i.c) 30 min after i.c 
injection of the CB1R antagonist AM251 (30 g/rat) or an equal volume of vehicle. The other 
two groups served as controls and received only vehicle (i.c) or AM251 (30 g/rat, i.c) followed 
by vehicle. The brains were collected at a time that coincided with the peak pressor response (10-
15 min) for subsequent measurement of RVLM orexin-A levels as described under methods. 
Additional non-treated animals were prepared for multiple co-localization studies of 
CB1R/orexin-A or OX1R within the C1 area of RVLM. C1 area of the brainstem was identified 
anatomically as described under general methods (Chapter 2) and by positive labeling for 
tyrosine hydroxylase immunoreactive neurons.  
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4. 4. 2 Experiment 2: Effect of central OX1R blockade (SB-408124) on i.c. orexin-A-
mediated cardiovascular effects 
There are no reported studies on the dose range of the selective OX1R antagonist (SB-
408124) needed to block central OX1R in rats. Therefore, as a first step, it was important to 
replicate in our model system the dose-pressor response curve elicited by i.c. orexin-A (0.1, 1 
and 3 nmoles; n=4) based on reported dose-range for the peptide (Samson, Gosnell et al. 1999; 
Chen, Hwang et al. 2000). In a parallel preliminary study, we identified a dose of the selective 
OX1R antagonist (SB-408124) and verified its ability to block the central OX1R. Two additional 
groups of rats received i.c. orexin-A (3 nmoles; n=8) or an equal volume of sterile saline (n=5) 
10 min after i.c. of the OX1R receptor antagonist SB-408124 (10 nmoles/rat). Notably, the 3 
nmoles of orexin-A produced a comparable pressor response to that caused by i.c. WIN55,212-2 
(15 g) in the previous experiment. 
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Table. 4.1. Combination of primary and secondary antibodies used in 
colocalization studies of CB1R and orexin-A/OX1R. All secondary conjugated 
antibodies were purchased from Jackson Immunoresearch, CA. TH: tyrosine 
hydroxylase; Ab: antibody. 
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Targets CB1R/OX1R/n-tubulin 
1
st
 primary Ab 
1
st
 secondary Ab 
Mouse anti-GAD65 (1:400; Chemicon., Temecula, CA) 
FITC conjugated donkey anti-mouse, 1:200 
2
nd
  primary Ab 
2
nd
  secondary Ab 
Mouse anti-n-tubulin (1:1000; Abcam, Cambridge, MA) 
FITC conjugated donkey anti-mouse; 1:200 
3
rd
  primary Ab 
3
rd
  secondary Ab 
Goat anti-CB1R (1:200; Santa Cruz Biotech, Santa Cruz, CA) 
Cy5 conjugated donkey anti-goat;1:200 
 
Targets CB1R/orexin-A/GAD65 
1
st
 primary Ab 
1
st
 secondary Ab 
Rabbit anti-orexin-A (1:500; Novus Biologicals, Littleton, CO) 
Cy3 conjugated donkey anti-rabbit;1:200 
2
nd
  primary Ab 
2
nd
  secondary Ab 
Rabbit anti-OX1R (1:200; Alpha diagnostic, San Antonio, TX ) 
Cy3 conjugated donkey anti-rabbit; 1:200 
3
rd
  primary Ab 
3
rd
  secondary Ab 
Goat anti-CB1R (1:200; Santa Cruz Biotech, Santa Cruz, CA) 
Cy5 conjugated donkey anti-goat;1:200 
  
Targets CB1R/TH/n-tubulin 
1
st
 primary Ab 
1
st
 secondary Ab 
Rabbit anti-TH (1:500; Chemicon., Temecula, CA) 
Cy3 conjugated donkey anti-rabbit, 1:200 
2
nd
  primary Ab 
2
nd
  secondary Ab 
Mouse anti-n-tubulin (1:1000; Abcam, Cambridge, MA) 
FITC conjugated donkey anti-mouse; 1:200 
3
rd
  primary Ab 
3
rd
  secondary Ab 
Goat anti-CB1R (1:200; Santa Cruz Biotech, Santa Cruz, CA) 
Cy5 conjugated donkey anti-goat;1:200 
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Fig. 4.1. Time line for surgical procedures and experimental protocols for experiment 
4. 4. 3. * In the AM251 pretreated group animals received orexin-A, 30 min later. 
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4. 4. 3. Experiment 3: Effect of central OX1R blockade on the pressor response elicited 
by i.c WIN55,212-2 
The objective of this experiment was to determine whether the increased release in orexin-
A in the RVLM (experiment 4. 4. 1) plays a causal role in the pressor response elicited by i.c. 
WIN55,212-2. To achieve this goal, one group of animals (n=8) received WIN55,212-2 (15 g, 
i.c) 10 min after central OX1R blockade (SB-408124; 10 nmoles, i.c). WIN55,212-2 evoked 
responses in experiment 3. 4. 2, Chapter 3, were re-blotted and compared to responses after SB-
408124. We also determined in another group (n=7) whether central CB1R blockade (AM251; 30 
g/rat), 30 min earlier, influenced the pressor effect elicited by orexin-A (3 nmoles, i.c). The 
cardiovascular responses elicited by WIN55,212-2 or orexin-A in this experiment were 
compared to the corresponding pressor response elicited by either agonist in the absence of the 
antagonist.  
4. 5. Statistical Analysis 
Analysis of hemodynamic data was performed as detailed in Chapter 3. A one way 
ANOVA was used to evaluate the effect of various treatments on RVLM-orexin-A levels in the 
RVLM (experiment 4. 3. 1.), compared to the baseline (vehicle alone) followed by Bonferroni 
post-hoc test. P<0.05 was considered significant. All values are expressed as means ± S.E.M. 
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4.6. Results 
4. 6. 1. Colocalization of orexin-A/OX1R and CB1R in rat RVLM  
Multiple labeling findings in brainstem coronal sections revealed numerous orexin-A 
immunoreactive (orexin-A ir) fibers with characteristic varicose like structures as well as OX1R 
immunoreactive neurons (OX1R-ir) in close proximity to CB1R (CB1R-ir) labeled neurons in the 
RVLM (Fig. 4.2). Many of these neuronal structures displayed tyrosine-hydroxylase 
immunoreactivity which was used as  marker of catecholaminergic neurons (TH-ir). 
4. 6. 2. Activation of brainstem CB1R elicits increase in RVLM-orexin-A levels 
 Baseline MAP and HR were not significantly different in all groups of rats used in the 
study (Table 4.2.). Further, MAP and HR were similar following the different pretreatments 
(vehicle, AM251 or SB-408124) at the time of WIN55,212-2 or orexin-A injection. During the 
10-15 min of hemodynamic measurements, i.c. WIN55,212-2 (15 g/rat) elicited similar 
responses to those previously shown in experiment 3. 4. 2, (Chapter 3), where it increased MAP 
and induced bradycardia in conscious rats. These cardiovascular responses were mediated via 
activation of central CB1R because pretreatment with the selective CB1R antagonist AM251 (30 
g/rat, i.c) virtually abolished the pressor and bradycardic responses elicited by WIN55,212-2 
(15 g/rat, i.c). Measurement of orexin-A levels in the RVLM of WIN55,212-2 (15 g/rat, i.c) or 
control (vehicle)-treated rats revealed significantly higher (P < 0.05) levels of the peptide in the 
treatment group (Fig. 4.3). The WIN55,212-2 (15 g/rat)-evoked increase in RVLM orexin-A 
levels were abrogated by prior treatment with the selective CB1R antagonist AM251 (30 g/rat). 
AM251 alone had no effect on RVLM orexin-A levels (P > 0.05) (Fig. 4.3). 
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Table. 4.2. MAP (mmHg) and HR (bpm) values before and after pretreatment 
(preceding i.c. vehicle, WIN55,212-2 or orexin-A). Values are means ± S.E.M.  
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Treatment n 
Before 
____________________ 
After 
________________ 
MAP HR MAP HR 
Vehicle  3 115.0±6.0 395±12 110.0±6.0 386±11 
Vehicle + 15 g WIN55,212-2 5 111.3±3.0 375±10 108.0±5.0 350± 11 
AM251 + vehicle 4 108 ± 6.0 360± 11 114.3±3.0 390±10 
AM251 + 15 g WIN55,212-2 5 112.0±6.0 356±15 117.0±6.0 376±15 
Vehicle + orexin-A 6 111.3±3.0 375±10 112.0±3.0 363±13 
SB-408124 + Vehicle 5 113.0 ±4.0 398±16 110.0 ±4.0 390±20 
SB-408124 + orexin-A 8 117.0±6.0 400±12 115.0±4.0 410±12 
SB-408124 + WIN55,212-2 8 110.0±4.0 392±16 111.0±2.0 388±16 
AM251 + orexin-A 7   109.0±3.0 360±18 113± 3.0 375±18 
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Fig. 4.2. Photomicrographs depicting anatomical colocalization of orexin-A/OX1R 
along with CB1R in the rats RVLM by multiple labeling immunofluorescence. 
confocal images depict: (A) CB1R-ir (A1, blue), OX1R immunoreactive cells (OX1R-Air) 
(A2, red) and n-tubulin (A3, green). Merged image (A4) shows colocalization of CB1R 
and OX1R (purple) in rat RVLM. (B) CB1R-ir (B1, blue) colocalization with orexin-A 
immunoreactive fibers (orexin-Air) (B2, red) and GABA presynaptic maker (GAD65-ir) 
(B3, green) punctuated structures in rats RVLM. Merged image (B4) shows close 
anatomical localization of CB1R-ir, orexin-A-ir fibers, and GAD65-ir cells and punctate-
like structures indicative of pre-and postsynaptic localization. (C) CB1R immunereactivity 
(CB1R-ir) (C1, blue) within the ventrolateral medulla (RVLM) along with tyrosine 
hydroxylase immunoreactive neurons (TH-ir) (C2, red) and neuronal marker n-tubulin 
(A3, green). Merged image (C4) showed that CB1R-ir is localized on TH-ir (arrow) and 
non-TH-ir (arrowhead and asterisk) neuronal structures. 
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Fig. 4.3. Brainstem CB1R stimulation evoked elevation of RVLM-orexin-A levels. 
Changes in RVLM-orexin-A levels determined by ELISA as detailed under methods 
in four groups of animals (n=3-5 each) that received one of the following i.c. 
treatments: (Vehicle; n=3), (Vehicle + WIN55,212-2; n=5), (AM251 + vehicle; n=4) 
or (AM251 + WIN55,212-2; n=5). Animals were sacrificed at a time that preceded the 
WIN55,212-2-elicited pressor response. Bar graphs represent mean ± S.E.M. (n=3-5 in 
each group) using one-way ANOVA followed by Bonferroni comparison test. * or # P 
<0.05 compared to either “vehicle” or “AM251 + WIN55,212-2” values, respectively. 
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Fig. 4.4. Orexin-A-evoked dose-related hemodynamic effects in conscious 
rats. Dose-related changes in mean arterial pressure (MAP, top panel) and 
heart rate (HR, bottom panel) evoked by intracisternal (i.c) orexin-A (0.1, 1, 
3 nmoles/rat) (n=4) in conscious unrestrained rats. Values are mean ± S.E.M. 
of. * or # P < 0.05 versus respective “0.1 nmole orexin-A” or “1 nmole orexin-
A” values, respectively.  
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Fig. 4.5. Orexin-A-evoked hemodynamic effects in conscious rats is mediated 
via OX1R. Time course of changes in mean arterial pressure ((MAP, top panel) 
and heart rate (HR, bottom panel) evoked by i.c. 3 nmoles of orexin-A (Vehicle 
+ orexin-A) (n=6) or an equal volume of its vehicle, indicated by the arrow (top 
panel), in conscious rats pretreated, 10 min earlier, with the selective OX1R 
receptor agonist SB-408124 (10 nmole/rat, i.c)  or equal volume of vehicle (SB-
408124 + orexin-A) (n=8) and (SB-408124 + Veh) (n=5). Values are mean ± 
S.E.M.. * or # P < 0.05 versus respective “SB-408124+ Veh” or “SB-408124 + 
orexin-A” values, respectively. 
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Fig. 4.6. Brainstem OX1R signaling is pivotal to i.c. WIN55,212-2-evoked 
sympathoexcitation in conscious rats. Time course of changes in mean arterial 
pressure (MAP, top panel), heart rate (HR, bottom panel) evoked by i.c. 
WIN55,212-2 (15 g/rat) (Veh + WIN55) or an equal volume of its vehicle, 
indicated by the arrow (top panel), in conscious rats pretreated, 10 min earlier, 
with the selective OX1R antagonist SB-408124 (10 nmoles /rat, i.c)  or equal 
volume of vehicle (SB-408124 + WIN55) and (SB-408124 + Veh). Values are 
mean ± S.E.M. of 5 to 8 observations. * or # P < 0.05 versus respective “SB-
408124 +Veh” or “SB-408124 + WIN55” values, respectively. 
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Fig. 4.7. Blockade of brainstem CB1R signaling has no effect on i.c. orexin-A-
evoked sympathoexcitation in conscious rats. Time course of changes in mean 
arterial pressure (MAP, top panel), heart rate (HR, bottom panel) evoked by i.c. 
orexin-A (3 nmoles/rat) (Veh + orexin-A), (reblotted from Fig. 4.5.) or an equal 
volume of its vehicle, indicated by the arrow (top panel), in conscious rats pretreated 
30 min earlier with selective CB1R antagonist, AM251 (30 g /rat, i.c)  (n= 7) or 
equal volume of vehicle (AM251 + orexin-A) and (AM251 + Vehicle) the later was 
reblotted from Fig. 3.5. Values are mean ± S.E.M. of 5 to 8 observations. * P < 0.05 
vs respective (AM251+vehicle) values. 
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4. 6. 3. Central OX1R activation underlies orexin-A-evoked pressor response in 
conscious rats 
Intracisternal orexin-A (0.1, 1, 3 nmoles/rat) elicited dose-related increases in MAP in 
conscious unrestrained rats (Fig. 4.4). This pressor response was mediated via activation of 
OX1R because i.c. pretreatment with the selective OX1R antagonist SB-408124 (10 nmoles/rat) 
virtually abolished the orexin-A-evoked pressor response (Fig. 4.5).  
4. 6. 4. Evidence for the involvement of orexin-A/ OX1R signaling in WIN55,212-2-
evoked pressor response 
In this experiment, we employed a dose of the selective CB1R and OX1R antagonists that 
adequately blocked the pressor response elicited by i.c. administration of the respective agonist 
(see above). Pretreatment with the selective OX1R antagonist SB-408124 (10 nmoles/rat, i.c) 
attenuated the WIN55,212-2 (15 g/rat, i.c)-evoked pressor response (Fig. 4.6). On the other 
hand, pretreatment with the selective CB1R antagonist AM251 (30 g/rat, i.c) had no significant 
effect on the pressor response elicited by orexin-A (3 nmoles/rat, i.c) (Fig. 4.7).  
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4. 7. Discussion  
In this study we tested the hypothesis that orexin-A/OX1R signaling in the brainstem 
contributes to the central CB1R-evoked pressor response. The most important findings of the 
current study are: (i) centrally administered WIN55,212-2 (CB1R agonist) elicited significant 
increases in blood pressure and orexin-A levels in the RVLM; (ii) the pressor response and 
elevation of RVLM orexin-A levels elicited by WIN55,212-2 were virtually abolished by prior 
blockade of central CB1R (AM251); (iii) prior blockade of  central OX1R (SB-408124) 
abrogated the elevations in blood pressure caused by CB1R activation; (iii) by contrast, prior 
blockade of CB1R (AM251) had no effect on the pressor response elicited by central OX1R 
activation by orexin-A; (iv) CB1R and OX1R are colocalized in tyrosine hydroxylase expressing 
(presympathetic) neurons along with orexin-A fibers in the RVLM. These findings implicate 
brainstem orexin-A/OX1R in the central CB1R-evoked pressor response in conscious rats. 
The CB1R exists mostly presynaptically and modulates synaptic transmission of both 
inhibitory (GABA) and excitatory (glutamate) neurotransmitters (Freund, Katona et al. 2003; 
Piomelli 2003; Drew, Mitchell et al. 2008). For this reason, it has been suggested that central 
CB1R-evoked sympathoexcitation is probably mediated via indirect modulation of the 
sympathetic neuronal activity in the RVLM, by converging excitatory and inhibitory inputs 
(Pilowsky and Goodchild 2002; Padley, Li et al. 2003). In support of this notion, findings in 
cultured RVLM neurons showed that CB1R activation inhibited GABAergic transmission 
(Vaughan, McGregor et al. 1999). Whether this mechanism results in activation of excitatory 
mediators, e.g. orexins, within the brainstem has not been investigated. Therefore, we reasoned 
that orexin and its receptors in the RVLM might play important role in the CB1R-mediated 
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pressor response because in vitro evidence suggests crosstalk between the CB1R and orexin 
systems (Hilairet, Bouaboula et al. 2003; Ellis, Pediani et al. 2006). Further, such crosstalk is 
functionally relevant as indicated by in vivo (feeding) studies (Crespo, Heras et al. 2008; Verty, 
Boon et al. 2009). Perhaps a potential crosstalk between these two systems in a neuronal pool 
that controls sympathetic flow (RVLM) has remained unexplored because orexins-containing 
neurons are restricted to the lateral hypothalamic area (de Lecea, Kilduff et al. 1998; Sakurai, 
Amemiya et al. 1998). Nonetheless, the axons of these neurons innervate different areas of the 
CNS, including the medullary cardiovascular regulatory nuclei RVLM and NTS (Machado, 
Bonagamba et al. 2002; Zheng, Patterson et al. 2005). Further, locally injected orexins directly 
excite RVLM presympathetic neurons (Chen, Hwang et al. 2000; Machado, Bonagamba et al. 
2002; Huang, Dai YW et al. 2010). In support of our hypothesis, we demonstrate, for the first 
time, that central CB1R activation significantly elevated orexin-A levels in the RVLM along with 
the pressor response. It was important, however, to determine if the increase in RVLM-orexin-A 
levels caused by WIN55-212-2 was CB1R-mediated and plays a causal role in the pressor 
response. Both assumptions were confirmed because selective blockade of central CB1R 
(AM251, i.c) abrogated both the neurochemical and blood pressure responses elicited by 
WIN55,212-2.  
In agreement with reported findings (Chen, Hwang et al. 2000), we show that i.c orexin-A 
elicited dose-dependent increases in MAP and HR in conscious rats. Because orexin-A has 10-
fold higher affinity for OX1R, unlike OX2R that possesses equal sensitivity to both orexins-A 
and B (Sakurai, Amemiya et al. 1998), we reasoned that orexin-A-evoked hemodynamic 
responses are mediated via OX1R. Contrary to this view, however, recent findings, which may 
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have been confounded by the use of anesthesia, suggest that i.c. orexin-A elicits cardiovascular 
responses, mostly via OX2R activation, with little contribution from OX1R (Huang, Dai YW et 
al. 2010). Nonetheless, the present finding that blockade of central OX1R (SB-408124, i.c)  
abrogated the orexin-A-evoked pressor response along with the following reported findings 
support our conclusion that the central pressor effect elicited by orexin-A is mediated via OX1R 
activation: (i) OX1R antagonist (SB-334867), but not OX2R-antiserum, totally abolished the 
cardiovascular responses elicited by intra-NTS (Shih and Chuang 2007) or i.c.  (Huang, Dai YW 
et al. 2010) orexin-A; (ii) orexin-A produced approximately 2 fold increases in 
MAP/sympathetic activity compared to the effects produced by same dose of orexin-B (Samson, 
Gosnell et al. 1999; Shirasaka, Nakazato et al. 1999; Chen, Hwang et al. 2000; Shih and Chuang 
2007). Together, we concluded that the pressor response elicited by i.c. orexin-A in our model 
system is mediated via central OX1R activation. We, then, utilized a dose of the OX1R selective 
antagonist SB-408124, which appropriately blocked the pressor response elicited by i.c. orexin-
A, to support our hypothesis that orexin-A signaling in the brainstem plays a pivotal role in the 
CB1R-mediated pressor response. .  
We present the first in vivo evidence that prior central blockade of OX1R (SB-408124) 
abolished the central CB1R (WIN55,212-2)-evoked pressor response. This finding is in line with 
the molecular and behavioral (feeding) studies that suggest reciprocal interactions between CB1R 
and OX1R (Hilairet, Bouaboula et al. 2003; Ellis, Pediani et al. 2006; Crespo, Heras et al. 2008). 
Indeed, it is not clear at what level these two receptors interact in central cardiovascular 
regulating areas. Nevertheless, our study has established a link between CB1R-evoked release of 
orexin-A and activation of OX1R in the RVLM in the pressor response elicited by central CB1R 
 100 
 
activation. Importantly, blockade of brainstem CB1R (AM251) did not alter the hemodynamic 
effects elicited by i.c. orexin-A. This latter observation strongly suggests that the i.c. orexin-A-
mediated pressor response is not dependent on CB1R signaling. This finding might be 
organ/tissue dependent because the CB1R antagonist SR-141716A attenuated the OX1R-evoked 
increase in p-ERK1/2 in cells co-expressing the two receptors (Hilairet, Bouaboula et al. 2003).  
In summary, we provide the first evidence for a functional crosstalk between cannabinoid 
and orexin systems within the medullary cardiovascular controlling centers. CB1R activation in 
the brainstem elicited a pressor response along with an elevation of orexin-A levels in the 
RVLM. Importantly, blockade of orexin-A/OX1R signaling abrogated the CB1R-evoked pressor 
response. On the other hand, the orexin-A/OX1R-evoked pressor response was not affected by 
blockade of CB1R. Colocalization studies have unraveled close proximity of orexin-A/OX1R to 
CB1R labeled neurons and punctuated structures, which support the pharmacological findings. It 
is important to highlight that characterizing the interaction between orexins and cannabinoids is 
clinically relevant given the established link between hypertension and obesity. 
 
 CHAPTER FIVE-DIFFERENTIAL MODULATION OF BRAINSTEM PI3K/Akt AND 
ERK1/2 SIGNALING UNDERLIES CENTRALCB1 RECEPTOR-MEDIATED PRESSOR 
RESPONSE IN CONSCIOUS RATS 
5. 1. Abstract 
We have previously shown that central activation of CB1R (WIN55,212-2) elicits pressor 
response in conscious rats. The cellular mechanisms that underlie the WIN55,212-2 pressor 
effect are not known. Because cellular and behavioral studies have identified a role for the 
PI3K/Akt and ERK1/2 pathway in CB1R signaling, we tested the hypothesis that brainstem 
CB1R-mediated modulation of PI3K/Akt and ERK1/2 signaling underlies the WIN55,212-2-
mediated pressor response. Intracisternal injection (i.c) of 15 g WIN55,212-2 significantly 
increased ERK1/2 and decreased Akt phosphorylation in the rostral ventrolateral medulla 
(RVLM) and the nucleus tractus solitarii (NTS). The cellular responses elicited by central CB1R 
activation were abrogated by pretreatment with the selective CB1R antagonist AM251 (30 g/rat, 
i.c). Further, pretreatment with PD98059 (ERK/MEK inhibitor, 10 g/rat, i.c) attenuated the 
WIN55,212-2-mediated pressor response and the increase in neuronal pERK phosphorylation. 
On the other hand, i.c. wortmannin (PI3K inhibitor, 0.428 g/rat) pretreatment augmented the 
dose-dependent pressor response and the elevation in neuronal pERK phosphorylation elicited by 
WIN55,212-2 (7.5 or 15 g/rat, i.c). The present study yields new insight into the role of the 
brainstem ERK1/2 and PI3K/Akt pathway in the pressor response elicited by central CB1R 
activation. 
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5. 2. Introduction 
The cellular mechanism(s) that underlie(s) the pressor effects of central CB1R activation 
are understudied. Cellular and behavioral studies have identified a crucial role for the PI3K/Akt 
and ERK1/2 signaling in many CB1R-evoked actions. For example, CB1R activation causes rapid 
ERK1/2 phosphorylation that is PI3K-dependent in some neuronal cell lines, e.g. U373 MG 
human astrocytoma cells (Galve-Roperh, Rueda et al. 2002), but not in hippocampal neurons 
(Derkinderen, Valjent et al. 2003). This difference might be accounted for, at least partly, by the 
dependence of PI3K/Akt signaling on ERK1/2 activation in some tissues but not in others. This 
notion is supported by the in vitro study showing that the (9)-THC-mediated anti-cancer effect 
in human prostate cells involved PI3K/Akt and ERK1/2 signaling pathway activation (Sanchez, 
Ruiz-Llorente et al. 2003). By contrast, systemic THC activated the PI3K/Akt pathway in mouse 
hippocampus, striatum, and cerebellum via a mechanism that does not involve activation of 
ERK1/2 (Ozaita, Puighermanal et al. 2007). On the other hand, it was demonstrated that CB1R 
activation inhibits both PI3K/Akt and ERK1/2 signaling in some in vitro studies (Ellert-
Miklaszewska, Kaminska et al. 2005; Greenhough, Patsos et al. 2007).   
Notably, brainstem ERK1/2 signaling plays an important role in central control of blood 
pressure. Prolonged inhibition of ERK1/2 phosphorylation in the RVLM gradually lowered 
blood pressure in both normotensive and hypertensive rats (Seyedabadi, Goodchild et al. 2001). 
Furthermore, both short and long-term activation of ERK1/2 underlies the angiotensin II-
mediated pressor response in the RVLM (Chan, Hsu et al. 2005; Chan, Wang et al. 2007). 
However, previous reports from the advisor‟s laboratory have shown that ERK1/2 
phosphorylation in the RVLM plays a causal role in the acute hypotensive response elicited by 
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activation of central 2A adrenergic and imidazoline receptors (Zhang and Abdel-Rahman 2005; 
Nassar and Abdel-Rahman 2008). Notably, PI3K/Akt signaling evokes a depressor response and 
its activation in the NTS mediates insulin-evoked hypotensive and bradycardic responses 
(Huang, Lu et al. 2004). Importantly, it was shown that both the brainstem (RVLM and NTS) 
and the hypothalamic (PVN) PI3K pathway is elevated in spontaneous hypertensive rats (SHR) 
compared to the normotensive counterparts, Wister-Kyoto rats (WKY) (Veerasingham, 
Yamazato et al. 2005; Zubcevic, Waki et al. 2009). In the latter  study, chronic blockade of PI3K 
in the NTS resulted in exacerbation of hypertension in SHR but not WKY, suggesting a 
restraining (depressor) role for PI3K pathway on BP in SHR. Importantly, indirect evidence 
based on studies in cultured neurons implicates ERK1/2 and PI3K/Akt signaling in CB1R 
modulation of neuronal signaling (Vaughan, McGregor et al. 1999; Wang, Liu et al. 2003); 
(Huang, Lu et al. 2004; Wang, Ou et al. 2005). Whether PI3K/Akt and or ERK1/2 signaling are 
involved in the pressor response elicited by central CB1R activation has not been investigated. 
The aim of the present study was to test the novel hypothesis that PI3K/Akt and/or ERK1/2 
signaling contributes to the central CB1R-mediated sympathoexcitation/pressor response. To test 
this hypothesis, we investigated the effect of i.c WIN55,212-2 on MAP and HR and the 
associated changes in phosphorylation of Akt, a PI3K downstream effector, and ERK1/2 in the 
RVLM and NTS. To ascertain a causal involvement of the observed changes in these signaling 
molecules in the central CB1R-mediated pressor response, we investigated the effects of 
pretreatment with CB1R antagonist (AM251), PI3K inhibitor (wortmannin) and ERK1/2 
inhibitor (PD98059) on the neurochemical (pAkt and pERK1/2) and blood pressure responses 
elicited by CB1R activation.  
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5. 3. Materials and Methods 
5. 3. 1. Western Blotting  
Samples were obtained at the conclusion of the hemodynamic measurement and prepared 
for western blotting to measure changes in Akt and ERK1/2 phosphorylation in the RVLM and 
NTS. Nitrocellulose membranes were prepared as described under general methods (Chapter 2) 
and then incubated for 48 hr at 4ºC with mixture of mouse monoclonal anti-phospho-Akt 
antibody (pSer473) (1:1000; cat. # 4051S) and rabbit polyclonal anti-Akt antibody (1:1000; cat. 
# 9272) or mouse monoclonal anti-phospho-ERK1/2 (T202/Y204) antibody (1:000; cat.# 9106S) 
and rabbit polyclonal anti-ERK antibody (1:1000; cat.# 9102) in Odyssey blocking buffer. All 
four antibodies were purchased from Cell Signaling Technology (Danvers, MA). Membranes 
were washed 4x with PBST then incubated for 60 min at room temperature with mixture 
containing IRDye680-conjugated goat anti-rabbit and IRDye800-conjugated goat anti-mouse 
(1:1500; LI-COR Biosceinces, Lincoln, NE). Membranes were washed 4x with PBST and once 
in PBS before being scanned. Bands representing phosphorylated and total protein were detected 
simultaneously using the Odyssey dual infrared fluorescence scanner (LI-COR Biosciences, 
Lincoln, NE). All data were averaged values of integrated density ratio of phosphorylated protein 
(pAkt or pERK1/2) normalized to corresponding total protein (tAkt or ERK1/2) expressed as 
percentage of control (vehicle), analyzed with Odyssey application software v.3 (LI-COR 
Biosciences, Lincoln, NE). 
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5. 3. 2. Drugs  
WIN55,212-2, wortmannin, PD98059 and DMSO were purchased from Sigma-Aldrich (St. 
Louis, MO). AM251 was purchased from Cayman Chemical (Ann Arbor, MI). Alkamus was 
purchased from Rhone-Poulenc (Cranbury, NJ). WIN55,212-2 and AM251 (30 g/rat) were 
dissolved in (1:1:18) mixture of DMSO/Alkamus/sterile saline. Wortmannin was dissolved in 
10% DMSO in saline (1nmole ~ 0.4283 g/rat). Wortmannin dose and vehicle were based  on 
previous report (Narita, Ohnishi et al. 2002). PD98059 was dissolved in DMSO (10 g/rat) as in 
a previous study (Zhang and Abdel-Rahman 2005). Each vehicle was tested on at least three 
animals prior to its utilization. As none of these vehicles significantly changed the basal MAP 
and HR, we refer to all of them as (vehicle). 
5. 4. Protocols and experimental groups 
5. 4. 1. Experiment 1: Effects of i.c. WIN55,212-2 on RVLM and NTS Akt and ERK1/2 
phosphorylation 
We investigated the effects of i.c WIN55,212-2 on Akt/ERK1/2 phosphorylation in the 
brainstem at a time that preceded the pressor response as was previously discussed in Chapter 3. 
Brain tissues were collected from animals sacrificed 5 min after i.c. WIN55,212-2 (15 g/rat) or 
vehicle (n=3-5) and prepared for Western blotting as detailed under methods to detect and 
quantify phosphorylated Akt (pAKt) and ERK1/2 (pERK1/2) phosphorylation in the RVLM and 
NTS. 
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Fig. 5.1. Time line for surgical procedures and experimental protocols for studies 
under this aim. * In the PD98059 pretreated group animals received WIN55,212-2, 20 
min later. 
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5. 4. 2. Experiment 2: Effect of PI3K inhibition on the dose-related pressor response 
elicited by central WIN55,212-2 administration 
This experiment aimed to elucidate the effect of PI3K/Akt inhibition (wortmannin) on the 
WIN55,212-2-evoked pressor response. Four groups (n=5-8) of rats received wortmannin (0.428 
g) 30 min prior to WIN55,212-2 (7.5 or 15 g/rat, i.c) or its vehicle. Hemodynamic 
measurements were continued for 30 min after WIN55,212-2 or vehicle. The data were 
compared to the hemodynamic effects of WIN55,212-2 given alone or its vehicle as reported in 
Chapter 3, experiment 3. 4. 2. 
5. 4. 3. Experiment 3: Effect of ERK1/2 inhibition on WIN55,212-2 centrally-elicited 
hemodynamic effects  
In this experiment we sought to delineate the effect of ERK1/2 inhibition on WIN55,212-
2-mediated central pressor and bradycardia responses. BP and HR were recorded in two groups 
of rats (n=6-8) that received the pharmacological ERK1/2 inhibitor, PD98059 (10 g/rat, i.c) 20 
min before WIN55,212-2 (15 g/rat, i.c) or its vehicle.  
Furthermore, we investigated the effect of i.c. WIN55,212-2 on phosphorylation levels of 
NTS and RVLM-Akt and ERK1/2 following blockade of CB1R (AM251), PI3K (wortmannin) or 
ERK1/2 (PD98059) signaling, by collecting brain tissues (NTS and RVLM) at the completion of 
the above experiments (5. 4. 2) and (5. 4. 3) and from animals in experiment (3. 4. 2) Chapter 3. 
Phosphorylation levels of Akt and ERK1/2 in NTS and RVLM neurons were measured by 
Western blotting and compared to corresponding total protein as detailed under methods.  
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5. 5. Statistical Analysis 
Analysis of hemodynamic data was performed as detailed in Chapter 3. A one-way 
ANOVA was used to evaluate the effect of various treatments on pAkt and pERK1/2 in the NTS 
or RVLM in experiments 5. 4. 2 and 5. 4. 3. P < 0.05 was considered significant. 
5. 6. Results 
Baseline MAP and HR were not significantly different in all groups of rats used in the 
study (Table. 5.1). Further, MAP and HR were similar following different pretreatments 
(vehicle, wortmannin or PD98059) at the time of WIN55,212-2 or vehicle injection (Table. 5.1).  
5. 6. 1. WIN55,212-2 enhances pERK1/2 and reduces pAkt in NTS and RVLM neurons 
WIN55,212-2 (15 g/rat, i.c) increased MAP and reduced HR as previously shown in 
Chapter 3; however, animals were sacrificed 5 min after treatment, at a time that preceded the 
peak pressor response. pERK1/2 phosphorylation was significantly (P < 0.05) elevated in NTS 
and RVLM of animals treated with WIN55,212-2 compared to vehicle treated animals as shown 
in (Fig. 5.2). Further, i.c. WIN55,212-2 significantly lowered NTS and RVLM pAkt 
phosphorylation compared to vehicle treated animals (P < 0.05). Fig. 5.2 shows representative 
pERK1/2 and pAkt bands along with total protein bands obtained as described under methods 
from representing animals for each WIN55,212-2 (n=5) or vehicle (n=3) treated groups. 
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Table. 5.1. Baseline MAP (mmHg) and HR (bpm) values before and after 
pretreatment (preceding i.c. vehicle or WIN55,212-2). Values are means ± S.E.M. 
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Treatment n 
Before 
 ____________________ 
After 
________________ 
MAP HR MAP HR 
Vehicle + 7.5 g WIN55,212-2 6 111.3±3.0 375±10 108.0±5.0 350± 11 
Wortmannin + Vehicle 5 112.0±6.0 356±15 117.0±6.0 376±15 
Wortmannin + 7.5 g WIN55,212-2 8 112 ± 6.0 360± 11 111.0 ±5.0   380±10 
Wortmannin + 15 g WIN55,212-2 8 111.3±3.0 375±10 112.0±3.0 363±13 
PD98059 + Vehicle 5 113.0 ±4.0 398±16 110.0 ±4.0 390±20 
PD98059 + 15 g WIN55,212-2 8 117.0±6.0 400±12 115.0±4.0 410±12 
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Fig. 5.2. Intracisternal WIN55,212-2 reduces Akt and enhances ERK1/2 
phosphorylation in NTS and RVLM neurons. 
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5. 6. 2. PI3K inhibition exacerbates the dose-dependent pressor response elicited by 
central CB1R activation.  
Pretreatment with the PI3K inhibitor, wortmannin (0.42 g/rat, i.c) significantly enhanced 
the WIN55,212-2 (15 g i.c)-evoked pressor and bradycardic responses (Fig. 5.3.B, re-blotted 
from Fig. 3.5, Chapter 3). To further confirm the involvement of PI3K phosphorylation in the 
WIN55,212-2-evoked pressor response, we investigated the effect of wortmannin pretreatment 
on a modest pressor response elicited by a lower dose of WIN55,212-2 (7.5 g/rat, i.c) in an 
additional group of rats. As shown in Fig. 5.3.A, pretreatment with wortmannin significantly 
enhanced the pressor response elicited by WIN55,212-2 (7.5 g/rat, i.c). However, wortmannin 
did not significantly alter the bradycardic effect of WIN55,212-2 (7.5 g) at this dose. 
Wortmannin pretreatment did not significantly alter baseline MAP or HR, Table. 5.1. 
5. 6. 3. ERK1/2 inhibition (PD98059) attenuates the pressor response elicited by central 
CB1R activation 
To investigate whether brainstem pERK1/2 signaling is implicated in the central CB1R-
mediated pressor response, conscious rats were pretreated with the MEK/ERK/1/2 inhibitor, 
PD98059, before WIN55,212-2 (15 g, i.c). PD98059 (10 g/rat, i.c) had no significant effects 
on baseline MAP and HR during the observation period (Table. 5.2). However, PD98059 
pretreatment significantly attenuated the pressor response elicited by central CB1R activation 
(Fig. 5.4).  
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5. 6. 4. Neurochemical effects of WIN55,212-2 (pAkt and pERK1/2) in the presence or 
absence of AM251, wortmannin or PD98059 in rat NTS and RVLM 
These molecular studies were undertaken to complement the findings with the 
pharmacological interventions described above and to more directly elucidate the role of the 
pAkt-ERK1/2 pathway in the pressor response elicited by central CB1R activation. Compared to 
vehicle treated rats, WIN55,212-2 elicited a significant (P < 0.05) elevation in ERK1/2 
phosphorylation and produced a dose-related reduction in Akt phosphorylation in the RVLM and 
NTS (Fig. 5.5 A and D) and (Fig. 5.6 A and D). Further, these WIN55,212-2-evoked 
neurochemical responses were abrogated by AM251 pretreatment (Fig. 5.5 A and D, and Fig. 5.6 
A and D). Further, PD98059 abrogated the WIN55,212-2-induced reduction in Akt 
phosphorylation (Fig. 5.5 C and F). Finally, PD98059 abrogated (P < 0.05), while wortmannin 
slightly enhanced (P > 0.05) the WIN55,212-2-evoked upregulation of ERK1/2 phosphorylation 
in the RVLM and NTS (Fig. 5.6 B, C, E and F). 
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Fig. 5.3. PI3K inhibition exacerbates the dose-dependent pressor response elicited 
by central CB1R activation. Time course of changes in mean arterial pressure 
(MAP) and heart rate (HR) evoked by intracisternal injection of WIN55,212-2 in 
presence or absence of PI3K inhibition. Effects of WIN55,212-2 (WIN; 7.5 g/rat) in 
A) or (WIN; 15 g/rat) in B) or an equal volume of its vehicle (Veh1) in conscious rats 
pretreated, 30 minutes earlier, with wortmannin (WORT) [phosphatidylinositol 3-
kinase (PI3K) inhibitor, 0.428 g/rat, i.c.] or an equal volume of its vehicle (Veh2). A) 
* or # P < 0.05 versus respective “Veh2 + Veh1” and “WORT + Veh1” or “Veh2 + 7.5 
g WIN” values. B) * or # P < 0.05 versus respective “Veh2 + Veh1” and “WORT + 
Veh1” or “Veh2 + 15 g WIN” values. 
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Fig. 5.4. pERK1/2 inhibition (PD98059) attenuates the pressor response elicited by 
central CB1R activation. Time course of changes in mean arterial pressure (MAP) 
and heart rate (HR) evoked by intracisternal injection of WIN55,212-2 (WIN; 15 
g/rat) or an equal volume of its vehicle (Veh1) in conscious rats pretreated, 20 minutes 
earlier, with PD98059 (PD098) [MEK/ERK1/2 phosphorylation inhibitor, 10 g/rat, 
i.c.] or equal volume of its vehicle (Veh3). Values are mean ± S.E.M. of 5 to 8 
observations. * or # P < 0.05 versus respective “Veh3 + Veh1” and “PD98059 + Veh1” 
or “Veh3 + 15 g WIN” values. 
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Fig. 5.5. Effects of WIN55,212-2 on pAkt in the presence or absence of AM251, 
wortmannin or PD98059 in rat NTS and RVLM. Changes in pAkt in rat NTS (top 
panel; A, B and C) and RVLM (bottom panel; D, E and F) neurons elicited by 
WIN55,212-2 (i.c) in animals pretreated with vehicle, AM251, (30 g/rat, i.c) (A and 
D), wortmannin (Wort; 0.42 g/rat, i.c) (B and E) or PD98059 (PD098; 10 g/rat, 
i.c) (C and F). Data are presented as integrated density ratio of phosphorylated Akt 
(pAkt) and total Akt (tAkt), expressed as percentage of control (vehicle). Values are 
mean ± S.E.M. of 4 to 5 observations. * or # P < 0.05 versus respective (vehicle) or 
(vehicle+ 15 g WIN) values, respectively.  
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Fig. 5.6. Effects of WIN55,212-2 on pERK1/2 in the presence or absence of 
AM251, wortmannin or PD98059 in rat NTS and RVLM. Changes in pERK 
levels in rat NTS (top panel; A, B and C) and RVLM (bottom panel; D, E and F) 
neurons elicited by WIN55,212-2 (i.c) in animals pretreated with vehicle, AM251, 
(30 g/rat, i.c) (A and D), wortmannin (Wort; 0.42 g/rat, i.c) (B and E) or 
PD98059 (PD098; 10 g/rat, i.c) (C and F). Data are presented as integrated 
density ratio of phosphorylated ERK1/2 (pERK1/2) and total ERK, expressed as 
percentage of control (vehicle). Values are mean ± S.E.M. of 4 to 5 observations. *, 
# or & P < 0.05 versus respective (vehicle), (vehicle+ 15 g WIN) or (vehicle + 7.5 
g WIN55,212-2) values, respectivly.  
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5.7. Discussion 
In this study, we tested the hypothesis that alteration in brainstem PI3K/Akt and/or 
ERK1/2 signaling contributes to the central CB1R-mediated pressor response. The most 
important findings of this study are: (i) centrally administered WIN55,212-2, a non-selective 
CB1-CB2 receptor agonist, elicited pressor and bradycardic responses along with significant 
enhancement of ERK1/2 and reduction of Akt phosphorylation, respectively, in the NTS and 
RVLM; (ii) the pressor and neurochemical responses elicited by WIN55,212-2 were virtually 
abolished by central CB1R blockade (AM251); (iii) prior inhibition of PI3K (wortmannin) 
enhanced the elevations in blood pressure and pERK1/2 phosphorylation and augmented the 
reductions in Akt phosphorylation caused by WIN55,212-2, (iv) by contrast, prior inhibition of 
brainstem ERK1/2 phosphorylation (PD98059) abrogated the elevations in blood pressure and 
brainstem ERK1/2 phosphorylation without significantly affecting the reduction in brainstem 
pAkt phosphorylation caused by WIN55,212-2. These findings implicate differential alteration of 
brainstem PI3K/Akt (reduced) and ERK1/2 (enhanced) signaling as potential cellular 
mechanisms for the central CB1R-evoked sympathoexcitation/pressor response in conscious rats. 
The sympathoexcitatory effect of central CB1R activation is well-documented (findings of 
Chapter 3); however, the underlying mechanisms are not well understood. Herein, we 
hypothesized that brainstem PI3K/Akt and/or ERK1/2 signaling contributes to the central CB1R-
mediated pressor response. In the current study, we provide the first evidence in support of our 
hypothesis. We showed that i.c. WIN55,212-2-evoked pressor response is paralleled with a 
reduction in pAkt phosphorylation in the NTS and RVLM neurons. The findings suggest that the 
reduction in brainstem Akt phosphorylation plays a causal role in the central CB1R-mediated 
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pressor response. In support of this conclusion are the findings that the dose-related inhibition of 
Akt phosphorylation in the NTS and RVLM elicited by WIN55,212-2 occurs within minutes and 
precedes the peak pressor response. Our Western blot findings are consistent with findings that 
CB1R activation resulted in down-regulation of the PI3K/Akt signaling (Ellert-Miklaszewska, 
Kaminska et al. 2005; Greenhough, Patsos et al. 2007). However, others have shown that CB1R 
activation up-regulated PI3K/Akt signaling in U373 MG human astrocytoma cells (Galve-
Roperh, Rueda et al. 2002), hippocampal slices (Derkinderen, Valjent et al. 2003), and in vivo 
(Ozaita, Puighermanal et al. 2007). The differences between the present and reported findings 
might be due to differences in the model system used or differences in PI3K-Akt signaling 
response to CB1R activation in different brain areas. For example, in the latter study, CB1R 
activation enhanced PI3K/Akt signaling in mouse hippocampus, striatum and cerebellum but not 
in the cortex. We are not aware of any reports on the effect of CB1R activation on PI3K-Akt 
signaling in the brainstem. Nonetheless, in further support of a causal role for the observed 
inhibition in brainstem Akt phosphorylation in the central CB1R-mediated pressor response are 
the findings that pharmacological inhibition of brainstem PI3K/Akt signaling (wortmannin) 
significantly enhanced the WIN55,212-2 evoked pressor response. Importantly, the selected 
wortmannin dose had no significant impact on neuronal pAkt phosphorylation in the NTS or 
RVLM or on basal blood pressure.  
The cellular mechanism that underlies the mediation of the pressor response following 
inhibition of brainstem PI3K-Akt signaling is not fully understood. There is evidence to suggest 
that activation of brainstem PI3K/Akt signaling in NTS mediates insulin-evoked hypotensive and 
bradycardic responses (Huang, Lu et al. 2004). Furthermore, it was shown that brainstem 
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(RVLM and NTS) and hypothalamic (PVN) PI3K signaling pathway is elevated in spontaneous 
hypertensive rats (SHR), compared with the normotensive counterparts, Wister-Kyoto rats 
(WKY) (Veerasingham, Yamazato et al. 2005; Zubcevic, Waki et al. 2009). In the latter study, 
chronic blockade of PI3K in the NTS increased blood pressure in SHR but not WKY, suggesting 
a restraining role (depressor) for PI3K pathway on BP in SHR. Accordingly; we reasoned that 
CB1R-evoked pressor response could be mediated, at least partially, via inhibition of brainstem 
PI3K/Akt signaling. As discussed above, the neurochemical data support this notion (Fig. 5.5). 
Equally important, the CB1R-evoked pressor response and brainstem ERK1/2 phosphorylation 
were both exacerbated in presence of wortmannin. Notably, in the RVLM, chronic inhibition of 
PI3K/Akt by wortmannin resulted in hypotension, and attenuation of the angiotensin II-evoked 
pressor response in SHR but not WKY (Seyedabadi, Goodchild et al. 2001). Taken together, 
these findings suggest different roles for brainstem PI3K/Akt in modulating BP taking into 
account the type of receptor activated, basal sympathetic tone and BP, and type of the targeted 
neuronal pool. Nonetheless, the ability of central CB1R activation to inhibit the restraining 
influence of brainstem PI3K/Akt pathway in our normotensive rats may unleash endogenous 
neuronal activators or cause an imbalance between excitatory and inhibitory neurotransmitters in 
the brainstem. 
Multiple lines of evidence suggest that the ERK1/2 pathway underlies diverse 
physiological functions evoked by CB1R. Herein, we provide the first evidence that brainstem-
ERK1/2 signaling is involved in central CB1R-mediated pressor response. i.c. WIN55,212-2 
significantly elevated pERK1/2 in the NTS and RVLM, two nuclei that were shown in many 
studies to be involved in the central CB1R-evoked pressor response (Padley, Li et al. 2003; 
 127 
 
Rademacher, Patel et al. 2003). Abrogation of the WIN55,212-2-mediated hemodynamic 
responses and attenuation of the concomitant activation of ERK1/2 pathway by pretreatment 
with AM251(i.c), a selective CB1R antagonist, precluded the involvement of CB2R. Brainstem 
pERK1/2 signaling plays a tonic role in the central control of blood pressure because; (i) 
blunting ERK1/2 (3-7 hours) activity in the RVLM lowered blood pressure in both normotensive 
and hypertensive rats (Seyedabadi, Goodchild et al. 2001); (ii) PD98059, a MEK/ERK inhibitor, 
attenuated i.c.v short-term urotensin-mediated pressor response but not the associated 
tachycardia (Lin, Matsumura et al. 2004); (iii) RVLM-ERK1/2 is pivotal for long-term 
angiotensin II-mediated central control of cardiovascular functions (Chan, Wang et al. 2007). 
However, studies from our laboratory suggested that ERK1/2 phosphorylation in the RVLM 
leads to hypotension in conscious animals (Zhang and Abdel-Rahman 2005; Nassar and Abdel-
Rahman 2008). These contradictory observations may suggest a bi-directional role for brainstem 
ERK1/2 pathway in the central regulation of blood pressure. In the current study, blockade of the 
brainstem ERK1/2 signaling by i.c. PD98059 abrogated the elevation of pERK1/2 
phosphorylation and the pressor response produced by WIN55,212-2; however it did not affect 
the bradycardic effect.  
Careful analysis of the neurochemical changes in pAkt and pERK1/2 detected by Western 
blot revealed that: whereas wortmannin had no effect on pERK1/2 phosphorylation, it 
substantially enhanced WIN55,212-2-induced ERK1/2 phosphorylation (more evident in the 
NTS than RVLM). Additionally, changes in pAkt were not significantly different in animals that 
received PD98059 alone or followed by WIN55,212-2 compared to vehicle treated animals. 
Together, we conclude that the effects of WIN55,212-2 on PI3K/Akt are upstream to ERK1/2 
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signaling because of the significant increase in ERK1/2 phosphorylation by WIN55,212-2 in 
presence of PI3K/Akt inhibitor, wortmannin. 
In summary, the present study highlights for the first time a novel PI3K/Akt/ERK1/2 
signaling system in the brainstem (RVLM and NTS) that seems to contribute, at least in part, to 
the sympathoexcitation caused by brainstem-CB1R activation in conscious rats. The findings of 
this study demonstrate that central CB1R activation elicits down-regulation of PI3K/Akt pathway 
in the RVLM and NTS along with the pressor response. This notion is further supported by the 
exacerbation of the WIN55,212-2 evoked pressor response when PI3K/Akt was inhibited by 
wortmannin. We speculate that inhibition of PI3K/Akt signaling in the brainstem might underlie 
the CB1R-mediated modulation of inhibitory (GABA) neurotransmission (addressed in chapter 
6). In contrast, CB1R-elecited sympathoexcitation was associated with an elevation in the 
pERK1/2 phosphorylation in the brainstem. Further, suppressing ERK1/2 signaling by PD98059 
(i.c) abolished CB1R-pressor response. We conclude that PI3K/Akt signaling is upstream to 
ERK1/2 signaling because of the significant increase in ERK1/2 phosphorylation by 
WIN55,212-2 in presence of PI3K/Akt inhibition (wortmannin). Further studies are needed to 
elucidate the signaling pathways between PI3K/Akt and ERK1/2, which seem to influence the 
balance between sympathoexcitatory and sympathoinhibitory modulators.  
 
 CHAPTER SIX-A CAUSAL LINK BETWEEN CENTRAL CB1R-EVOKED INHIBITION OF 
BRAINSTEM GABAERGIC NEUROTRANSMISSION AND THE PRESSOR RESPONSE; 
IMPLICATION FOR RVLM-nNOS-NO SIGNALING 
6. 1. Abstract  
Activation of neuronal nitric oxide synthase (nNOS), which leads to NO release, underlies 
a wide array of CB1R-evoked pharmacological actions. As discussed earlier, central CB1R, 
activation enhances brainstem ERK1/2 phosphorylation and the latter enhances nNOS activity. 
Therefore, we elucidated the role of p-nNOS-NO in the central CB1R-evoked pressor response. 
We simultaneously measured blood pressure, heart rate and real time rostral ventrolateral 
medulla (RVLM)-NO levels following unilateral intra-RVLM microinjection of the CB1R 
agonist WIN55212-2 (100, 200 or 300 pmol/80nL, n=4) in conscious rats. WIN55,212-2-elicited 
increases in blood pressure were associated with a slight increase in heart rat. Interestingly, 
RVLM NO levels significantly increased in parallel to the WIN55212-2-evoked hemodynamic 
effects (n=4, P < 0.05). The vehicle for WIN55212-2 had no effect on the measured variables. 
Additionally, nNOS phosphorylation was significantly higher in the injected RVLM compared to 
the contralateral (control) RVLM (n=4, P < 0.05). Finally, given the well-established link 
between nNOS-NO signaling and GABAergic transmission in cardiovascular regulatory area, we 
explored the possibility that enhanced NO generation might inhibit GABAergic transmission and 
subsequently account for the central CB1R-mediated pressor response. Activation of central 
GABAA receptor by muscimol (0.1 g/rat, i.c) virtually abolished the WIN55,212-2 (15 g/rat, 
i.c)-evoked hemodynamic responses. Additionally, we measured the catecholaminergic (tyrosine 
hydroxylase immunoreactivity, TH-ir) and nitroxidergic (nNOS-ir) neuronal activity, indirectly 
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via a marker of neuronal activity, c-Fos, within the RVLM following activation of CB1R in the 
presence or absence of AM251 or muscimol. WIN55,212-2 (15 g/rat, i.c) significantly (P < 
0.05) increased the percentage of TH-ir and nNOS-ir neurons expressing c-Fos; AM251 or 
muscimol pretreatment mitigated the increase in RVLM-catecholaminergic and nitroxidergic 
neuronal activity. Together, these findings suggest a pivotal role for p-nNOS-NO/GABAergic 
transmission in central CB1R-evoked pressor response. 
6. 2. Introduction 
nNOS-NO signaling in the RVLM has been shown to be critically implicated in the central 
regulation of autonomic functions (Martins-Pinge, Araujo et al. 1999; Martins-Pinge, Garcia et 
al. 2007; Mayorov 2007; Nassar and Abdel-Rahman 2008). Interestingly, multiple studies have 
demonstrated a link between nNOS-NO signaling and GABAergic transmission in the 
cardiovascular regulatory area, e.g. nNOS-generated NO reduced GABA release in the dorsal 
periaqueductal gray matter and RVLM and was associated with pressor responses (Samuel H H 
Chan, Ling-Lin Wang et al. 2003; Karlsson, Chaitoff et al. 2007; Martins-Pinge, Garcia et al. 
2007). Pertinent to the current investigation, many of CB1R mediated effects involve activation 
of nNOS-NO signaling pathway including locomotor activity and thermoregulation (Azad, 
Marsicano et al. 2001; Jones, Carney et al. 2008). Moreover, presynaptic CB1R activation 
inhibits the release of GABA and glutamate at both inhibitory as well as excitatory synapses 
(Vaughan, McGregor et al. 1999; Kreitzer and Regehr 2001; Ohno-Shosaku, Maejima et al. 
2001; Neu, Foldy et al. 2007). Interestingly, studies on hippocampus suggest that nNOS-
generated NO is involved in CB1R-mediated suppression of GABA release (see Chapter 1) 
(Makara, Katona et al. 2007). Because GABA is the primary inhibitory transmitter which exerts 
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tonic inhibition on RVLM-presympathetic neurons, Padley et al. and others have proposed that 
RVLM CB1R-evoked sympathoexcitation is, presumably, mediated via disinhibition of 
GABAergic neurotransmission within the RVLM (Randall, Harris et al. 2002; Padley, Li et al. 
2003). To our current knowledge, this was only tested in vitro by Vaughan et al. in cultured 
RVLM neurons, where CB1R ligands inhibited the release of GABA (Vaughan, McGregor et al. 
1999) and has not addressed the nNOS-NO implication. Notably, we have discussed in Chapter 4 
that CB1R-evoked pressor response is mediated via OX1R/orexin-A signaling in the brainstem. 
Intriguingly, a recent study has demonstrated a causal link between orexins-evoked 
cardiovascular effects and nNOS-NO-GABA signaling in the NTS (Shih and Chuang 2007). 
Moreover, molecular and pharmacological evidence in Chapter 5 has indicated that inhibition 
and activation of PI3K/pAkt or pERK1/2 signaling, respectively, underlies the CB1R-evoked 
pressor response. There is evidence to suggest that GABAergic transmission is enhanced or 
ameliorated, respectively, following Akt or ERK1/2 phosphorylation (Wang, Liu et al. 2003; 
Bell-Horner, Dohi et al. 2006). Taken together we hypothesize that nNOS-NO suppression of 
GABAergic neurotransmission in the RVLM mediates, at least partly, the central CB1R-evoked 
pressor response.  
6. 3. Material and Methods 
6. 3. 1. Intra-arterial catheterization, and intracisternal (i.c) and intra-RVLM 
cannulation 
Male SD rats (Charles River, NC) were prepared for intra-arterial catheterization and intra-
RVLM cannulation. Under sterile conditions and anesthesia (ketamine [9 mg/100g] and xylazine 
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[1mg/100 g], i.p.), an arterial catheter for BP measurement and a guide cannula for i.c. injections, 
as applicable, were placed into the abdominal aorta via the femoral artery as detailed under 
general methods, Chapter 2. For intra-RVLM cannulation, the method described in several 
studies from the advisor‟s laboratory was followed (Li, Wang et al. 2005; Zhang and Abdel-
Rahman 2005; Guichu Li and Abdel-Rahman AA 2007). A stainless steel guide cannula (21.5 
gauge, 14mm in length) was implanted 2 mm above the RVLM level at coordinate of -2.8 
posterior, ± 2 lateral and -0.5 mm dorsoventral with the interaural line as the reference according 
to rat brain atlas (Paxinos and Watson 2005). The guide cannula was then secured in place with 
small metal screws and dental acrylic cement. At least five days were allowed for recovery.  
6. 3. 2. Preparation and calibration of the carbon fiber electrodes 
 The carbon fiber electrodes were prepared according to procedure detailed in a recent 
publication from the laboratory and elsewhere (Friedemann MN, Robinson SW  et al. 1996; 
Guichu Li and Abdel A. Abdel-Rahman 2009) and then coated with a 2-step coating process 
prior to use; first with nafion and then with o-phenylenediamine (o-PD). Nafion coating 
performed by dip-coating in 5% nafion (Aldrich, Milwaukee, WI), drying at 85 ºC for 5 minutes 
repeated 7 times, to enhance its selectivity for monoamine neurotransmitters over anionic species 
such as ascorbic acid and DOPAC. Then the probes were electrochemically coated in 5 mM o-
phenylenediamine dihydrochloride (1,2-benzenediamine, Sigma Chemical Co., St Louis, MO). A 
constant voltage (+0.9 V vs. Ag ⁄ AgCl reference) was applied to the electrode for 20 minutes. 
The solution was continually stirred during the coating process. Coated electrodes were 
calibrated before use by a response to an increasing concentration of NO, by adding increasing 
volume of standard 2 mM NO solution while the selectivity was measured against ascorbic acid. 
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Electrodes whose sensitivity was >50,000 and displayed a NO: ascorbic acid sensitivity ratio 
>500:1, and linearly responded to increasing conc. of NO (2 to 10 M) (r > 0.997) were used in 
the subsequent experiment. 
6. 3. 3. Real time measurement of RVLM NO- and drug microinjections  
A probe that combines a stainless steel injector (30-gauge, 21.5 mm in length) and the NO-
carbon fiber electrode that permits intra-RVLM microinjections was inserted directly into the 
RVLM of unrestrained rats through the previously implanted guide cannula (Guichu Li and 
Abdel A. Abdel-Rahman 2009). In vivo NO monitoring was performed using the IVEC-10 
system that is computer-controlled (Medical SystemsCorp., Greenvale, NY). An oxidation 
potential of + 0.9 V, with respect to the Ag⁄ AgCl reference electrode, was applied to the carbon 
fiber electrode for 0.1 second at a rate of 5 Hz. Each data point represented the average of 5 
measurements. The system can measure 1-second NO concentration change, and its detection 
limit is 35 ± 7 nM NO (Friedemann MN, Robinson SW  et al. 1996) 
The injector was connected to PE-10 tubing via PE-50 tubing attached to a Hamilton 
microsyringe (1µl). Chemical identification of the RVLM was based on obtaining a pressor 
response elicited by injecting 1 nmol L-glutamate at the beginning of the experiment, as reported 
in previous studies (Limin Mao 1998; Zhang and Abdel-Rahman 2002; Li, Wang et al. 2005; 
Guichu Li and Abdel-Rahman AA 2007). To avoid potential problems because of microinjecting 
the drugs following the removal and reinsertion of the injector, microinjections of different drugs 
was accomplished by separating drugs or vehicle with a small air bubble as reported (Limin Mao 
1998; Li, Wang et al. 2005; Guichu Li and Abdel-Rahman AA 2007). At the end of the 
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experiment, fast green dye 40 nL (minimal volume is used so as not to affect the tissue integrity 
and the biochemical studies) was injected for histological verification. Coronal sections 
containing the RVLM region- before being micro-punched for protein extraction and measuring 
p-nNOS (see below)- as shown in Fig. 6. B (references are shown on the diagram) were 
examined under light microscopy (4X) for the correct placement of the injector tip. Animals that 
failed the positive verification were excluded from data interpretation. 
6. 3. 4. Blood pressure and heart rate measurements 
Hemodynamic measurements were performed as detailed under general methods (Chapter 
2) for experiments included i.c. injections. For experiments with intra-RVLM microinjections, 
90 min were allowed following the chemical identification of the intra-RVLM injection site to 
permit full recovery from the L-glutamate elicited pressor and bradycardic responses.  
6. 3. 5. Western Blotting 
RVLM micropunches were prepared as detailed under general methods (see Chapter 2) 
from rats used in experiment 1 at the conclusion of hemodynamic measurements to detect 
changes in phosphorylation of nNOS. Briefly, prepared membranes were incubated for 48 h at 
4ºC in mix of rabbit anti-p-nNOS and mouse anti-nNOS diluted 1:500 and 1:200 (BD 
Biosciences, San Diego, CA) in Odyssey blocking buffer, respectively. Procedure of image 
acquisition and band quantification detailed under general methods (see Chapter 2) was followed 
to detect changes in RVLM-p-nNOS/t-NOS in the injected site and compared to those of the 
contra-lateral site (served as control).  
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6. 3. 6. Immunofluorescence  
6. 3. 6. 1. Tissue and slide preparation 
At the conclusion of the experiment, free-floating sections were prepared as detailed under 
general methods (see Chapter 2). For co-labeling and quantification of TH and nNOS-ir neurons 
expressing c-Fos, brainstem sections containing the RVLM were incubated with either mixture 
of primary antibodies outlined in Table 6.1 for 48 h at 4 ºC. Sections were then washed and 
incubated with one of the mixtures of secondary antibodies for 2 h as indicated in Table 6.1.  
6. 3. 6. 2. Quantification of labeled neurons  
Images were acquired and projected simultaneously on the attached monitor for 
quantification of co-localization. For immunohistochemical analysis of brainstem sections, the 
RVLM of 4-6 sections per animal was examined in rostral–caudal sections -12.8 to -11.8 mm 
relative to the bregma. Criteria used to identify positively labeled cells were: c-Fos-ir labeling 
was identified as nuclear staining (red) with a visible nucleolus. TH-ir or nNOS-ir cells were 
identified by cytosolic labeling (green) with visible processes and a blank nuclear region. c-Fos, 
TH or nNOS positive cells were counted manually using 20 X objective. Cells were considered 
to be co-labeled if the location of nuclear c-Fos staining corresponded to the blank region in 
cytosolic labeling of nNOS or TH-ir in the same focal plane. All slides were coded and the 
examiner was blinded to the treatment at all time.  
6. 3. 6. 3. Image acquisition and processing: 
Representative images were acquired and processed following procedures outlined under general 
methods (Chapter 2).   
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Fig. 6.1. Chemical and histological verification of the site of intra-RVLM 
microinjections. A) Typical tracing showing effect of injection of 1nmol L-
glutamate on arterial pressure (AP) and heart rate (HR). B) Typical 
photomicrograph (left panel) and schematic diagrams (right panel) of coronal 
sections of rat brainstem identifying intra-RVLM injection site produced by 
injecting 40 nL fast green dye at the conclusion of the experiment. Numbers on 
upper right corner reflect the rostro-caudal coordinates relative to bregma 
according to rat brain atlas (Paxinos and Watson 2005). NA: Nucleus Ambiguous 
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Table. 6.1. Combination of primary and secondary antibodies used in 
colocalization studies of c-Fos and TH-ir or nNOS-ir in RVLM neurons. 
All secondary conjugated antibodies were purchased from Jackson 
Immunoresearch, CA. TH: tyrosine hydroxylase; Ab: antibody. 
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 c-Fos/TH 
1
st
 primary Ab 
1
st
 secondary Ab 
Mouse anti-TH (1:500; Chemicon., Temecula, CA) 
FITC conjugated donkey anti-mouse; 1:200 
2
nd
  primary Ab 
2
nd
  secondary Ab 
Rabbit anti-c-Fos (1:2000; Calbiochem, San Diego, CA) 
Cy3 conjugated donkey anti-rabbit, 1:200 
 
 c-Fos/nNOS 
1
st
 primary Ab 
1
st
 secondary Ab 
Mouse anti-nNOS (1:200; BD Biosciences, San Diego, CA) 
FITC conjugated donkey anti-mouse; 1:200 
2
nd
  primary Ab 
2
nd
  secondary Ab 
Rabbit anti-c-Fos (1:2000; Calbiochem, San Diego, CA) 
Cy3 conjugated donkey anti-rabbit, 1:200 
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6. 3. 7. Drugs  
Muscimol was purchased from Sigma-Aldrich (St. Louis, MO) and was dissolved in sterile 
saline.  
6. 4. Protocols and experimental groups 
6. 4. 1. Experiment 1: Effects of intra-RVLM WIN55,212-2 on BP, HR, p-nNOS and NO  
In this experiment (n= 4) conscious rats prepared as above for simultaneous in vivo real-
time measurement of NO and BP, received 80 nL of vehicle or three successive doses of 
WIN55,212-2 (100, 200, 300 pmole), as shown in Fig. 6.2 at 10 min intervals. Injections were 
made unilaterally into the RVLM of all rats. The use of previously reported dose-ranges for 
WIN55,212-2 (0.5-50 pmole) (Padley, Li et al. 2003) failed to produce any changes in BP or NO 
in our hands. Ten min after the last dose, a micropunch from the injected RVLM was collected 
as detailed under methods and used for determining changes in nNOS phosphorylation (n=3) by 
Western blotting from each rat. The contra-lateral (non-injected) RVLM was also collected and 
served as control (n=4). 
6.4. 2. Experiment 2: Effect of brainstem GABAA receptor stimulation (muscimol) on the 
pressor response elicited by i.c. WIN55,212-2  
We elucidated the effect of GABAA receptor stimulation on the i.c. WIN55,212-2-evoked 
pressor response previously discussed in Chapter 3; animals received muscimol (0.1 g/rat, i.c) 
10 min prior to i.c. WIN55,212-2 (15 g/rat, i.c) (n=8) or its vehicle (n=5). Hemodynamic 
measurements were continued for 30 min after WIN55,212-2 or vehicle. The data were 
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compared to hemodynamic effects of WIN55,212-2 given alone or its vehicle (Chapter 3; 
experiment 3.5.2). Blood samples were collected to measure plasma NE levels. 
6. 4. 3. Experiment 3: Effects of WIN55,212-2 on RVLM-catecholaminergic and 
nitroxidergic neurons activity (c-Fos) in presence or absence of blockade of CB1 
(AM251) or activation of GABAA receptors (muscimol) 
 We have discussed in Chapter 3 that CB1R-stimulation enhanced RVLM-
catecholaminergic neuronal activity (c-Fos-ir). We investigated the neuronal activity, of 
catecholaminergic and nitroxidergic neurons, indirectly via measuring c-Fos abundance, 
following i.c. WIN55,212-2 or its vehicle. To elucidate whether these effects are GABAAR-
dependent, brain tissues were collected and prepared for quantification of the number of tyrosine 
hydroxylase immunoreactive neurons (TH-ir), marker of catecholaminergic neurons, or nNOS-ir 
neurons expressing c-Fos at the conclusion of Exp. 2. Results were compared to those produced 
from four additional groups of rats treated as indicated earlier (Chapter 3; experiment 3. 4. 2) 
where rats received WIN55,212-2 (15 g/rat, i.c) or an equal volume of its vehicle 30 min after 
i.c. administration of the selective CB1R antagonist, AM251 (30 g). Brainstem sections that 
contained the RVLM were processed for c-Fos/TH-ir or c-Fos/nNOS-ir quantification as 
described above. 
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Fig. 6.2. Time line for surgical procedures and experimental protocols for 
experiment 1. 
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Fig. 6.3. Time line for surgical procedures and experimental protocols for 
experiments 2 and 3. 
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6.5. Statistical Analysis  
A one way ANOVA followed by Bonferroni comparison test was used to evaluate the 
effect of intra-RVLM WIN55,212-2 on p-nNOS or NO (Exp. 1) and the effect of various 
treatments on co-localization of c-Fos-ir and TH-ir or nNOS-ir neurons of the  RVLM (Exp 3). P 
< 0.05 was considered significantly different 
6. 6. Results 
6. 6. 1. Intra-RVLM WIN55,212-2 elicited dose-dependent increase in blood pressure 
and RVLM-NO, and enhanced RVLM-p-nNOS 
Intra-RVLM WIN55,212-2 elicited dose-dependent increases in blood pressure and  
RVLM-NO (P < 0.05; n=4). The effect on HR was insignificant. The vehicle of WIN55,212-2 
had no effect on the measured variables (Fig. 6.4). Additionally, WIN55,212-2 significantly (P < 
0.05) increased p-nNOS phosphorylation in the RVLM microinjected with WIN55,212-2 
compared  to the contra-lateral (control) RVLM (Fig. 6.5). 
6. 6. 2. Brainstem GABAAR stimulation (muscimol) abolishes CB1R-evoked 
hemodynamic effects 
Muscimol (0.1 g/rat, i.c) slightly decreased MAP and HR but the values were not 
significantly different from baseline at the time of WIN55,212-2 injection (Table 6.2). Plasma 
NE prior to WIN55,212-2 injection was 950 ± 90 pg/ml (n=10) The pressor response and the 
elevation of plasma NE levels induced by WIN55,212-2 (15 g/rat, i.c) were abolished by 
muscimol (0.1 g/rat, i.c). Muscimol had no effect on WIN55,212-2-evoked bradycardia (Fig. 
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6.6). Interestingly, we noticed a brief depressor response caused by WIN55,212-2 in animals 
pretreated with muscimol.  
6. 6. 3. Central CB1R activation (WIN55,212-2) increases RVLM-catecholaminergic 
(TH-ir) and nitroxidergic neurons (nNOS-ir) activity 
WIN55,212-2 (15 g/rat, i.c) significantly (P < 0.05) increased the percentage of TH-ir 
(Figs. 6.7 and 6.8) and nNOS-ir (Figs. 6.9 and 6.10) neurons expressing c-Fos, compared to 
control (vehicle). AM251 (30 g/rat, i.c) or muscimol (0.1 g/rat, i.c) did not significantly alter 
the basal TH-ir/c-Fos or nNOS/c-Fos ratio (P > 0.05). However, AM251 or muscimol 
pretreatment significantly (P < 0.05) attenuated the WIN55,212-2-evoked increases in number 
and percentage of TH-ir or nNOS-ir neurons expressing c-Fos. The total number of TH-ir or 
nNOS-ir (sum of expressing or not expressing c-Fos neurons) was not significantly different in 
all groups (P > 0.05). 
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Fig. 6.4. Intra-RVLM WIN55,212-2 dose-dependently increases blood 
pressure and RVLM-NO levels. A) Typical tracings depicting the dose-
dependent real time changes in arterial pressure (AP), heart rate (HR) and 
RVLM-Nitric Oxide (NO) elicited by intra-RVLM microinjection of 
WIN55,212-2 or its vehicle in conscious freely moving rats. B) Pooled values of 
intra-RVLM microinjection of 200 pmol CB1R agonist WIN55,212-2 or its 
vehicle on real time NO concentration detected electrochemically in RVLM by 
a nafion coated microelectrode. Values are Mean± SEM. * P < 0.05 vs 
respective control value. 
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Fig. 6.5. Intra-RVLM WIN55,212-2 enhances p-nNOS level. 
Quantification of changes in integrated density of RVLM p-nNOS detected 
by Western blotting following unilateral intra-RVLM WIN55,212-2 as 
compared to the contra-lateral RVLM (control). Bands of p-nNOS and total 
nNOS were detected simultaneously from the same membrane using a dual 
infra-red fluorescence imager. p-nNOS integrated density was normalized 
to the corresponding total nNOS. Values are Mean± S.E.M.* P < 0.05 vs. 
the contra-lateral (control) RVLM. 
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Table. 6.2. MAP (mmHg) and HR (bpm) values before and after pretreatment with the 
GABAAR agonist  muscimol. Values are means ± S.E.M 
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Treatment n 
Before 
 ____________________ 
After 
________________ 
MAP HR MAP HR 
Muscimol + Vehicle 5 110.0±4.0 440±12 103.0±4.0 400±12 
Muscimol + 15 g WIN55,212-2 8 106.0±2.0 450±16 99.0±5.0 410±18 
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Fig. 6.6. Intracisternal muscimol (GABAAR agonist) abolishes CB1R-evoked 
hemodynamic effects. Time course of changes in mean arterial pressure (MAP, 
top panel), heart rate (HR, middle panel) and plasma NE (bottom panel) evoked by 
intracisternal median dose (15 g/rat) of WIN55,212-2 (Veh + 15 g WIN55) or an 
equal volume of its vehicle, indicated by the arrow (top panel), in conscious rats 
pretreated, 10 minutes earlier, with the selective GABAAR agonist muscimol (0.1 
g/rat, i.c) (Muscimol + 15 g WIN55) or an equal volume of vehicle (Muscimol + 
Veh). Values are mean ± S.E.M. of 5 to 8 observations. * or # P < 0.05 vs. 
respective “Muscimol + Veh” or “Muscimol + 15 g WIN55” values, respectively. 
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Fig. 6.7. Photomicrographs depicting CB1R-induced c-Fos expression in 
catecholaminergic neurons in the RVLM. Confocal dual-channel images 
showing tyrosine hydroxylase immunoreactive (TH-ir) neurons (green) and c-
Fos immunoreactive (Fos-ir) cell nuclei (red) in RVLM of rats treated as 
described under methods section with (A) vehicle, (B) 15 g WIN55,212-2, (C) 
AM251 + 15 g WIN55,212-2 (re-blotted from Fig. 3.6) and (D) Muscimol + 
15 g WIN55,212-2. White or yellow arrowheads indicate single labeled TH-ir 
neurons or c-Fos-ir cell nuclei, respectively. White arrows denote c-Fos/TH 
colabeled cells. Scale bar, 20 µm. 
 157 
 
 
 
 
 
 
 
 
  
 158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 6.8. Quantitative analysis of CB1R-induced c-Fos expression in RVLM 
catecholaminergic neurons. The number of TH-ir neurons, c-Fos/ TH double-
labeled neurons and percentage of TH-ir neurons colabeled with c-Fos in the 
RVLM of rats treated as described under methods with either vehicle, 
WIN55,212-2 (.15 g/rat, i.c), AM251 (30 g/rat, i.c), AM251 prior to 
WIN55,212-2 (re-blotted from Fig. 3.7), muscimol (0.1 g/rat, i.c) or muscimol 
prior to WIN55,212-2 are shown. Bar graphs represent mean ± S.E.M. counts in 
coronal brainstem sections from 4-6/animal, (n=3-5)/group using one-way 
ANOVA followed by Bonferroni comparison test. * or # P <0.05 vs respective 
vehicle or all other treatments values, respectively.  
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Fig. 6.9. Photomicrographs depicting CB1R-induced c-Fos expression in 
nitroxidergic neurons in the RVLM by double labeling immunofluorescence. 
Confocal dual-channel images showing neuronal nitric oxide synthase (nNOS-ir) 
neurons (green) and c-Fos immunoreactive (Fos-ir) cell nuclei (red) in RVLM of 
rats treated as described under methods section with (A) vehicle, (B) 15 g 
WIN55,212-2, (C) AM251 + 15 g WIN55,212-2 and (D) Muscimol + 15 g 
WIN55,212-2. White or yellow arrow heads indicate single labeled nNOS-ir 
neurons or c-Fos-ir cell nuclei, respectively. White arrows denote c-Fos/nNOS 
colabeled cells. Scale bar, 20 µm. 
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Fig. 6.10. Quantitative analysis of CB1R-induced c-Fos expression in RVLM 
nitroxidergic neurons. The number of nNOS-ir neurons, c-Fos/ nNOS double-labeled 
neurons and percentage of nNOS-ir neurons colabeled with c-Fos in the RVLM of rats 
treated as described under methods with either vehicle, WIN55,212-2 (15 g/rat, i.c), 
AM251 (30 g/rat, i.c), AM251 prior to WIN55,212-2, muscimol (0.1 g/rat, i.c) or 
muscimol prior to WIN55,212-2 are shown. Bar graphs represent mean ± S.E.M. counts 
in coronal brainstem sections from 4-6/animal, (n=3-5)/group using one-way ANOVA 
followed by Bonferroni comparison test. * or # P <0.05 vs respective vehicle or all other 
treatments values, respectively. 
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6.7. Discussion 
The most important findings of the current study are: (i) intra-RVLM microinjection of the 
cannabinoid receptor agonist WIN55,212-2 elicited dose-dependent increases in BP and 
enhancement of RVLM p-nNOS-NO signaling; (ii) stimulation of brainstem CB1R (WIN55,212-
2) activated RVLM-catecholaminergic and nitroxidergic neurons (c-Fos) and elevated plasma 
NE levels; (iii) these neurochemical, biochemical and cardiovascular responses were virtually 
abolished by prior central CB1R blockade (AM251) or activation of central GABAAR 
(muscimol). These findings suggest a pivotal role for brainstem p-nNOS-NO-GABAergic 
signaling in the central CB1R-evoked sympathoexcitation/pressor response in conscious rats. 
In this study, we provided preliminary evidence that implicates RVLM nNOS-NO 
signaling in the central CB1R-evoked pressor response. We utilized a technique that permitted 
simultaneous measurement of blood pressure, heart rate and real time neuronal NO level in 
conscious rats following unilateral intra-RVLM microinjection of the CB1R agonist WIN55,212-
2 (100, 200 or 300 pmol); this technique has been verified in previous studies in the laboratory 
(Guichu Li and Abdel A. Abdel-Rahman 2009). In agreement with previous findings (Padley, Li 
et al. 2003), intra-RVLM WIN55,212-2 elicited dose-dependent increases in blood pressure 
along with a slight increase in heart rate. These effects were not due to a volume increase, 
because the WIN55,212-2 vehicle administered in the same volume had no effect on the 
measured variables. The slight increase in HR is contrary to the bradycardia induced by i.c. 
WIN55,212-2, which was discussed in Chapter 3. The difference in the heart rate response might 
be due to the localized effect of WIN55,212-2 within the RVLM compared to the more 
widespread effect following i.c. injection. Importantly, hemodynamic responses elicited by intra-
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RVLM WIN55,212-2 replicated the human response to marijuana/THC smoking (Benowitz, 
Rosenberg et al. 1979) and also agree with similar findings in anesthetized animals (Padley, Li et 
al. 2003), despite the difference in the dose range. The justification of the higher dose used in the 
present study is: (i) the use of microcapillary tubing for the microinjection in the reported study 
(Padley, Li et al. 2003) vs. a stainless steel microinjector used in the preliminary study for 
RVLM drug delivery, that provided targeted delivery into specific RVLM neurons; (ii) the 
conscious state of the animals used in this study vs. anesthetized rats in the reported study, which 
was shown to alter CB1R-mediated hemodynamic responses (Lake, Martin et al. 1997).  
Evidence suggests that nNOS-generated NO plays a significant role in central CB1R-
mediated responses (Azad, Marsicano et al. 2001; Makara, Katona et al. 2007; Jones, Carney et 
al. 2008). This study demonstrated, for the first time, that the central CB1R-evoked pressor 
response is, at least partly, mediated via enhanced RVLM p-nNOS-NO signaling because intra-
RVLM WIN55,212-2 elicited: (i) dose-dependent increases in RVLM-NO that paralleled the 
pressor response in conscious rats; (ii) significantly increased nNOS phosphorylation; (iii) 
enhanced the activity (c-Fos) of nNOS-ir and TH-ir neurons was and these responses were 
abrogated by prior blockade of central CB1R (AM251). Although possible roles for eNOS or 
iNOS cannot be excluded and require further investigation, it should be remembered that only 
RVLM nNOS-derived NO is implicated in centrally-evoked hypertension (Kishi, Hirooka et al. 
2001; Ally, Kabadi et al. 2007; Martins-Pinge, Garcia et al. 2007).  
We hypothesized that inhibition of GABAergic neurotransmission and localized 
enhancement of NO generation within the RVLM underlies, at least partly, the 
sympathoexcitatory/pressor response elicited by WIN55,212-2. In support of this hypothesis is 
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the finding that prior stimulation of brainstem GABAAR (muscimol, i.c) abrogated the central 
CB1R-evoked pressor response, and the biochemical and neurochemical markers of 
sympathoexcitation (Fig. 6.6). These findings agree with reported in vitro findings that 
demonstrated inhibition of GABAergic transmission in cultured RVLM neurons following CB1R 
activation (Vaughan, McGregor et al. 1999). Further, the present novel neurochemical findings 
in our model system complement our molecular and pharmacological findings discussed in 
Chapter 5, which demonstrated that inhibition of PI3K/pAkt and activation of ERK1/2 signaling 
contribute to the central CB1R-evoked pressor response because: (i) First, in vivo and in vitro 
findings associated reduced PI3K/Akt signaling with reduced postsynaptic GABAAR 
phosphorylation and number (Wang, Liu et al. 2003). (ii) Second, activation of ERK1/2 
(phosphorylation) caused a reduction in GABAergic transmission (Bell-Horner, Dohi et al. 
2006). Finally, activation of NTS CB1R by the endogenous CB1R agonist anandamide enhanced 
baroreflex-mediated sympathoinhibition, at least partly, via presynaptic inhibition of GABA 
release (Seagard, Dean et al. 2004). It is imperative to note that the differences between the 
sympathetic neuronal activity due to the CB1R-evoked inhibition of GABAergic transmission in 
the RVLM in the present study vs. NTS in the latter study are expected because GABAAR 
activation elicits sympathoinhibition in the RVLM vs. sympathoexcitation in the NTS 
(Dampney, Horiuchi et al. 2003; Dampney, Polson et al. 2003; Samuel H H Chan, Ling-Lin 
Wang et al. 2003; Mueller and Hasser 2006). Together, the present results and reported studies 
suggest a pivotal role for the suppression of GABAergic neurotransmission in the brainstem in 
the neurobiological effects elicited by central CB1R activation. Equally important, the findings 
might explain, at least partly, the complex nature of the blood pressure responses elicited by i.c. 
WIN55,212-2, which gains access to different neuronal pools within the brainstem.  
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In summary, the present study highlights a pivotal role for p-nNOS-NO/GABAergic 
transmission within the RVLM in the central CB1R-evoked sympathoexcitation/pressor 
response in conscious rats. The findings are the first to establish a causal link between 
suppression of brainstem GABAergic neurotransmission and the sympathoexcitatory/pressor 
response elicited by central CB1R activation. The pharmacological (central CB1R blockade 
and GABAAR activation) along with the biochemical (plasma NE) and neurochemical 
(Western blot and immunofluorescence) data suggest a role for enhanced nNOS-NO signaling 
in the RVLM in the suppression of localized GABAergic transmission and the subsequent 
sympathoexcitation and pressor response. Further studies are needed to establish whether 
RVLM-nNOS activation plays a causal role in these neuronal events. 
 
 CHAPTER SEVEN-GENERAL DISCUSSION AND SUMMARY 
The main goal of the current study was to elucidate the mechanisms implicated in the 
central CB1R-evoked sympathoexcitation/pressor response. In pursuit of this goal, we 
characterized the centrally-elicited hemodynamic effects of CB1R in conscious SD rats. We have 
confirmed the expression of CB1R (protein) in the RVLM by: (i) detecting the two bands at 64 
and 53 kDa, representing the N-glycosylated and non-glycosylated forms of CB1R, respectively 
(Fig. 3.3) (Song C and Howlett 1995); (ii) dual-labeling immunofluorescence, which revealed its 
expression in the C1 area within the RVLM (Fig. 4.2 C). In the present study, i.c. administration 
of WIN55,212-2 dose-dependently increased MAP and NE plasma levels, denoting an increase 
in central sympathetic tone in conscious rats. Notably, the pressor response elicited by central 
WIN55,212-2 administration fully agrees with reported findings in experimental animals 
(Niederhoffer and Szabo 1999; Niederhoffer and Szabo 2000; Pfitzer, Niederhoffer et al. 2004), 
and reflects similar responses observed in humans (Foltin, Fischman et al. 1987; Sidney 2002). 
Additionally, i.c. WIN55,212-2 elicited a profound and immediate dose-dependent reduction in 
HR. Our studies were conducted in conscious rats, to circumvent the negative impact of 
anesthesia that was shown to dramatically compromise cannabinoid-evoked hemodynamic 
responses (Stein, Fuller et al. 1996; Lake, Martin et al. 1997; Gardiner, March et al. 2001). 
Throughout the study we demonstrated that the hemodynamic, biochemical and molecular 
responses elicited by WIN55,212-2 are CB1R mediated. This is important because: (i) there are 
no currently available selective CB1R agonists; WIN55,212-2, which is routinely used in 
cannabinoid research, is a mixed CB1R/CB2R agonist (Showalter, Compton et al. 1996; Griffin, 
Atkinson et al. 1998); (ii) both CB receptor subtypes are expressed in the brain (Herkenham, 
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Lynn et al. 1991; Viscomi, Oddi et al. 2009) including the brainstem, which plays a major role in 
the sympathoexcitatory/pressor response elicited by CB1R activation (Padley, Li et al. 2003). 
The ability of the selective CB1R antagonist, AM251 (Niederhoffer and Szabo 1999; 
Niederhoffer and Szabo 2000; Pfitzer, Niederhoffer et al. 2004) to virtually abolish the pressor, 
biochemical and neurochemical responses elicited by i.c. WIN55,212-2 clearly implicates the 
CB1R in the investigated responses. It is important to note, however, that the lack of change in 
blood pressure, as well as other neurochemical responses, following AM251 administration 
argues against the involvement of central CB1R signaling in tonic control of blood pressure in 
conscious rats. 
A main objective of the current study was to provide direct evidence for a functional role 
for RVLM neurons in the central CB1R-evoked pressor response. We present the first in vivo 
evidence that central CB1R-evoked sympathoexcitation/pressor response involves activation of 
RVLM-catecholaminergic neurons as represented by the significant increase in TH-ir neurons 
expressing c-Fos, a marker of neuronal activity, following i.c WIN55,212-2. While the CB1R 
antagonist AM251 did not alter the number of c-Fos expressing neurons in the RVLM, it 
abrogated the WIN55,212-2-induced increase in c-Fos expressing neurons. These effects parallel 
to and further confirm the involvement of the RVLM neurochemical responses in the 
hemodynamic effects elicited by WIN55,212-2 as discussed above. 
In the second part of this study, we provided evidence of a functional crosstalk between 
central CB1R and OX1R signaling and identified the enhanced release of RVLM-orexin-A as a 
possible neuronal mediator of the CB1R-evoked pressor response in conscious rats. We 
investigated the anatomical localization of CB1R and orexin-A/OX1R in the RVLM. Multiple 
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immunofluorescence studies have unraveled that CB1R labeled neurons and punctuated 
structures are in close proximity to or colocalized with orexin-A or OX1R, respectively, in the C1 
of the RVLM (immunoreactive to tyrosine hydroxylase) (Chapter 4, Fig. 4.2). In support of our 
hypothesis, we demonstrated, the novel finding that central CB1R activation significantly 
elevated orexin-A levels in the RVLM along with the pressor response (Chapter 4, Fig. 4.3). 
Interestingly, the finding that activation of cannabinoid receptors via i.c. WIN55,212-2 increased 
RVLM-orexin-A content, and probably its release, was a CB1R-mediated response as it was 
abolished by prior selective blockade of central CB1R (AM251, i.c.). Because there were no 
reported studies on the dose of the selective OX1R antagonist (SB-408124), needed to block 
central orexin-A-evoked pressor response in rats, we constructed in our model system the dose-
pressor response curve elicited by i.c. orexin-A (Fig. 4.4) (Samson, Gosnell et al. 1999; Chen, 
Hwang et al. 2000). We, then, utilized the dose of the OX1R selective antagonist SB-408124, 
which appropriately blocked the pressor response elicited by i.c. orexin-A (Fig. 4.5), to provide 
the first in vivo evidence that prior central blockade of OX1R (SB-408124) abrogates central 
CB1R (WIN55,212-2)-evoked pressor response (Fig. 4.6). This finding is in line with the 
molecular and behavioral (feeding) studies that suggest a reciprocal interaction between CB1R 
and OX1R (Hilairet, Bouaboula et al. 2003; Ellis, Pediani et al. 2006; Crespo, Heras et al. 2008). 
Indeed, it is not clear at what level these two receptors interact in central cardiovascular 
regulating areas. Nevertheless, our study has established a link between CB1R-evoked release of 
orexin-A and activation of OX1R in the RVLM in the pressor response elicited by central CB1R 
activation. While the CB1R-evoked pressor response is dependent on OX1R signaling, orexin-A-
elicited sympathoexcitation seems not to involve CB1R signaling, because, blockade of 
brainstem CB1R (AM251) did not alter the hemodynamic effects elicited by i.c. orexin-A (Fig 
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4.7). This latter observation strongly suggests that the i.c. orexin-A-mediated pressor response is 
not dependent on CB1R signaling. Nevertheless, this finding might be organ/tissue dependent 
because the CB1R antagonist SR-141716A attenuated OX1R-evoked increase in pERK1/2 in 
vitro in cells co-expressing the two receptors (Hilairet, Bouaboula et al. 2003).  
Our findings have elucidated the role of PI3K/Akt and ERK1/2 as potential downstream 
molecular mediators of the central CB1R-evoked sympathoexcitation/pressor response as 
suggested by multiple lines of evidence (discussed in Chapters 1 and 5). For example, consistent 
with a diverse physiological role of PI3K/Akt-ERK1/2 pathway, we showed that a dose-related 
reduction in pAkt phosphorylation levels in the NTS and RVLM contributes to the i.c. 
WIN55,212-2-evoked pressor response (Chapter 5, Fig. 5.2). In support of this conclusion are the 
findings that the inhibition of Akt phosphorylation in the NTS and RVLM preceded the peak 
WIN55,212-2-evoked pressor response (5 min). Our Western blot findings are consistent with 
reported findings that CB1R activation resulted in down-regulation of the PI3K/Akt signaling 
(Ellert-Miklaszewska, Kaminska et al. 2005; Greenhough, Patsos et al. 2007). However, others 
have shown that CB1R activation up-regulated PI3K/Akt signaling in U373 MG human 
astrocytoma cells (Galve-Roperh, Rueda et al. 2002),  hippocampal slices (Derkinderen, Valjent 
et al. 2003), and in vivo (Ozaita, Puighermanal et al. 2007). We are not aware of any reports on 
the effect of CB1R activation on PI3K/Akt signaling in the brainstem. Nonetheless, in further 
support of a causal role for the observed inhibition in Akt phosphorylation in the brainstem in the 
central CB1R-mediated pressor response are the findings that pharmacological inhibition of 
brainstem PI3K-Akt signaling (wortmannin) significantly enhanced the WIN55,212-2 evoked 
dose-related pressor response (Fig. 5.3). Interestingly, we observed an increase in Akt 
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phosphorylation elicited by WIN55,212-2 following CB1R blockade with AM251 in the NTS but 
not in the RVLM (Fig. 5.5 A and D). This finding clearly highlights differences between 
neurochemical responses elicited by CB1R activation in the RVLM vs. NTS. Although such a 
finding might be expected, given the physiological differences between these two neuronal 
pools, future studies are warranted to investigate the role of this neuronal response in the central 
blood pressure effects of CB1R activation.    
Furthermore, the data provide the first evidence that brainstem-ERK1/2 signaling is 
involved in central CB1R-mediated sympathoexcitation. Central administration of WIN55,212-2 
(i.c.) significantly, elevated pERK1/2 in the NTS and RVLM (Fig. 5.2 B) and (Fig. 5.6 A and D). 
Abrogation of the WIN55,212-2-mediated hemodynamic responses by PD98059 (Fig. 5.4)  and 
attenuation of the concomitant activation of ERK1/2 pathway by pretreatment with the selective 
CB1R antagonist AM251(i.c.) precluded the involvement of CB2R in these responses (Fig. 5.6 A 
and D). In view of the crucial role of brainstem pERK1/2 signaling in central control of blood 
pressure, previous studies from the laboratory (Zhang and Abdel-Rahman 2005; Nassar and 
Abdel-Rahman 2008) and others (Seyedabadi, Goodchild et al. 2001; Lin, Matsumura et al. 
2004; Chan, Wang et al. 2007), in addition to findings from this study, it was suggested that 
brainstem ERK1/2 has a bi-directional role in central regulation of blood pressure. Based on the 
molecular findings from Western blotting (Fig. 5.5 B, C, E and F) and (Fig. 5.6 B, C, E and F), 
we concluded that the effect of WIN55,212-2 on PI3K/Akt may contribute to the enhancement of 
ERK1/2 phosphoryation because in the presence of the PI3K/Akt inhibitor wortmannin 
WIN55,212-2-induced ERK1/2 phosphorylation was exacerbated (more evident in the NTS than 
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RVLM). Additionally, PD98059 alone or in the presence of WIN55,212-2 had no effect on 
brainstem pAkt phosphorylation levels.  
We have investigated whether nNOS-NO plays a significant role in the central CB1R-
mediated pressor response. This hypothesis was based on a well-documented role of NOS-NO 
signaling in the RVLM regulation of autonomic function (Martins-Pinge, Araujo et al. 1999; 
Martins-Pinge, Garcia et al. 2007; Mayorov 2007). We have demonstrated that intra-RVLM 
WIN55212,2 microinjection elicited dose-dependent increases in real-time RVLM-NO and blood 
pressure; the latter  was measured using in vivo electrochemistry (Chapter 6, Fig. 6.4) and is 
possibly nNOS-generated because: (i) parallel to the WIN55,212-2 dose-dependent enhancement 
of NO-release, we detected a significant increase in nNOS phosphorylation in the RVLM, which 
received WIN55,212-2 compared to the contra-lateral side (control) (Fig. 6.5); (ii) i.c. 
WIN55,212-2 increased the number of nNOS-ir neurons expressing c-Fos, denoting an increase 
in nNOS neuronal  activity and this effect was abolished following selective CB1R blockade 
(AM251) (Figs. 6.9 and 6.10); (iii) only RVLM nNOS, but not eNOS or iNOS, derived NO is 
implicated in centrally evoked hypertension (Martins-Pinge, Garcia et al. 2007).  
It is highly likely that central CB1R-elicited sympathoexcitation is mediated via indirect 
modulation of presympathetic neurons in the brainstem whose activity is regulated by an array of 
tonic excitatory and inhibitory inputs (Pilowsky and Goodchild 2002; Padley, Li et al. 2003). 
Notably, CB1R modulates synaptic transmission of both inhibitory (GABA) and excitatory 
(glutamate) neurotransmitters (Freund, Katona et al. 2003; Piomelli 2003; Drew, Mitchell et al. 
2008; Jelsing, Galzin et al. 2009). Interestingly, stimulation of central GABAA receptors 
(muscimol) caused the following: (i) abolished the CB1R-evoked pressor response and the 
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elevation in plasma NE (Fig. 6.6); (ii) attenuated the WIN55,212-2 evoked increase in the 
activity (c-Fos) of catecholamine (TH-ir) as well as nitroxidergic (nNOS-ir) neurons (Figs. 6.7 
and 7.8) and (Figs. 6.9 and 6.10), respectively. These findings are consistent with reported in 
vitro findings that demonstrated CB1R-evoked inhibition of GABAergic transmission in cultured 
RVLM neurons (Vaughan, McGregor et al. 1999). Yet, in the NTS, studies have demonstrated a 
controversial role for CB1R-mediated presynaptic modulation of excitatory (glutamate) and 
inhibitory (GABA) neurotransmitters. Anandamide (AEA), an endogenous CB1R agonist, 
increased baroreflex-mediated sympathoinhibition in the NTS, presumably, via presynaptic 
inhibition of GABA release because the response was reversed in presence of the GABAAR 
antagonist (Seagard, Dean et al. 2004).  
In summary, the present study highlights the predominant sympathoexcitatory effect of 
brainstem CB1R activation in conscious rats as shown in Fig. 1.7. Moreover, it demonstrated that 
CB1R stimulation enhanced neuronal activity of presympathetic neurons in the RVLM, which 
are essential for the central regulation of cardiovascular function. We provided the first evidence 
for a functional crosstalk between cannabinoid and orexins systems within the medullary centers 
controlling cardiovascular function. CB1R activation in the brainstem elicited pressor response 
along with elevation of an orexin-A levels in the RVLM. Importantly, blockade of orexin-
A/OX1R signaling abolished CB1R-evoked pressor effect. On the other hand, orexin-A/OX1R 
pressor response was not altered by prior blockade of central CB1R. Colocalization studies have 
unraveled close proximity of orexin-A/OX1R to CB1R labeled neurons and punctate-like 
structures (indicative of presynaptic location), which support the pharmacological findings. 
Furthermore, the present study delineated a novel role for PI3K/Akt/ERK1/2 signaling in the 
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brainstem (RVLM and NTS) that seems to contribute, at least in part, to the sympathoexcitatory 
responses elicited by the central CB1R activation in conscious rats. The findings of this study 
demonstrated that CB1R activation in the RVLM and NTS elicits down-regulation of PI3K/Akt 
pathway in the RVLM and NTS along with the pressor response. This notion is further supported 
by exacerbation of WIN55,212-2 evoked hemodynamic responses when PI3K/Akt was inhibited 
with wortmannin. We speculated that inhibition of PI3K/Akt signaling in the brainstem might 
underlie the CB1R-mediated modulation of inhibitory (GABA) neurotransmission. By contrast, 
the CB1R-evoked sympathoexcitation was associated with an elevation in the pERK1/2 
phosphorylation in the brainstem. Further, suppressing ERK1/2 signaling abolished the central 
CB1R-evoked pressor response. Finally, the findings of this study demonstrated that CB1R 
activation in the RVLM enhanced neuronal activity in two distinct neuronal populations 
(catecholaminergic and nitroxidergic) essential for the central regulation of cardiovascular 
function. These latter neuronal responses may be linked to the modulation of brainstem 
GABAergic neurotransmission and subsequently to the central CB1R-evoked sympathoexcitatory 
and pressor response.  
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Fig. 7.1 Schematic presentation of the major findings of the study and 
proposed future studies. See details in the text. 
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Future directions 
The present findings suggest a novel role for brainstem PI3K/Akt/ERK1/2 signaling in the 
central CB1R-evoked pressor response (Chapter 5). Importantly, the findings established a causal 
link between suppression of brainstem GABAergic neurotransmission and the 
sympathoexcitatory/pressor response elicited by central CB1R activation (Chapter 6). Notably, in 
vivo and in vitro findings associated the reduced PI3K/Akt or enhanced pERK1/2 signaling with 
modulation of GABAergic transmission (Wang, Liu et al. 2003; Bell-Horner, Dohi et al. 2006). 
Therefore, it will be interesting to determine whether inhibition of PI3K (wortmannin) or 
ERK1/2 (PD98059) underlies CB1R-evoked suppression of GABAergic transmission. We 
concluded that PI3K/Akt signaling is upstream to ERK1/2 signaling because the significant 
increase in ERK1/2 phosphorylation by WIN55,212-2 was exacerbated in presence of PI3K/Akt 
inhibition (wortmannin) (Chapter 5). Further studies are needed to elucidate the signaling 
pathways between PI3K/Akt and ERK1/2, which seem to influence the balance between 
sympathoexcitatory and sympathoinhibitory modulators in the brainstem. The pharmacological 
(central CB1R blockade and GABAAR activation) along with the biochemical (plasma NE) and 
neurochemical (Western blot and immunofluorescence) findings suggest a role for enhanced 
nNOS-NO signaling in the RVLM in the suppression of localized GABAergic transmission and 
the subsequent sympathoexcitation and pressor response. The use of the specific nNOS inhibitor 
(NPLA; N
ω-
Propyl-L-arginine) (Kakoki, Zou et al. 2001) will address whether RVLM-nNOS 
activation plays a causal role in these neuronal events. 
 
 179 
 
 
 
 
 
 REFERENCES 
Aicher, S. A., J. A. Kraus, et al. (2001). "Selective distribution of mu-opioid receptors in C1 
adrenergic neurons and their afferents." Journal of Comparative Neurology 433(1): 23-
33. 
Aicher, S. A., O. S. Kurucz, et al. (1995). "Nucleus tractus solitarius efferent terminals synapse 
on neurons in the caudal ventrolateral medulla that project to the rostral ventrolateral 
medulla." Brain Research 693(1-2): 51-63. 
Aicher, S. A. and A. Randich (1990). "Antinociception and cardiovascular responses produced 
by electrical stimulation in the nucleus tractus solitarius, nucleus reticularis ventralis, and 
the caudal medulla." Pain 42(1): 103-119. 
Aicher, S. A., R. H. Saravay, et al. (1996). "Monosynaptic projections from the nucleus tractus 
solitarii to C1 adrenergic neurons in the rostral ventrolateral medulla: comparison with 
input from the caudal ventrolateral medulla." Journal of Comparative Neurology 373(1): 
62-75. 
Alen, F., G. Moreno-Sanz, et al. (2008). "Pharmacological activation of CB1 and D2 receptors in 
rats: predominant role of CB1 in the increase of alcohol relapse." European Journal of 
Neuroscience 27(12): 3292-3298. 
Ally, A., S. Kabadi, et al. (2007). "Neuronal nitric oxide synthase (nNOS) blockade within the 
ventrolateral medulla differentially modulates cardiovascular responses and nNOS 
expression during static skeletal muscle contraction." Brain Research 1150: 21-31. 
Andrezik, J. A., V. Chan-Palay, et al. (1981). "The nucleus paragigantocellularis lateralis in the 
rat." Anatomy and Embryology 161(4): 355-371. 
Azad, S. C., G. Marsicano, et al. (2001). "Differential role of the nitric oxide pathway on 9-
THC-induced central nervous system effects in the mouse." European Journal of 
Neuroscience 13(3): 561-568. 
 181 
 
Bell-Horner, C. L., A. Dohi, et al. (2006). "ERK/MAPK pathway regulates GABAA receptors." 
Journal of Neurobiology 66(13): 1467-1474. 
Bender, T. S. and A. A. Abdel-Rahman (2009). "Alpha 2A-adrenergic receptor signaling 
underlies synergistic enhancement of ethanol-induced behavioral impairment by 
clonidine." Alcoholism: Clinical & Experimental Research 33(3): 408-418. 
Benowitz, N. L., J. Rosenberg, et al. (1979). "Cardiovascular effects of intravenous delta-9-
tetrahydrocannabinol: autonomic nervous mechanisms." Clinical Pharmacology & 
Therapeutics 25(4): 440-446. 
Bidaut-Russell, M., W. A. Devane, et al. (1990). "Cannabinoid Receptors and Modulation of 
Cyclic AMP Accumulation in the Rat Brain." Journal of Neurochemistry 55(1): 21-26. 
Boone, J. B., Jr. and J. M. Corry (1996). "Proenkephalin gene expression in the brainstem 
regulates post-exercise hypotension." Brain Research. Molecular Brain Research 42(1): 
31-38. 
Bouaboula, M., C. Poinot-Chazel, et al. (1995). "Activation of mitogen-activated protein kinases 
by stimulation of the central cannabinoid receptor CB1." Biochemical Journal 312(Pt 2): 
637-641. 
Chan, S. H., L.-L. Wang, et al. (2007). "Upregulation of AT1 receptor gene on activation of 
protein kinase C[beta]/nicotinamide adenine dinucleotide diphosphate oxidase/ERK1/2/c-
fos signaling cascade mediates long-term pressor effect of angiotensin II in rostral 
ventrolateral medulla." Journal of Hypertension 25(9): 1845-1861 
1810.1097/HJH.1840b1013e328217b328286. 
Chan, S. H. H., K.-S. Hsu, et al. (2005). NADPH Oxidase-Derived Superoxide Anion Mediates 
Angiotensin II-Induced Pressor Effect via Activation of p38 Mitogen-Activated Protein 
Kinase in the Rostral Ventrolateral Medulla. 97: 772-780. 
 182 
 
Chen, C. T., L. L. Hwang, et al. (2000). "Pressor effects of orexins injected intracisternally and 
to rostral ventrolateral medulla of anesthetized rats." American Journal of Physiology - 
Regulatory Integrative & Comparative Physiology 278(3): R692-697. 
Childers, S. R., L. Fleming, et al. (1992). "Opioid and Cannabinoid Receptor Inhibition of 
Adenylyl Cyclase in Braina." Annals of the New York Academy of Sciences 654(1): 33-
51. 
Ciriello, J., Z. Li, et al. (2003). "Cardioacceleratory responses to hypocretin-1 injections into 
rostral ventromedial medulla." Brain Research 991(1-2): 84-95. 
Crespo, I., R. G. d. Heras, et al. (2008). "Pretreatment with subeffective doses of Rimonabant 
attenuates orexigenic actions of orexin A-hypocretin 1." Neuropharmacology 54(1): 219-
225. 
Dampney, R. A., J. Czachurski, et al. (1987). "Afferent connections and spinal projections of the 
pressor region in the rostral ventrolateral medulla of the cat." Journal of the Autonomic 
Nervous System 20(1): 73-86. 
Dampney, R. A., J. Horiuchi, et al. (2003). "Medullary and supramedullary mechanisms 
regulating sympathetic vasomotor tone." Acta Physiologica Scandinavica 177(3): 209-
218. 
Dampney, R. A., J. W. Polson, et al. (2003). "Functional organization of brain pathways 
subserving the baroreceptor reflex: studies in conscious animals using immediate early 
gene expression." Cellular & Molecular Neurobiology 23(4-5): 597-616. 
de Bruin, N. M. W. J., J. Prickaerts, et al. (2010). "SLV330, a cannabinoid CB1 receptor 
antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition 
Tasks in rodents." Neurobiology of Learning and Memory 93(4): 522-531. 
 183 
 
de Lecea, L., T. S. Kilduff, et al. (1998). "The hypocretins: Hypothalamus-specific peptides with 
neuroexcitatory activity." Proceedings of the National Academy of Sciences of the United 
States of America 95(1): 322-327. 
Derkinderen, P., E. Valjent, et al. (2003). "Regulation of extracellular signal-regulated kinase by 
cannabinoids in hippocampus." Journal of Neuroscience 23(6): 2371-2382. 
Drake, C. T., S. A. Aicher, et al. (2005). "Redistribution of mu-opioid receptors in C1 adrenergic 
neurons following chronic administration of morphine." Experimental Neurology 196(2): 
365-372. 
Drew, G. M., V. A. Mitchell, et al. (2008). "Glutamate spillover modulates GABAergic synaptic 
transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors 
and endocannabinoid signaling." Journal of Neuroscience 28(4): 808-815. 
Dudek, F. E., W. A. Pouliot, et al. (2010). "The effect of the cannabinoid-receptor antagonist, 
SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat." 
Epilepsia 51: 126-130. 
El-Mas, M. M. and A. A. Abdel-Rahman (2004). "Differential modulation by estrogen of alpha2-
adrenergic and I1-imidazoline receptor-mediated hypotension in female rats." Journal of 
Applied Physiology 97(4): 1237-1244. 
Ellert-Miklaszewska, A., B. Kaminska, et al. (2005). "Cannabinoids down-regulate PI3K/Akt 
and Erk signalling pathways and activate proapoptotic function of Bad protein." Cellular 
Signalling 17(1): 25-37. 
Ellis, J., J. D. Pediani, et al. (2006). "Orexin-1 receptor-cannabinoid CB1 receptor 
heterodimerization results in both ligand-dependent and -independent coordinated 
alterations of receptor localization and function." Journal of Biological Chemistry 
281(50): 38812-38824. 
 184 
 
Farlow, D. M., A. K. Goodchild, et al. (1984). "Evidence that vasomotor neurons in the rostral 
ventrolateral medulla project to the spinal sympathetic outflow via the dorsomedial 
pressor area." Brain Research 298(2): 313-320. 
Farr, S. A., W. A. Banks, et al. (2005). "Orexin-A-induced feeding is dependent on nitric oxide." 
Peptides 26(5): 759-765. 
Feldberg, W. and P. G. Guertzenstein (1976). "Vasodepressor effects obtained by drugs acting 
on the ventral surface of the brain stem." Journal of Physiology 258(2): 337-355. 
Felder, C. C., K. E. Joyce, et al. (1998). "LY320135, a Novel Cannabinoid CB1 Receptor 
Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP 
Accumulation." Journal of Pharmacology and Experimental Therapeutics 284(1): 291-
297. 
Feng, P., D. Vurbic, et al. (2007). "Brain orexins and wake regulation in rats exposed to maternal 
deprivation." Brain Research 1154: 163-172. 
Foltin, R. W., M. W. Fischman, et al. (1987). "Marijuana and cocaine interactions in humans: 
cardiovascular consequences." Pharmacology, Biochemistry & Behavior 28(4): 459-464. 
Freund, T. F., I. Katona, et al. (2003). "Role of endogenous cannabinoids in synaptic signaling." 
Physiological Reviews 83(3): 1017-1066. 
Friedemann MN, Robinson SW , et al. (1996). "o-Phenylenediamine-modified carbon fiber 
electrodes for the detection of nitric oxide." Analytical Chemistry 68: 2621-2628. 
Galve-Roperh, I., D. Rueda, et al. (2002). "Mechanism of extracellular signal-regulated kinase 
activation by the CB(1) cannabinoid receptor." Molecular Pharmacology 62(6): 1385-
1392. 
 185 
 
Gardiner, S. M., J. E. March, et al. (2001). "Regional haemodynamic responses to the 
cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, 
transgenic rats." British Journal of Pharmacology 133(3): 445-453. 
Gardiner, S. M., J. E. March, et al. (2002). "Complex regional haemodynamic effects of 
anandamide in conscious rats." British Journal of Pharmacology 135(8): 1889-1896. 
Gerard, C. M., C. Mollereau, et al. (1991). "Molecular cloning of a human cannabinoid receptor 
which is also expressed in testis." Biochemical Journal 279(Pt 1): 129-134. 
Glass, M. and C. C. Felder (1997). "Concurrent stimulation of cannabinoid CB1 and dopamine 
D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage 
to the CB1 receptor." Journal of Neuroscience 17(14): 5327-5333. 
Goodchild, A. K., J. K. Phillips, et al. (2001). "Differential expression of catecholamine 
synthetic enzymes in the caudal ventral pons." Journal of Comparative Neurology 438(4): 
457-467. 
Greenhough, A., H. A. Patsos, et al. (2007). "The cannabinoid delta(9)-tetrahydrocannabinol 
inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated 
apoptosis in colorectal cancer cells." Int J Cancer 121(10): 2172-2180. 
Griffin, G., P. J. Atkinson, et al. (1998). "Evaluation of Cannabinoid Receptor Agonists and 
Antagonists Using the Guanosine-5′-O-(3-[35S]thio)-triphosphate Binding Assay in Rat 
Cerebellar Membranes." Journal of Pharmacology and Experimental Therapeutics 
285(2): 553-560. 
Guertzenstein, P. G. (1972). "Vasodepressor and pressor responses to drugs topically applied to 
the ventral surface of the brain stem." Journal of Physiology 224(2): 84P-85P. 
Guertzenstein, P. G. and A. Silver (1974). "Fall in blood pressure produced from discrete regions 
of the ventral surface of the medulla by glycine and lesions." Journal of Physiology 
242(2): 489-503. 
 186 
 
Guichu Li and Abdel-Rahman AA (2007). "Direct Evidence for Imidazoline (I1) Receptor 
Modulation of Ethanol Action on Norepinephrine-Containing Neurons in the Rostral 
Ventrolateral Medulla in Conscious Spontaneously Hypertensive Rats." Alcoholism: 
Clinical and Experimental Research 31(4): 684-693. 
Guichu Li and Abdel A. Abdel-Rahman (2009). "Estrogen-Dependent Enhancement of NO 
Production in the Nucleus Tractus Solitarius Contributes to Ethanol-Induced Hypotension 
in Conscious Female Rats." Alcoholism: Clinical and Experimental Research 33(2): 366-
374. 
Guyenet, P. G. (2006). "The sympathetic control of blood pressure." Nat Rev Neurosci 7(5): 
335-346. 
Guyenet, P. G., T. M. Filtz, et al. (1987). "Role of excitatory amino acids in rat vagal and 
sympathetic baroreflexes." Brain Research 407(2): 272-284. 
Guyenet, P. G., J. R. Haselton, et al. (1989). Chapter 7 Sympathoexcitatory neurons of the 
rostroventrolateral medulla and the origin of the sympathetic vasomotor tone. Progress in 
Brain Research. M. M. C. John Ciriello and P. Canio, Elsevier. Volume 81: 105-116. 
Guyenet, P. G., J. R. Haselton, et al. (1989). "Sympathoexcitatory neurons of the 
rostroventrolateral medulla and the origin of the sympathetic vasomotor tone." Progress 
in Brain Research 81: 105-116. 
Guyenet, P. G., N. Koshiya, et al. (1996). Chapter 8 Role of medulla oblongata in generation of 
sympathetic and vagal outflows. Progress in Brain Research. R. B. G. Holstege and C. B. 
Saper, Elsevier. Volume 107: 127-144. 
Hara, J., C. T. Beuckmann, et al. (2001). "Genetic ablation of orexin neurons in mice results in 
narcolepsy, hypophagia, and obesity." Neuron 30(2): 345-354. 
 187 
 
Herkenham, M., A. B. Lynn, et al. (1991). "Characterization and localization of cannabinoid 
receptors in rat brain: a quantitative in vitro autoradiographic study." Journal of 
Neuroscience 11(2): 563-583. 
Hilairet, S., M. Bouaboula, et al. (2003). "Hypersensitization of the Orexin 1 receptor by the 
CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, 
SR141716." Journal of Biological Chemistry 278(26): 23731-23737. 
Hirooka, Y., J. W. Polson, et al. (1997). "Hypoxia-induced Fos expression in neurons projecting 
to the pressor region in the rostral ventrolateral medulla." Neuroscience 80(4): 1209-
1224. 
Hokfelt T., Johansson O., et al. (1984). "Central catecholamine neurons as revealed by 
immunohistochemsitry with special reference to adrenaline neurons." Classical 
Transmitters in the CNS: 157-276. 
Horiuchi, J., P. D. Potts, et al. (1999). "Distribution of neurons projecting to the rostral 
ventrolateral medullary pressor region that are activated by sustained hypotension." 
Neuroscience 89(4): 1319-1329. 
Howlett, A. C. (1998). "The CB1Cannabinoid Receptor in the Brain." Neurobiology of Disease 
5(6): 405-416. 
Howlett, A. C. and S. Mukhopadhyay (2000). "Cellular signal transduction by anandamide and 
2-arachidonoylglycerol." Chemistry & Physics of Lipids 108(1-2): 53-70. 
Howlett, A. C., J. M. Qualy, et al. (1986). "Involvement of Gi in the inhibition of adenylate 
cyclase by cannabimimetic drugs." Molecular Pharmacology 29(3): 307-313. 
Huang, H.-N., P.-J. Lu, et al. (2004). "In Situ Akt Phosphorylation in the Nucleus Tractus 
Solitarii Is Involved in Central Control of Blood Pressure and Heart Rate." Circulation 
110(16): 2476-2483. 
 188 
 
Huang, H., C. Acuna-Goycolea, et al. (2007). "Cannabinoids excite hypothalamic melanin-
concentrating hormone but inhibit hypocretin/orexin neurons: implications for 
cannabinoid actions on food intake and cognitive arousal." Journal of Neuroscience 
27(18): 4870-4881. 
Huang, S.-C., Dai YW, et al. (2010). "Orexins Depolarize Rostral Ventrolateral Medulla 
Neurons and Increase Arterial Pressure and Heart Rate in Rats Mainly via Orexin 2 
Receptors." journal of Pharmacology & Experimental Therapeutics 334(2): 522-529. 
Hubbard, J. W., R. A. Buchholz, et al. (1986). "Plasma norepinephrine concentration reflects 
pharmacological alteration of sympathetic activity in the conscious cat." Journal of the 
Autonomic Nervous System 15(1): 93-100. 
Javanmardi, K., M. Parviz, et al. (2005). "Involvement of N-methyl-D-aspartate Receptors and 
Nitric Oxide in the Rostra Ventromedial Medulla in Modulating Morphine Pain-
Inhibitory Signals From the Periaqueductal Grey  Matter in Rats." Clinical and 
Experimental Pharmacology and Physiology 32(7): 585-589. 
Jelsing, J., A.-M. Galzin, et al. (2009). "Localization and phenotypic characterization of 
brainstem neurons activated by rimonabant and WIN55,212-2." Brain Research Bulletin 
78(4-5): 202-210. 
Jeske, I. and K. E. McKenna (1992). "Quantitative analysis of bulbospinal projections from the 
rostral ventrolateral medulla: Contribution of C1-adrenergic and nonadrenergic neurons." 
The Journal of Comparative Neurology 324(1): 1-13. 
Jones, J. D., S. T. Carney, et al. (2008). "Cannabinoid receptor-mediated translocation of NO-
sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells." 
Neuropharmacology 54(1): 23-30. 
Kakoki, M., A. P. Zou, et al. (2001). "The influence of nitric oxide synthase 1 on blood flow and 
interstitial nitric oxide in the kidney." Am J Physiol Regul Integr Comp Physiol 281(1): 
R91-97. 
 189 
 
Kanjhan, R., J. Lipski, et al. (1995). "A comparative study of pre-sympathetic and Bötzinger 
neurons in the rostral ventrolateral medulla (RVLM) of the rat." Brain Research 699(1): 
19-32. 
Karlsson, G. A., K. A. Chaitoff, et al. (2007). "Modulation of cardiovascular responses and 
neurotransmission during peripheral nociception following nNOS antagonism within the 
periaqueductal gray." Brain Research 1143: 150-160. 
Karlsson, G. A., C. V. Preuss, et al. (2006). "Medullary monoamines and NMDA-receptor 
regulation of cardiovascular responses during peripheral nociceptive stimuli." 
Neuroscience Research 55(3): 316-326. 
Kearn, C. S., K. Blake-Palmer, et al. (2005). "Concurrent stimulation of cannabinoid CB1 and 
dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-
talk?" Molecular Pharmacology 67(5): 1697-1704. 
Kishi, T., Y. Hirooka, et al. (2001). "Overexpression of eNOS in the RVLM Causes Hypotension 
and Bradycardia Via GABA Release." Hypertension 38(4): 896-901. 
Kreitzer, A. C. and W. G. Regehr (2001). "Retrograde Inhibition of Presynaptic Calcium Influx 
by Endogenous Cannabinoids at Excitatory Synapses onto Purkinje Cells." Neuron 29(3): 
717-727. 
Lake, K. D., D. R. Compton, et al. (1997). "Cannabinoid-induced hypotension and bradycardia 
in rats mediated by CB1-like cannabinoid receptors." Journal of Pharmacology & 
Experimental Therapeutics 281(3): 1030-1037. 
Lake, K. D., B. R. Martin, et al. (1997). "Cardiovascular effects of anandamide in anesthetized 
and conscious normotensive and hypertensive rats." Hypertension 29(5): 1204-1210. 
Lauckner, J. E., B. Hille, et al. (2005). "The cannabinoid agonist WIN55,212-2 increases 
intracellular calcium via CB1 receptor coupling to Gq/11 G proteins." Proceedings of the 
National Academy of Sciences of the United States of America 102(52): 19144-19149. 
 190 
 
Li, G., X. Wang, et al. (2005). "Neuronal norepinephrine responses of the rostral ventrolateral 
medulla and nucleus tractus solitarius neurons distinguish the I1- from the alpha2-
receptor-mediated hypotension in conscious SHRs." Journal of Cardiovascular 
Pharmacology 46(1): 52-62. 
Limin Mao, A. A. A.-R. (1998). "Ethanol Counteraction of Clonidine-Evoked Inhibition of 
Norepinephrine Release in Rostral Ventrolateral Medulla of Rats." Alcoholism: Clinical 
and Experimental Research 22(6): 1285-1291. 
Lin, Y. Z., K. Matsumura, et al. (2004). "Role of ERK and Rho kinase pathways in central 
pressor action of urotensin II." Journal of Hypertension 22(5): 983-988. 
Machado, B. H., L. G. Bonagamba, et al. (2002). "Pressor response to microinjection of 
orexin/hypocretin into rostral ventrolateral medulla of awake rats." Regulatory Peptides 
104(1-3): 75-81. 
Makara, J. K., I. Katona, et al. (2007). "Involvement of Nitric Oxide in Depolarization-Induced 
Suppression of Inhibition in Hippocampal Pyramidal Cells during Activation of 
Cholinergic Receptors." J. Neurosci. 27(38): 10211-10222. 
Malinowska, B., A. Zakrzeska, et al. (2010). "Involvement of central β2 adrenergic, NMDA and 
thromboxane A2 receptors in the pressor effect of anandamide in rats." Naunyn-
Schmiedeberg's Archives of Pharmacology 381(4): 349-360. 
Martins-Pinge, M. C., G. C. Araujo, et al. (1999). "Nitric Oxide-Dependent Guanylyl Cyclase 
Participates in the Glutamatergic Neurotransmission Within the Rostral Ventrolateral 
Medulla of Awake Rats." Hypertension 34(4): 748-751. 
Martins-Pinge, M. C., M. R. Garcia, et al. (2007). "Differential influence of iNOS and nNOS 
inhibitors on rostral ventrolateral medullary mediated cardiovascular control in conscious 
rats." Autonomic Neuroscience-Basic & Clinical 131(1-2): 65-69. 
 191 
 
Matias, I., L. Cristino, et al. (2008). "Endocannabinoids: some like it fat (and sweet too)." 
Journal of Neuroendocrinology 20 Suppl 1: 100-109. 
Matsuda, L. A., S. J. Lolait, et al. (1990). "Structure of a cannabinoid receptor and functional 
expression of the cloned cDNA." Nature 346(6284): 561-564. 
Mayorov, D. N. (2007). "Nitric oxide synthase inhibition in rostral ventrolateral medulla 
attenuates pressor response to psychological stress in rabbits." Neuroscience Letters 
424(2): 89-93. 
McAllen, R. M. and R. A. Dampney (1989). "The selectivity of descending vasomotor control by 
subretrofacial neurons." Progress in Brain Research 81: 233-242. 
McIntosh, B. T., B. Hudson, et al. (2007). "Agonist-dependent cannabinoid receptor signalling in 
human trabecular meshwork cells." Br J Pharmacol 152(7): 1111-1120. 
Mendizabal, V. E. and E. Adler-Graschinsky (2007). "Cannabinoids as therapeutic agents in 
cardiovascular disease: a tale of passions and illusions." British Journal of Pharmacology 
151(4): 427-440. 
Micalizzi, E. R. and D. T. Pals (1979). "Evaluation of plasma norepinephrine as an index of 
sympathetic neuron function in the conscious, unrestrained rat." Life Sciences 24(22): 
2071-2076. 
Miura, M. and D. J. Reis (1972). "The role of the solitary and paramedian reticular nuclei in 
mediating cardiovascular reflex responses from carotid baro- and chemoreceptors." The 
Journal of Physiology 223(2): 525-548. 
Morrish, A. C., M. N. Hill, et al. (2009). "Protracted cannabinoid administration elicits 
antidepressant behavioral responses in rats: Role of gender and noradrenergic 
transmission." Physiology & Behavior 98(1-2): 118-124. 
 192 
 
Mu, J., S. Y. Zhuang, et al. (1999). "Cannabinoid receptors differentially modulate potassium A 
and D currents in hippocampal neurons in culture." Journal of Pharmacology & 
Experimental Therapeutics 291(2): 893-902. 
Mueller, P. J. and E. M. Hasser (2006). "Putative role of the NTS in alterations in neural control 
of the circulation following exercise training in rats." Am J Physiol Regul Integr Comp 
Physiol 290(2): R383-392. 
Narita, M., O. Ohnishi, et al. (2002). "Implications of phosphoinositide 3-kinase in the mu- and 
delta-opioid receptor-mediated supraspinal antinociception in the mouse." Neuroscience 
113(3): 647-652. 
Nassar, N. and A. A. Abdel-Rahman (2006). "Central adenosine signaling plays a key role in 
centrally mediated hypotension in conscious aortic barodenervated rats." Journal of 
Pharmacology & Experimental Therapeutics 318(1): 255-261. 
Nassar, N. and A. A. Abdel-Rahman (2008). "Brainstem phosphorylated extracellular signal-
regulated kinase 1/2-nitric-oxide synthase signaling mediates the adenosine A2A-
dependent hypotensive action of clonidine in conscious aortic barodenervated rats." 
Journal of Pharmacology & Experimental Therapeutics 324(1): 79-85. 
Nattie, E. E. and A. H. Li (1990). "Fluorescence location of RVLM kainate microinjections that 
alter the control of breathing." J Appl Physiol 68(3): 1157-1166. 
Neu, A., C. Foldy, et al. (2007). "Postsynaptic origin of CB1-dependent tonic inhibition of 
GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the 
CA1 region of the rat hippocampus." J Physiol 578(1): 233-247. 
Niederhoffer, N., K. Schmid, et al. (2003). "The peripheral sympathetic nervous system is the 
major target of cannabinoids in eliciting cardiovascular depression." Naunyn-
Schmiedebergs Archives of Pharmacology 367(5): 434-443. 
 193 
 
Niederhoffer, N. and B. Szabo (1999). "Effect of the cannabinoid receptor agonist WIN55212-2 
on sympathetic cardiovascular regulation." British Journal of Pharmacology 126(2): 457-
466. 
Niederhoffer, N. and B. Szabo (2000). "Cannabinoids cause central sympathoexcitation and 
bradycardia in rabbits." Journal of Pharmacology & Experimental Therapeutics 294(2): 
707-713. 
Nomura, S. and N. Mizuno (1982). "Central distribution of afferent and efferent components of 
the glossopharyngeal nerve: an HRP study in the cat." Brain Research 236(1): 1-13. 
O'Sullivan, S. E., M. D. Randall, et al. (2007). "The in vitro and in vivo cardiovascular effects of 
Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-
oxide synthase." Journal of Pharmacology & Experimental Therapeutics 321(2): 663-672. 
Ohno-Shosaku, T., T. Maejima, et al. (2001). "Endogenous Cannabinoids Mediate Retrograde 
Signals from Depolarized Postsynaptic Neurons to Presynaptic Terminals." Neuron 
29(3): 729-738. 
Ozaita, A., E. Puighermanal, et al. (2007). "Regulation of PI3K/Akt/GSK-3 pathway by 
cannabinoids in the brain." J Neurochem 102(4): 1105-1114. 
Padley, J. R., Q. Li, et al. (2003). "Cannabinoid receptor activation in the rostral ventrolateral 
medulla oblongata evokes cardiorespiratory effects in anaesthetised rats." British Journal 
of Pharmacology 140(2): 384-394. 
Paxinos, G. and C. Watson (2005). The rat brain in stereotaxic coordinates. Amsterdam ; Boston, 
Elsevier Academic Press. 
Pfitzer, T., N. Niederhoffer, et al. (2004). "Central effects of the cannabinoid receptor agonist 
WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats." British 
Journal of Pharmacology 142(6): 943-952. 
 194 
 
Pilowsky, P., J. Minson, et al. (1986). "Does substance P coexist with adrenaline in neurones of 
the rostral ventrolateral medulla in the rat?" Neuroscience Letters 71(3): 293-298. 
Pilowsky, P. M. and A. K. Goodchild (2002). "Baroreceptor reflex pathways and 
neurotransmitters: 10 years on." Journal of Hypertension 20(9): 1675-1688. 
Piomelli, D. (2003). "The molecular logic of endocannabinoid signalling." Nature Reviews 
Neuroscience 4(11): 873-884. 
Polson, J. W., G. M. Halliday, et al. (1992). "Rostrocaudal differences in morphology and 
neurotransmitter content of cells in the subretrofacial vasomotor nucleus." Journal of the 
Autonomic Nervous System 38(2): 117-137. 
Potts, P. D., A. M. Allen, et al. (2000). "Does angiotensin II have a significant tonic action on 
cardiovascular neurons in the rostral and caudal VLM?" American Journal of Physiology 
- Regulatory Integrative & Comparative Physiology 279(4): R1392-1402. 
Rademacher, D. J., S. Patel, et al. (2003). "Microinjection of a cannabinoid receptor antagonist 
into the NTS increases baroreflex duration in dogs." American Journal of Physiology - 
Heart & Circulatory Physiology 284(5): H1570-1576. 
Ralevic, V. (2000). "P2 receptors in the central and peripheral nervous systems modulating 
sympathetic vasomotor tone." Journal of the Autonomic Nervous System 81(1-3): 205-
211. 
Randall, M. D., D. Harris, et al. (2002). "Cardiovascular effects of cannabinoids." Pharmacology 
& Therapeutics 95(2): 191-202. 
Randall, M. D., D. A. Kendall, et al. (2004). "The complexities of the cardiovascular actions of 
cannabinoids." British Journal of Pharmacology 142(1): 20-26. 
Ross, C., D. Ruggiero, et al. (1984). "Tonic vasomotor control by the rostral ventrolateral 
medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline 
 195 
 
neurons on arterial pressure, heart rate, and plasma catecholamines and vasopressin." J. 
Neurosci. 4(2): 474-494. 
Ross, C. A., D. A. Ruggiero, et al. (1984). "Rostral ventrolateral medulla: selective projections to 
the thoracic autonomic cell column from the region containing C1 adrenaline neurons." 
Journal of Comparative Neurology 228(2): 168-185. 
Ross, C. A., D. A. Ruggiero, et al. (1985). "Projections from the nucleus tractus solitarii to the 
rostral ventrolateral medulla." Journal of Comparative Neurology 242(4): 511-534. 
Ruggiero DA, Cravo SL, et al. (1989). "Central control of the circulation by the rostral 
ventrolateral reticular nucleus: anatomical substrates." Progress in Brain Research 81: 49-
79. 
Sakurai, T., A. Amemiya, et al. (1998). "Orexins and Orexin Receptors: A Family of 
Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding 
Behavior." Cell 92(4): 573-585. 
Samson, W. K., B. Gosnell, et al. (1999). "Cardiovascular regulatory actions of the hypocretins 
in brain." Brain Research 831(1-2): 248-253. 
Samuel H H Chan, Ling-Lin Wang, et al. (2003). "Differential engagements of glutamate and 
GABA receptors in cardiovascular actions of endogenous nNOS or iNOS at rostral 
ventrolateral medulla of rats." British Journal of Pharmacology 138(4): 584-593. 
Sanchez, M. G., L. Ruiz-Llorente, et al. (2003). "Activation of phosphoinositide 3-kinase/PKB 
pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. 
Involvement in Raf-1 stimulation and NGF induction." Cellular Signalling 15(9): 851-
859. 
Schreihofer, A. M. and P. G. Guyenet (1997). "Identification of C1 presympathetic neurons in rat 
rostral ventrolateral medulla by juxtacellular labeling in vivo." The Journal of 
Comparative Neurology 387(4): 524-536. 
 196 
 
Scotter, E., S. Graham, et al. (2009). Cannabinoid Receptor Signal Transduction Pathways. The 
Cannabinoid Receptors. P. H. Reggio, Humana Press: 153-171. 
Seagard, J. L., C. Dean, et al. (2004). "Anandamide content and interaction of 
endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked 
sympathoinhibition." American Journal of Physiology - Heart & Circulatory Physiology 
286(3): H992-1000. 
Seagard, J. L., C. Dean, et al. (2004). "Anandamide content and interaction of 
endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked 
sympathoinhibition." Am J Physiol Heart Circ Physiol 286(3): H992-1000. 
Seagard, J. L., F. A. Hopp, et al. (2005). "Effects of endocannabinoids on discharge of 
baroreceptive NTS neurons." Neuroscience Letters 381(3): 334-339. 
Seiders, E. P. and S. L. Stuesse (1984). "A horseradish peroxidase investigation of carotid sinus 
nerve components in the rat." Neuroscience Letters 46(1): 13-18. 
Seyedabadi, M., A. K. Goodchild, et al. (2001). Differential Role of Kinases in Brain Stem of 
Hypertensive and Normotensive Rats. 38: 1087-1092. 
Shih, C. D. and Y. C. Chuang (2007). "Nitric oxide and GABA mediate bi-directional 
cardiovascular effects of orexin in the nucleus tractus solitarii of rats." Neuroscience 
149(3): 625-635. 
Shirasaka, T., M. Nakazato, et al. (1999). "Sympathetic and cardiovascular actions of orexins in 
conscious rats." American Journal of Physiology 277(6 Pt 2): R1780-1785. 
Showalter, V. M., D. R. Compton, et al. (1996). "Evaluation of binding in a transfected cell line 
expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid 
receptor subtype selective ligands." Journal of Pharmacology and Experimental 
Therapeutics 278(3): 989-999. 
 197 
 
Sidney, S. (2002). "Cardiovascular consequences of marijuana use." J Clin Pharmacol 
42(90110): S64-70. 
Smart, D., J. C. Jerman, et al. (1999). "Characterization of recombinant human orexin receptor 
pharmacology in a Chinese hamster ovary cell-line using FLIPR." British Journal of 
Pharmacology 128(1): 1-3. 
Song C and A. Howlett (1995). "Rat brain cannabinoid receptors are N-linked glycosylated 
proteins." Life Sciences 56(23-24): 1983-1989. 
Stein, E. A., S. A. Fuller, et al. (1996). "Physiological and behavioural effects of the endogenous 
cannabinoid, arachidonylethanolamide (anandamide), in the rat." British Journal of 
Pharmacology 119(1): 107-114. 
Strack, A. M., W. B. Sawyer, et al. (1989). "A general pattern of CNS innervation of the 
sympathetic outflow demonstrated by transneuronal pseudorabies viral infections." Brain 
Research 491(1): 156-162. 
Tsou, K., S. Brown, et al. (1997). "Immunohistochemical distribution of cannabinoid CB1 
receptors in the rat central nervous system." Neuroscience 83(2): 393-411. 
Tucker, D. C., C. B. Saper, et al. (1987). "Organization of central adrenergic pathways: I. 
Relationships of ventrolateral medullary projections to the hypothalamus and spinal 
cord." Journal of Comparative Neurology 259(4): 591-603. 
Twitchell, W., S. Brown, et al. (1997). "Cannabinoids inhibit N- and P/Q-type calcium channels 
in cultured rat hippocampal neurons." Journal of Neurophysiology 78(1): 43-50. 
van den Pol, A. N., X. B. Gao, et al. (1998). "Presynaptic and postsynaptic actions and 
modulation of neuroendocrine neurons by a new hypothalamic peptide, 
hypocretin/orexin." Journal of Neuroscience 18(19): 7962-7971. 
 198 
 
Van Sickle, M. D., M. Duncan, et al. (2005). "Identification and functional characterization of 
brainstem cannabinoid CB2 receptors." Science 310(5746): 329-332. 
Van Sickle, M. D., L. D. Oland, et al. (2001). "Cannabinoids inhibit emesis through CB1 
receptors in the brainstem of the ferret.[see comment]." Gastroenterology 121(4): 767-
774. 
Varga, K., K. Lake, et al. (1995). "Novel antagonist implicates the CB1 cannabinoid receptor in 
the hypotensive action of anandamide." European Journal of Pharmacology 278(3): 279-
283. 
Varga, K., K. D. Lake, et al. (1996). "Mechanism of the hypotensive action of anandamide in 
anesthetized rats." Hypertension 28(4): 682-686. 
Vaughan, C. W., I. S. McGregor, et al. (1999). "Cannabinoid receptor activation inhibits 
GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro." Br J 
Pharmacol 127(4): 935-940. 
Veerasingham, S. J., M. Yamazato, et al. (2005). "Increased PI3-Kinase in Presympathetic Brain 
Areas of the Spontaneously Hypertensive Rat." Circulation Research 96(3): 277-279. 
Verberne, A. J., R. L. Stornetta, et al. (1999). "Properties of C1 and other ventrolateral medullary 
neurones with hypothalamic projections in the rat." Journal of Physiology 517(Pt 2): 477-
494. 
Verty, A. N. A., W. M. Boon, et al. (2009). "Involvement of hypothalamic peptides in the 
anorectic action of the CB1 receptor antagonist rimonabant (SR 141716)." European 
Journal of Neuroscience 29(11): 2207-2216. 
Villanueva, L., J. de Pommery, et al. (1991). "Spinal afferent projections to subnucleus 
reticularis dorsalis in the rat." Neuroscience Letters 134(1): 98-102. 
 199 
 
Viscomi, M. T., S. Oddi, et al. (2009). "Selective CB2 Receptor Agonism Protects Central 
Neurons from Remote Axotomy-Induced Apoptosis through the PI3K/Akt Pathway." J. 
Neurosci. 29(14): 4564-4570. 
Walsh, S., K. Mnich, et al. (2010). "Loss of cannabinoid CB1 receptor expression in the 6-
hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in 
the rat." Brain Research Bulletin 81(6): 543-548. 
Wang, L.-L., C.-C. Ou, et al. (2005). "Receptor-Independent Activation of GABAergic 
Neurotransmission and Receptor-Dependent Nontranscriptional Activation of 
Phosphatidylinositol 3-kinase/Protein Kinase Akt Pathway in Short-Term Cardiovascular 
Actions of Dexamethasone at the Nucleus Tractus Solitarii of the Rat." Molecular 
Pharmacology 67(2): 489-498. 
Wang, Q., L. Liu, et al. (2003). "Control of Synaptic Strength, a Novel Function of Akt." Neuron 
38(6): 915-928. 
Wang, X. and A. A. Abdel-Rahman (2005). "Effect of chronic ethanol administration on hepatic 
eNOS activity and its association with caveolin-1 and calmodulin in female rats." 
American Journal of Physiology - Gastrointestinal & Liver Physiology 289(3): G579-
585. 
Watanabe, S., T. Kitamura, et al. (2003). "Projections from the nucleus reticularis 
magnocellularis to the rat cervical cord using electrical stimulation and iontophoretic 
injection methods." Anatomical Science International 78(1): 42-52. 
Weinstock, M., A. P. Zavadil, et al. (1979). "The effect of oxotremorine on blood pressure and 
plasma catecholamines in conscious and anesthetized rats." Life Sciences 24(4): 301-309. 
Wheal, A. J., T. Bennett, et al. (2007). "Cardiovascular effects of cannabinoids in conscious 
spontaneously hypertensive rats." British Journal of Pharmacology 152(5): 717-724. 
 200 
 
Wheal, A. J., T. Bennett, et al. (2007). "Effects of chronic nitric oxide synthase inhibition on the 
cardiovascular responses to cannabinoids in vivo and in vitro." British Journal of 
Pharmacology 150(5): 662-671. 
Xiao Hong, Y., C. Chang Qing, et al. (2010). "A peripherally restricted cannabinoid receptor 
agonist produces robust anti-nociceptive effects in rodent models of inflammatory and 
neuropathic pain." Pain 151(2): 337-344. 
Zhang, J. and A. A. Abdel-Rahman (2002). "The hypotensive action of rilmenidine is dependent 
on functional N-methyl-D-aspartate receptor in the rostral ventrolateral medulla of 
conscious spontaneously hypertensive rats." Journal of Pharmacology & Experimental 
Therapeutics 303(1): 204-210. 
Zhang, J. and A. A. Abdel-Rahman (2002). "The Hypotensive Action of Rilmenidine is 
Dependent on Functional N-Methyl-D-aspartate Receptor in the Rostral Ventrolateral 
Medulla of Conscious Spontaneously Hypertensive Rats." J Pharmacol Exp Ther 303(1): 
204-210. 
Zhang, J. and A. A. Abdel-Rahman (2005). "Mitogen-activated protein kinase phosphorylation 
in the rostral ventrolateral medulla plays a key role in imidazoline (i1)-receptor-mediated 
hypotension." Journal of Pharmacology & Experimental Therapeutics 314(3): 945-952. 
Zhang, J. and A. A. Abdel-Rahman (2008). "Inhibition of nischarin expression attenuates 
rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 
1/2 production in the rostral ventrolateral medulla of rats." Journal of Pharmacology & 
Experimental Therapeutics 324(1): 72-78. 
Zhang, W., Y. Fukuda, et al. (2005). "Respiratory and cardiovascular actions of orexin-A in 
mice." Neuroscience Letters 385(2): 131-136. 
Zhang, Y., A. Gilliam, et al. (2010). "Synthesis and Biological Evaluation of Bivalent Ligands 
for the Cannabinoid 1 Receptor." Journal of Medicinal Chemistry: null-null. 
 201 
 
Zhang, Y., D. Perrey, et al. (2010). "Synthesis and Evaluation of Bivalent Ligands for CB1-OX1 
Receptor Heterodimers." 20
th
 Annual Symposium on the Cannabinoids, International 
Cannabinoid Research Society, Research Triangle Park, NC, USA, P:47. 
Zheng, H., L. M. Patterson, et al. (2005). "Orexin-A projections to the caudal medulla and 
orexin-induced c-Fos expression, food intake, and autonomic function." The Journal of 
Comparative Neurology 485(2): 127-142. 
Zhu, Y., Y. Miwa, et al. (2003). "Orexin Receptor Type-1 Couples Exclusively to Pertussis 
Toxin-Insensitive G-Proteins, While Orexin Receptor Type-2 Couples to Both Pertussis 
Toxin-Sensitive and -Insensitive G-Proteins." Journal of Pharmacological Sciences 92(3): 
259-266. 
Zubcevic, J., H. Waki, et al. (2009). "Chronic Blockade of Phosphatidylinositol 3-Kinase in the 
Nucleus Tractus Solitarii Is Prohypertensive in the Spontaneously Hypertensive Rat." 
Hypertension 53(1): 97-103. 
 
  
 APPENDIX I 
 
ANIMAL CARE AND USE COMMITTEE APPROVAL LETTER 
  
 203 
 
 
  
 APPENDIX II 
 
ELSEVIER LICENSE AGREEMENT TO USE CB1R FIGURE BY ALLYN C. HOWLETT 
1998 
 
 
 205 
 
 
 206 
 
APPENDIX III 
 
 APPENDIX III 
 
PERMISSION TO USE AN IMAGE FROM CNSFORUM.COM WEBSITE 
  
 207 
 
  
 APPENDIX IV 
 
SPRINGER LICENSE AGREEMENT TO USE CB1R RETROGRADE SIGNALING FIGURE 
BY EMMA SCOTTER et al 2009 
  
 209 
 
 
